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Abstract 
 
Protein-protein interactions (PPIs) play an important role in numerous biological processes. 
Consequently, modulating PPIs is fundamental for understanding and manipulating mechanisms 
that govern many diseases. Among the wide range of topographies that PPIs display, the α-helix 
is the most common secondary structure in nature and thus represents a good generic template 
for inhibitor design.
1
 Some of the most relevant approaches in this field are the proteomimetic 
approach, which recapitulate the key binding residues of an α-helix on a non-peptidic scaffold; 
and the constrained peptides, which aim to reproduce the helical structure by stabilising a 
helical peptide. Both approaches have generated potent inhibitors of a great diversity of α-helix 
mediated PPIs. However, developing a better understanding of the key features that govern the 
modulation of protein recognition is necessary to further advance the field and fully exploit each 
class of foldamer.  
 
In that context, we developed functionalised aromatic oligoamide backbones to mimic residues 
located on multiple faces of an -helix to target the ER/co-activator PPI. The novel scaffolds 
are based on bis-benzamide and N-(4-aminophenyl)terephthalamidic acid backbones 
functionalised with isobutyl groups to reproduce the key side chains of the co-activator α-helix. 
Conformational studies in combination with molecular modeling and docking analysis provide 
evidence that the new oligomers can adopt conformations that mimic the residues at i, i+3 and 
i+4 positions of the native co-activator α-helix. 
 
In addition, the rules that govern molecular recognition of protein surfaces were further 
investigated through the optimisation of the oligobenzamide hybrid scaffold using a structure-
activity relationship (SAR) study. A library of compound analogues has been synthesised 
incorporating five variable sites. The modifications focused on size, polarity and 
stereochemistry to obtain more potent and selective proteomimetic inhibitors of the p53/hDM2 
and Mcl-1/NOXA B PPIs.  
 
Finally, using existing methodologies a 3-O-alkylated proteomimetic scaffold and hydrocarbon 
stapling peptide strategy, have been used to design inhibitors of the Asf1/H3 interaction. The 
application of both approaches allowed the different inhibitor designs to be directly compared 
when targeting the same PPI.  
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Chapter 1. Inhibition of protein-protein interactions 
1.1. Inhibition of protein-protein interactions  
 
Protein-protein interactions (PPIs) are probably the most complex and diverse biological 
macromolecules, and have the highest regulatory impact among the class of macromolecular 
interactions.
2
 They mediate a large number of important regulatory pathways and control 
essential cellular processes involved in signalling, growth and survival.
3, 4
 Thus, there is much 
interest in targeting the interfaces between interacting proteins for therapeutic purposes.
2
 
However, they display greater structural and chemical diversity than the classical targets, such 
as protein kinases and proteases. Therefore, the use of small-molecules to modulate PPIs is 
important for the aforementioned key therapeutic benefits, as well as to gain further insight 
complex biological signalling pathways.
1 
 
1.2. Structural features of PPIs 
 
Protein-protein interactions are generally not considered attractive targets for small molecule 
drug design. As a result of the unique characteristics of each of these interfaces, it is difficult to 
establish general guidelines for effective and selective inhibition of PPIs using small 
molecules.
5
 The contact surfaces involved in PPIs are large (~1500-3000 Å
2
) compared with 
those involved in protein-small-molecule interactions (~300-1000 Å
2
).
2
 In addition, PPIs present 
flat or moderately convex surfaces with fewer well-defined concave binding sites, such as 
grooves and pockets, than classical enzymes (Figure  1.1b a).4 The interacting regions present 
both hydrophobic and charged recognition elements with a poorly defined spatial relationship. 
Furthermore, PPIs may contain discontinuous epitopes formed by peptidic strands from 
different regions of the protein sequence (Figure  1.1b).3, 4  
 
However, most contact surfaces are dynamic. They display adaptability and flexibility, 
involving motions of side chains and small perturbations of loops. The reorganization of the 
surface residues occasionally creates available ligand-binding cavities that are not seen in 
structures of either the free-protein or the protein-protein complex.
2
 These transient pockets and 
temporary structures represent promising targets for small molecule PPI inhibition.
6
 
 
  
2 
 
Figure  1.1 (a) Recognition and inhibition of enzymes; (b) Recognition and inhibition of PPIs.
[2] 
 
1.2.1. Binding features of PPIs 
 
Numerous studies have focused on protein–protein complex formation. However, the principles 
governing PPIs are still not fully understood.
7
 The most important factor that has obstructed 
their elucidation is the role of plasticity in protein–protein interfaces, including protein 
flexibility, presence of disordered regions, protein promiscuity and cooperativity in PPIs.
8, 9
 
 
Nevertheless, there are tools that allow the study of protein-protein association. In 1995 
Clackson and Wells used the alanine scanning mutagenesis technique to explore the energetic 
contributions of individual side-chains in protein binding. This study showed that a PPI usually 
involves a few key residues that contribute the majority of the binding affinity to the interaction. 
These residues are known as “hot spots”10 and are usually densely packed in clusters where they 
form a network of interactions (Figure  1.2).11 Bogan and Thorn made a further contribution in 
1998 and found that certain amino acid residues, particularly tryptophan (21%) and tyrosine 
(12%), appear more frequently in hot spots. These residues can perform aromatic-π interactions 
and hydrogen bonds through the indole nitrogen on the tryptophan and the phenolic hydroxyl on 
the tyrosine. Furthermore, their large hydrophobic surfaces presumably protect these hydrogen 
bonding interactions from water molecules. Arginine (13%) residues are also important, as they 
can form a similar range of favourable interactions in addition to ion pairs. Importantly, an 
energetically less important ring of residues, known as an O-ring, often surrounds the hot spots 
and seems to occlude bulk-solvent access.
4, 11, 12
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Figure  1.2 Binding site for human growth hormone (hGH) on the human growth hormone 
receptor (hGHbp). The “hot spot” residues identified by alanine scanning mutagenesis are 
shown in green (PDB ID: 3HHR).
10, 13 
 
1.3. Inhibition of α-helix mediated protein-protein 
interactions  
 
The α-helix is the most common secondary structure in nature; over 30% of protein structure is 
helical. Therefore, α-helices represent a good generic template for inhibitor design given the 
high likelihood of PPIs involving this structural motif.
5, 14
 Nevertheless, α-helix mediated PPIs 
still exhibit considerable diversity. They can vary in the number of proteins involved in the 
interaction, as well as in the number of helical faces found at the interface.  
 
A typical α-helix has 3.4 amino acid residues per turn, is defined by backbone dihedral angles 
close to Φ= -60º and Ψ= -45º and has a rise of 1.5 Å/residue or 5.4 Å/turn (Figure  1.3).14 The 
helix can be considered to have three distinct faces; side chains placed at a distance of 3-4 
residues in the peptide sequence are located above one another and, therefore, are projected 
from the same face (Figure  1.3c). This structural characteristic plays a major role in its 
molecular function; the residues located on the central polypeptide backbone of an α-helix 
structure are projected along individual faces of the scaffold, which allows selective and specific 
molecular recognition.
1
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Figure  1.3 (a) α-Helix with the residues at i, i+4 and i+7 positions shown in red; (b) peptide 
bond showing the dihedral angles Φ and Ψ, and planar segments in purple and pink rectangles; 
(c) α-Helix with the three distinct faces highlighted in red, green and blue (side and top views 
are given). 
1.3.1. Lead discovery in α-helix mediated PPIs 
 
Different approaches have been established with the final aim of developing molecules that 
effectively and selectively inhibit α-helix mediated PPIs. The most important strategies can be 
classified according to the backbone that they utilise to connect the binding functionalities:
15
 
 
- Type I mimetics: They mimic the topography of the original structural α-helix backbone at 
the atomic level. 
 
- Type II mimetics: They mimic the function rather than the structure of the original α-helix; 
they are generally small non-peptidic molecules that bind to the corresponding target protein. 
 
- Type III mimetics: They mimic the side chain projection of the key amino acid residues of 
the original α-helix; they use non-peptidic scaffolds.  
 
1.3.1.1. Type I mimetics 
 
Peptides are attractive candidates for stabilizing or disrupting PPIs. However, they present some 
severe drawbacks for therapeutic purposes, such as i) limited secondary structure as isolated 
sequences;
16
 ii) poor cell permeability and transport properties;
17
 iii) low stability due to 
proteolysis.
18
 Type I mimetics consist of short peptidic oligomers that reproduce the local 
topography of an α-helical structural motif and focus on maximizing helicity whilst enhancing 
the proteolytic stability and the pharmacokinetic properties. The different strategies developed 
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within this approach can be classified in two main groups: helical foldamers and constrained 
peptides.
1
  
 
Helical foldamers 
 
Helical foldamers are structures that adopt well-defined conformations reminiscent of protein 
secondary structures.
19
 Their synthesis is based on the oligomerization of building blocks and 
their structure is stabilized by intramolecular non-covalent interactions between non-
consecutive residues along the peptide. The most extensively studied examples are β-peptides 
and α/β-peptides.20 
 
β-peptides 
 
The use of β-peptides in substitution of their natural α-counterparts has been extensively studied 
due to some of their attractive features for therapeutic use. The addition of an α-methylene 
group in the β-peptides provides them with an increased degree of freedom compared to the α-
peptides. Consequently, β-peptides were expected to be entropically disfavoured from adopting 
well defined folded states in solution. However, this minor backbone modification resulted in 
higher propensity to adopt helical conformations, which permits the presence of defined 
structures within relatively short sequences. Moreover, β-peptides presented an increased 
number of accessible helical secondary structures (Figure  1.4b) when compared with the natural 
α-peptides (Figure  1.4a). In addition, this class of compounds is characterized by an enhanced 
resistance to proteolysis and thus a more favorable pharmacodynamic profile.
21
 Different types 
of β-amino acids have been described: β2- or β3-amino acids bearing a single side chain either at 
C2 or C3, and β2,3-building blocks with both carbon atoms substituted. 
 
Figure  1.4 Intramolecular hydrogen bonding interactions occurring in different helical 
secondary structures of: (a) α-peptides; (b) β-peptides. 
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Several β-peptidic scaffolds have been used to inhibit PPIs due to the above described desirable 
therapeutic properties. Seebach and co-workers were the first to report the synthesis and 
complete characterisation of a β-peptide sequence.22 They used circular dichroism (CD) and X-
ray analysis to elucidate the intramolecular hydrogen bonding network that allows the β-
peptides to adopt the desired helical conformation. Continuing with this research, they also 
reported short-chain amphipathic β-peptides that mimicked lipoproteins and inhibited intestinal 
cholesterol absorption.
23
 Despite exhibiting subtle structural differences, the synthetic peptides 
exploited their increased resistance against pancreatic proteases compared to the corresponding 
proteins and natural α-peptide based inhibitors of lipid absorption. 
 
The biological relevance of β-peptides was further explored by the Schepartz group, which 
reported a series of β3-decapeptides that effectively inhibited the human double minute 
2/tumour protein 53 (hDM2/p53) PPI.
20
 Their 14-helical conformation was stabilized by 
intramolecular salt bridges and an electrostatic macrodipole interaction. Subsequent structure-
activity relationship (SAR) studies exploited the introduction of non-natural side chains to 
increase the affinity of the β3-decapeptides to the hDM2 protein. In particular, the substitution of 
the key tryptophan residue of p53 by a 6-chlorotryptophan analogue resulted in a 10-fold 
increase in activity. The β3-peptides has also been used to successfully target other PPIs of 
interest, such as such as glycoprotein 41/human immunodeficiency virus type 1 (gp41/HIV)
24, 25
 
and glucagon-like peptide-1/glucagon-like peptide-1 receptor (GLP-1/GLP-1R).
26
 The poor cell 
permeability of these types of molecules made deeper understanding of the correlation between 
affinity and cell uptake necessary, in order to obtain derivatives with improved pharmacokinetic 
properties.
27, 28
 
 
α/β-peptides 
 
The synthesis of foldamers containing α- and β-amino acids generated a wide range of 
accessible heterogeneous combinations. Importantly, conformational control and predictable 
folding patterns can be achieved by modifications of the peptide residue arrangement.
29-31
 The 
main purposes of the α/β-peptides were to increase α-helix mimicry whilst retaining resistance 
to proteolysis.
32
 Consequently, this type of foldamer contains an epitope formed by the α-amino 
acids responsible for surface recognition, whereas the β-amino acids increase the helical 
secondary structure through intramolecular salt bridges or by introducing structural constraints. 
 
The Gellman group has extensively studied the use of α/β-peptidic scaffolds as ligands for the 
BH3-recognition cleft of the B-cell lymphoma 2 (Bcl-2) protein family. Early efforts focused on 
the structure-based design of pure α/β-foldamer backbones, which proved ineffective.31, 33 These 
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studies led to the chimeric (α/β + α)-peptide family, which was formed by a 1:1 α/β-residue 
alternation in the N-terminal segment and exclusively α-residues at the C-termini.34 This class of 
foldamers inhibited the Bcl extralarge/Bak (a homologous antagonist killer peptide) (Bcl-
xL/Bak) interaction with IC50 values in the low nM range and showed high proteolytic stability. 
Subsequent studies following the chimeric approach identified weak inhibitors of the Bcl-
xL/BIM (a Bcl-2 interacting mediator of cell death peptide) PPI.
35
 The first crystal structure of 
the chimeric foldamers bound to Bcl-xL provided fundamental insight into the peptide binding 
mode, highlighting the importance of the subtle changes on the α-helix for side chain matching, 
and the relevance of the solvent exposed β-amino acids for backbone helicity.36 
 
Building on these results, the Gellman group adapted their chimeric approach to a novel 
sequence-based design approach.
37
 This approach involved replacing subsets of regularly spaced 
α-residues with the corresponding β3-residues, creating patterns such as “ααβαααβ” or “αααβ”. 
This strategy was applied to the design of hybrid peptide mimetics of Puma (another pro-
apoptotic member of the Bcl-2 family) (Figure  1.5), which led to the identification of potent 
inhibitors of Bcl-xL and induced myeloid leukemia cell differentiation protein (Mcl-1) and 
demonstrated that the affinity and selectivity of the α/β-peptides were dependent on the position 
of the β-residues along the sequence.38 
 
 
Figure  1.5 (a) X-Ray structure of the complex between the Bcl-xL protein and the ααβαααβ-
peptide derivative of the native PUMA-BH3 domain (PDB ID: 2YJ1); (b) top view illustrating 
the alignment of the α- and β-amino acids. 
 
The scope of the sequence-based strategy has expanded in recent years with introduction of new 
β-residues, achievement of selectivity between target molecules, and enhancement of potency 
and proteolytic stability.
39, 40
 Moreover, this approach has been used to successfully inhibit other 
PPIs of therapeutic interest, such as gp41/HIV
41
 and GLP-1/GLP-1R.
42
 However, the use of α/β-
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peptides as drug candidates is still limited by their poor cell membrane permeability 
properties.
43
 
 
Constrained peptides 
 
In principle, peptides retain excellent surface recognition properties whilst presenting reduced 
toxicity. However, in most cases they suffer from proteolytic instability and low cell 
permeability. These limitations are related to the unstructured conformation that short peptides 
adopt in solution. This fact causes entropic penalties when the peptides transition to more 
restricted conformational states upon binding, which ultimately has an effect on the target 
affinity.
44
  
 
Therefore, major efforts have focused on the introduction of conformational constraints into 
peptides in order to stabilize bioactive conformations. This would presumably reduce the 
entropic penalty upon binding and thus engender more drug-like properties whilst increasing 
target affinity.
45
 The structural stabilization of helical peptides by covalent linkages between 
residues suitably positioned in space is one of the most important approaches in this area.
46
 
Some of the most relevant methodologies for these purposes are described below.  
  
Thiol-based crosslinks 
 
One of the first methods used to stabilise the helical conformation of peptides was the 
introduction of thiol-based crosslinks (Figure  1.6). Spatola and co-workers used a simple 
disulfide bond between cysteine residues to constrain a nonapeptide inhibitor of the estrogen 
receptor (ER)/co-activator PPI. Interestingly, the X-ray structure of the complex revealed the 
helical conformation adopted by the constrained peptide when bound to the protein surface, 
which contrasted with the minimal helicity shown in solution.
47
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Figure  1.6 Generic structure of a peptide constrained with a Cys-Cys disulfide bridge. 
One of the main disadvantages of the disulfide cross-links is their lability under the reductive 
conditions found in most eukaryotic cells. For this reason, chemically more stable thioether 
moieties have been designed; most of them including the use of electrophiles that selectively 
react with the thiol side chain. A variety of biselectrophilic molecules have been used to cross-
link two properly aligned cysteine residues of peptides thus stabilizing their helical 
conformation. In particular, aryl and bis-aryl methylene bromides were introduced by Lin and 
co-workers (Figure  1.7a).48, 49 They were successfully utilised to crosslink cysteine containing 
peptides providing inhibitors for the p53/murine double minute 2 (mDM2) and Mcl-1/NOXA B 
(another pro-apoptotic member of the Bcl-2 family) (Figure  1.7) PPIs. Likewise, the Pentelute 
group has reported a new class of α-helix-induced peptides which utilised perfluorinated aryl 
linkers to mildly functionalize cysteine containing peptides (Figure  1.7a).50 Recently, Chou and 
co-workers expanded the variety of thiol-based crosslinks with the introduction of a robust and 
versatile thiol-ene coupling approach (Figure  1.7a), which has provided p53 constrained 
derivatives that bind to the hDM2 protein partner and retain activity in cells.
51
 
 
 
 
Figure  1.7 (a) Different cross-linking systems between cysteine residues resulting from the 
reaction with: an aryl and a bis-aryl methylene bromides, a fluorinated aryl and an alkyl thiol-
ene linkers, respectively from left to right. (b) X-Ray structure of the complex between the Mcl-
1 protein and a cysteine bisaryl methylene bridged peptide derivative of the native NOXA-BH3 
  
10 
domain (PDB ID: 4G35); (c) top view illustrating the alignment of the binding α-residues in 
green and the solvent exposed bisaryl methylene linkage between cysteine residues. 
Photo-controlled helices or azobenzene photo-switches 
 
A slightly different approach introduced by Woolley and co-workers was based on an 
azobenzene molecule that crosslinked suitably positioned cysteine residues of a peptide.
52
 
Photo-isomerization of the crosslinker can be used to switch peptides between the α-helical and 
random coil-like conformations. Building on that work, the Allemann group developed a family 
of photo-controllable peptide-based switches based on the BH3 region of Bak and BIM proteins 
(Figure  1.8).53 Interestingly, the resulting helix-stabilized peptides bound to the Bcl-xL target 
protein with greater affinities than the helix-de-stabilized forms. Recently, this group have fused 
a BID modified peptide to the LOV2 domain of Avena Sativa phototropin 1(AsLOV2) protein 
to create optically controlled intracellular modulators of the Bcl-xL protein.
54
 
 
 
Figure  1.8 Peptide conformational change controlled by photo-isomerisation of the azobenzene 
cross-linker. The example illustrates helical conformation stabilised in the cis configuration 
with i, i+4 and i, i+7 Cys linkages. 
 
Lactam bridge 
 
The lactam linkage was another of the earliest approaches for constraining peptides (Figure  1.9). 
This strategy was introduced by the Rosenblatt group, who for the first time stabilised the 
helical secondary structure of a peptide by forming a lactam bridge between a lysine and an 
aspartic acid residue located at i and i+4 positions of the peptide sequence.
55
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Figure  1.9 Generic structure of a peptide constrained with a Lys-Glu lactame bridge. 
 
This work was followed up by Kim and co-workers, who stabilised a 14-residue C-terminal 
peptide of gp41 by crosslinking two glutamic acid residues at i and i+7 positions with an α,ω 
diaminoalkane group (Figure  1.10). The introduction of this constraint resulted in a potent 
inhibitor of the HIV-1/gp41 PPI.
56
 Additionally, the extensive work of the Fairlie group in this 
area focused on downsizing protein helical epitopes by strategically locking them in highly -
helical structures through the introduction of two adjacent lactam cross-links.
57
 Following this 
approach, they managed to successfully constrain a wide variety of peptides from viral, 
bacterial, or human proteins. One of the most remarkable examples is the nociceptin peptide, 
which was constrained to produce a pM agonist of the nociceptin receptor (NOP), the most 
potent known to date.
58
 Likewise, the constrained 11-residue analogue of the N-terminus GLP-1 
was recently identified as a potent agonist of GLP-1R.
59
 
 
 
Figure  1.10 (a) X-Ray structure of one of the domains from the trimeric coil-coil complex 
between the HIV-1 protein and a glutamic acid α,ω diaminoalkane bridged peptide derivative of 
the native gp41 (PDB ID: 1GZL); (b) top view illustrating the alignment of the binding α-
residues in green and the solvent exposed α,ω diaminoalkane linkage between glutamic acid 
residues. 
  
12 
Hydrocarbon staple  
 
Inspired by the initial work of Grubbs with cross-linked O-allyl serine residues,
60
 Verdine and 
co-workers established the hydrocarbon stapling methodology by introducing unnatural α,α’-
disubstituted amino acids with olefin tethers into the peptide sequence and cross-linking them 
via ring-closing metathesis (RCM) (Figure  1.11).61 Initial studies focused on the role of residue 
positioning, stereochemistry and linker length, in order to obtain higher binding affinities and 
enhanced proteolytic stability. The use of this strategy by Korsmeyer and co-workers generated 
ligands based on the BID BH3 sequence, which represented one of the main breakthroughs in 
the field.
46
 It generated peptides with a significant enhancement in peptide α-helicity, protease 
resistance and in vitro and in vivo biological activity, showing tumour suppression and 
regression in leukaemia xenografts.
62
 
 
 
Figure  1.11 Generic structure of a hydrocarbon stapled peptide. 
 
The Walensky group has extensively expanded the use of hydrocarbon stapled peptides to study 
in depth the interactions between members of the Bcl-2 family and identify potent inhibitors for 
those PPIs (Figure  1.12).63-65 In addition, they also reported a hydrocarbon double-stapled 
peptide, which achieved helical conformations in long peptides whilst maintaining resistance to 
proteases both in vitro and in vivo and enhanced inhibitory activity against the HIV-1/gp41 
interaction.
66
  
  
13 
 
Figure  1.12 (a) X-Ray structure of the complex between the Mcl-1 protein and a stapled peptide 
derivative of a stabilized α-helix of a Bcl-2 domain (SAHBs) (PDB ID: 3MK8); (b) side view 
illustrating the alignment of the binding α-residues in green and the solvent exposed 
hydrocarbon linkage. 
 
Furthermore, it is important to highlight the crystal structures of the stapled peptides targeting 
the p53/hDM2
67
 (Figure  1.13a) and ERα/co-activator (Figure  1.13b).68 Both structures showed 
the hydrocarbon staple chain actively participating in the interaction with the binding cleft from 
the corresponding protein partners. These discoveries highlighted the need for careful case by 
case analysis of these kinds of molecules, in order to avoid miss-interpretation of the structure-
potency relationships. 
 
 
Figure  1.13 (a) X-Ray structure of the complex between the hDM2 protein and a stapled 
peptide derivative of p53 (PDB ID: 3V3B); (b) X-Ray structure of the complex between the 
ERα protein and a co-activator stapled peptide derivative (PDB ID: 2YJD). Both illustrating the 
participation of the hydrocarbon staple in binding to the protein surface. 
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In that context, the Wilson group has recently reported an α-alkenyl mono-substituted amino 
acid which has been incorporated in the BID peptide sequence.
69
 Significantly, it was 
demonstrated to increase peptide helicity, enhance proteolytic stability and provide similar 
inhibitory activity towards Bcl-xL/Bak whilst involving a simpler synthetic route than the α,α’-
disubstituted amino acid. Furthermore, an extensive investigation on the mode of action of these 
mono-substituted stapled peptides, in particular BID and BIM derivatives, has recently shown 
evidence for induced-fit binding and enthalpy-entropy compensation.
70
 Those findings join the 
concerns raised by Czabotar and co-workers on the need for more in-depth understanding of the 
effects of pre-organisation in protein-ligand binding processes and its ultimate role in binding 
potency.
71, 72
 
 
Nevertheless, hydrocarbon stapled peptides might represent the most successful example of 
therapeutic PPI inhibitors, resulting in the creation of AILERON Therapeutics who have 
brought this class of compounds into Phase I clinical trials.
73
 
 
Hydrogen bond surrogate  
 
Inspired by the original hydrazone linker from Cabezas and Satterthwait,
74, 75
 the hydrogen bond 
surrogate (HBS) methodology was established by Arora and co-workers (Figure  1.14).76 It 
substitutes the natural intramolecular hydrogen bond between residues at i and i+4 positions of a 
peptide employing a non-natural carbon-carbon bond formed by ring-closing metathesis (RCM). 
This approach has the advantage of not adding steric constraints to the natural helix; however, 
its use is limited to the N-terminal position of a peptide. It has been extensively exploited to 
inhibit PPIs of interest,
77
 such as Bcl-xL/Bak,
78
 p53/mDM2,
79
 hypoxia-inducible factor 1 
alpha/E1A binding protein 300 (HIF-1α/p300)80 and more recently in cellulo inhibition has been 
reported for the  RAS/son of sevenless (SOS) interaction.
81
 The Arora group also developed a 
reversible disulfide and thioether-linked versions of the HBS peptide, which disrupted the 
p53/mDM2 PPI.
82, 83
 Another remarkable HBS is the covalent ethylene bridge from Alewood, 
which can be positioned anywhere on the peptide sequence.
84
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Figure  1.14 Generic structures of the most relevant HBS covalent constraints developed to date. 
 
1.3.1.2. Type II mimetics 
 
Type II mimetics are based on small non-peptidic molecules that inhibit α-helix mediated PPIs 
by binding to the target receptor.
85
 Distinctively, they inhibit PPIs without necessarily 
mimicking the original helix.
1
 Several examples of potent inhibitors identified using this 
strategy have been reported, such as the tetra-substituted imidazoles (Nutlins)
86
 and the ABT-
737-based compounds,
87
 which represent some of the more relevant and ground breaking 
examples in the utilisation of small molecules to effectively inhibit PPIs. 
 
Nutlin-3 
 
F. Hoffmann-La Roche identified by a high throughput screen (HTS) a series of tetra-
substituted cis-imidazoline analogues known as Nutlins.
86
 These compounds were used as lead 
structures for the development of p53/hDM2 inhibitors. Several rounds of chemical 
optimization finally yielded Nutlin-3, a potent and selective inhibitor of the p53/hDM2 
interaction with an IC50 of 90 nM. An X-ray crystal structure verified the mode of binding of 
this family of compounds and provided the first structural information of a non-peptidic small-
molecule inhibitor bound to the mDM2 protein. The Nutlins display analogous interactions to 
the natural p53 peptide, with the chlorophenyl moieties and the isopropyl substituent occupying 
the Trp, Leu and Phe pockets from the mDM2 binding site respectively. 
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Nutlin-3 was the first mDM2 inhibitor to enter Phase I clinical trials and proved its activity in 
vitro and in tumour xenografts in vivo, providing the first in vivo proof-of-concept of this 
approach to cancer therapy (Figure  1.15a). Additional efforts from F. Hoffmann-La Roche 
around this compound series has led to candidates such as RG7112
88, 89
 and RG7388
90
 with 
increased binding affinity (Figure  1.15b), cellular potency, pharmacokinetic properties and 
chemical stability, and which are currently in Phase I/II clinical trials. 
 
                                   
 
Figure  1.15 Small molecule inhibitors of PPIs identified via HTP screening (a) X-Ray structure 
of the Nutlin 3a/mDM2 complex (PDB ID: 4J3E), Nutlin 3a chemical structure and 
corresponding mDM2 binding affinity; (b) Chemical structures of RG7112 and RG7388 and 
corresponding mDM2 binding affinities. 
 
ABT-737 
Abbott Laboratories discovered, by an NMR-based high throughput fragment screen, a group of 
high-affinity small molecules that bind to some members of the Bcl-2 family, such as Bcl-xL 
(a) 
(b) 
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and Bcl-2, through their helical binding site.
91
 The most potent inhibitor was ABT-737,
62
 which 
binds to the BH3 α-helix binding grove of Bcl-xL with a Ki of 0.6 nM (Figure  1.16a). However, 
ABT-737 ultimately failed in clinical trials due to its poor bioavailability. Further structural 
optimization resulted in derivative ABT-263 (Navitoclax) (Figure  1.16b),87 which displayed 
improved oral bioavailability and similar affinity (Ki < 1 nM) for the Bcl-2 family proteins. 
ABT-263 failed phase II clinical trials for small-cell lung carcinoma treatment due to its 
hematologic toxicity; however, it led to the selective Bcl-2 candidate ABT-199 (Venetoclax) (Ki 
< 0.01 nM), which has been approved for some forms of chronic lymphocytic leukaemia 
(Figure  1.16b),92 being one of the first success stories of PPI inhibition originate from fragment 
based screening.
93
 
 
      
 
              
 
 
 
 
Figure  1.16 Small molecule inhibitors of PPIs identified via structure-based screening (a) X-
Ray structure of the ABT-737/Bcl-xL complex (PDB ID: 2YXJ) and ABT-737 chemical 
structure;94 (b) Chemical structures of ABT-263 and ABT-199. 
 
Despite the increasing number of reported small molecules as potent inhibitors of PPI, the 
significant developments in computational design and docking algorithms and the assembly of 
more focused screening libraries, the use of traditional drug discovery approaches to target PPI 
is still challenging. Furthermore, these approaches usually focus on the development of 
(a) 
(b) 
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inhibitors that specifically target a particular PPI, which may not directly contribute to the 
elucidation of the general guidelines for PPI inhibition. Therefore, this type of inhibitors will 
not further be discussed. 
 
1.3.1.3. Type III mimetics (or proteomimetics) 
 
The proteomimetic approach is based on non-peptidic scaffolds that mimic the spatial 
orientation of the key recognition residues on the native α-helix surface (Figure  1.17). The 
method focuses on simplifying the pharmacophore to a rod-shaped object which projects the 
side chains in a similar orientation to the original α-helix. The ligands potentially present more 
accessible syntheses and improved drug-like properties than the original peptides. Furthermore, 
due to its modular synthesis, this approach could be easily adapted to different PPIs by changing 
the side chains according to the target of interest.
1
  
 
 
Figure  1.17 Schematic illustrating the proteomimetic approach.  
 
Early scaffolds 
 
The first small molecules designed to inhibit PPIs by mimicking the side chain residues of an α-
helix were the trisubstituted indanes reported by Horwell et al. which mimic the residues at i-1, 
i and i+1 positions (Figure  1.18a). However, due to its small size and limited mimicry potential 
of just two consecutive residues, they cannot be considered effective inhibitors for α-helix 
mediated PPIs.
95, 96
 Inspired by that work, the Hamilton group established the field of 
proteomimetics by reporting the terphenyl as the first real α-helix mimetic scaffold 
(Figure  1.18b).97 In the tris-functionalised 3,2’,2’’-terphenyl derivatives the aryl core adopts a 
staggered conformation which projects the ortho-substituents in a spatial orientation that mimic 
the i, i+3, and i+7 residues of an α-helix. 
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Figure  1.18 (a) Indane scaffold: helix mimetics proof-of-concept; (b) Terphenyl scaffold: first 
true proteomimetics.  
 
Since its development, the terphenyl scaffold was an attractive template due to the simplicity of 
the structure and the synthetic potential. Thus, terphenyl derivatives incorporating a wide 
variety of functionalized side chains were developed and used to successfully target many PPIs 
of interest, such as calmodulin/smooth muscle myosin light chain kinase (CaM/smMLCK),
97
 
gp41/HIV-1,
98
 Bcl-xL/Bak
98
 and p53/hDM2.
99
 This family of mimetics has achieved inhibition 
of PPIs with high potency, good selectivity and proven activity in cells.
100, 101
 
 
 
Figure  1.19 Terphenyl derivatives inhibitors of (a) CaM/smMLCK; (b) Bcl-xL/Bak; (c) 
p53/hDM2. 
 
Next generation of scaffolds 
 
Despite the success of the terphenyl scaffold, some of its disadvantages include difficulties in 
the synthesis and most importantly its highly hydrophobic character.
102
 Considerable effort has 
therefore been focused on the development of scaffolds with more versatile synthetic strategies 
leading to molecules with enhanced drug-like properties. Some of the most remarkable scaffolds 
developed by Hamilton and co-workers include the terephtalamide
103
 (Figure  1.20a) and 4,4ꞌ-
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dicarboxamide
104
 (Figure  1.20b) templates, which benefit from accessible syntheses, hold 
rigidity due to intramolecular hydrogen bonding and present good water solubility due to the 
their higher polarity. These scaffolds inhibited Bcl-xL/Bak; however, with lower affinity than 
the original terphenyl derivatives. Importantly, the mimicry of an additional fourth hot spot in 
the 4,4'-dicarboxamide template compared with the terephtalamide did not result in an increase 
of the binding affinity. Thus, highlighting the complexity of drug design for disruption of 
protein surface recognition processes.  
 
 
Figure  1.20 Second generation of Hamilton’s scaffolds: (a) Terephtalamide; (b) 4,4ꞌ-
dicarboxamide; (c) Enaminone; (d) Benzoylurea. 
 
Further investigation on extended α-helix mimetics was accomplished with the introduction of 
the enaminone scaffold (Figure  1.20c), a development of the previously reported terphenyl.105 In 
this template the central aromatic ring is substituted for a six-membered isostere formed via an 
intramolecular hydrogen bond, which locks the molecule in the desired conformation. Similarly, 
the benzoylurea template (Figure  1.20d) contains a central core formed by six membered 
hydrogen-bonded acylurea structures.
106
 These scaffolds gave access to longer oligomers with 
improved water solubility properties.
107
 In addition, the benzoylurea inhibited the Bcl-xL/Bak 
interaction with lower binding affinity than the terphenyl and the 4,4ꞌ-dicarboxamide 
scaffolds,
108
 further stressing the importance of the balance between the number of hot spots 
mimicked and the molecular size of the inhibitor. 
 
Continuing the search towards more soluble scaffolds, Rebek and co-workers developed new 
amphiphilic α-helix mimetics with a series of scaffold based on oxazole-pyridazine-piperazine 
rings as backbones (Figure  1.21a).109-111 The design included a hydrophobic face for protein 
surface recognition and another face rich in hydrogen bonding groups, also known as the “wet 
edge”, which was anticipated to be directed towards the solvent thus increasing water solubility. 
However, the compounds obtained from this scaffold presented low inhibition towards the Bcl-
xL/Bak interaction. Similarly, the Hamilton group introduced the 5-6-5-imidazole–phenyl–
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thiazole scaffold (Figure  1.21b),112, 113 in which the terminal monomers of the terphenyl 
backbone are replaced with more hydrophilic five-membered heterocycles. The resulting 
compound also had limited success, inhibiting the Dbl’s big sister/cell division control protein 
42 (Dbs/Cdc42) interaction with an IC50 value of 67.0 M. In addition, Lim and co-workers 
reported a pyrrolopyrimidine-based scaffold
114
 (Figure  1.21c) containing a “wet edge”, which 
showed potent activity against p53/hDM2 and improved solubility and cell permeability 
properties. Importantly, this scaffold is accessed by a facile solid-phase synthetic route, 
amenable to large library generation. Recently, the Fletcher group has reported a similar 
scaffold based on a purine derivative.
115
 
 
Figure  1.21 Amphipilic α-helix mimetics scaffolds: (a) Oxazole-pyridazine-piperazine; (b) 5-6-
5-Imidazole-phenyl-thiazole; (c) Pyrrolopyrimidine. 
 
The continuous efforts of Hamilton and co-workers in the field yielded the trispyridylamide 
scaffold (Figure  1.22a).116, 117 Importantly, the preferred conformation adopted by this template 
is controlled by intramolecular H-bonds between the amide NH proton, the ortho alkoxy 
functionalities and the pyridyl nitrogen. The resulting geometry is almost planar and projects the 
three side chains on the same face of the backbone and in a similar orientation as the i, i+3/4 
and i+7 residues of an α-helix. Moreover, the modular synthetic route to the trispyridylamide 
scaffold permitted the production of small libraries of compounds as inhibitors of the Bcl-
xL/Bak PPI and the islet amyloid polypeptide (IAPP) aggregation.
118, 119
 Since then, other 
groups have designed derived scaffolds where some of the pyridyl monomers were 
substituted by benzene rings, thus increasing the flexibility of the backbone and favouring 
an “induce-fit” interaction. The Fletcher group introduced a series of mixed scaffolds 
mimicking the BH3 sequence (Figure  1.22b),120 which resulted in nM inhibitors of the Bcl-
xL/Bak interaction and induced apoptosis on multiple cell lines.
121
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Figure  1.22 (a) Trispyridylamide scaffold; (b) Trispyridylamide mixed scaffold. 
 
Oligobenzamides 
 
The Wilson group introduced the 3-O-alkylated oligobenzamide scaffold (Figure  1.23a),122 
which presented increased flexibility in the backbone and thus was anticipated to maximise 
interactions with the target protein surfaces. This template has proven effective to generate low 
μM inhibitors against the p53/hDM2, Bcl-xL/Bak, Mcl-1/NOXA B and HIF-1α/p300 
interactions.
123, 124
 The extensive studies performed in this class of analogues resulted in the 
development of a microwave-assisted solid phase synthetic route, which permitted the assembly 
of larger libraries of compounds.
125
 In order to improve the drug-like properties of these 
derivatives, a “wet edge” approach was designed with the introduction of a poly ethylene glycol 
(PEG) chain in one side of the helix mimetic (Figure  1.23b).126 An analogous 2-O-alkylated 
scaffold was also developed (Figure  1.23c), which provided significant structural and 
conformational insight into this class of mimetics.
127, 128
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Figure  1.23 O-alkylated oligobenzamide scaffolds: (a) 3-O-alkylated; (b) 3-O-alkylated with 
“wet edge”; (c) 2-O-alkylated. 
 
In parallel, nitro-acid derivatives of the 3-O-alkylated scaffold were reported by the Ahn
129
 and 
Boger
130
 groups. In particular, Boger and co-workers assembled a large library (>8000 
members), which resulted in low affinity inhibitors of the p53/hDM2 interaction and inhibitors 
with low μM activity against gp41/HIV-1.131 
 
Additionally, the N-alkylated oligobenzamide scaffold (Figure  1.24a) was reported in 2010 by 
Wilson and co-workers as the first helix mimetic family which could be accessed by solid phase 
methodology.  It generated low μM inhibitors of the p53/hDM2 and Mcl-1/NOXA B 
interactions, which have been studied in depth in a biophysical and cellular context.
132-134
 
Recently, the Wilson group reported a hybrid oligobenzamide scaffold (Figure  1.24b), where 
the central building block is replaced by an amino acid residue. This structural change provided 
a significant increase in backbone flexibility, which is envisioned to aid induce-fit recognition. 
This template also benefits from a highly accessible modular synthesis and has provided low 
μM inhibitors of the p53/hDM2 and Mcl-1/NOXA B interactions, which have also proven to be 
active in cells. Importantly, selective molecular recognition determined by the stereochemistry 
of the helix mimetic has been achieved for first time using this scaffold. In addition, quantitative 
structure-activity relationship (QSAR) analyses have also been reported to aid the elucidation of 
the non-covalent contributions in molecular recognition.
135, 136
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Figure  1.24 Other oligobenzamide scaffolds: (a) N-alkylated; (b) Hybrid. 
 
Bifacial scaffolds 
 
The development of scaffolds that can mimic residues located on more than one face of an α-
helix is an important step towards successfully controlling the modulation of biologically 
relevant PPIs. In that context, the Hamilton group designed the pyridylpyridone scaffold 
(Figure  1.25a) to mimic key side chain residues of an α-helical LXXLL (where L is leucine and 
X any amino acid) motif from the co-activator peptide of the ER, which resulted in inhibitors 
with affinities within the low µM range.
137
 Later work focused on modifying the benzoylurea 
scaffold (Figure  1.25b) to achieve bifacial mimicry of the residues at i, i+4, i+8 and i+1, i+6 
positions of an α-helical strand.138 Ahn and co-workers reported a bis-benzamide scaffold to 
create amphiphilic α-helix mimetics with four side chains at i, i+2, i+5, and i+7 positions of a 
helix (Figure  1.25c).139 
 
 
Figure  1.25 Bifacial scaffolds: (a) Pyridylpyridone; (b) Bifacial benzoylurea; (c) Bis-
benzamide. 
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Using a combination of computational design and experimental SAR data, Arora and co-
workers described the oxopiperazine scaffold (Figure  1.26a), identifying sub-µM inhibitors of 
the p53/hDM2 and p300/CREB-binding protein (CPB) interactions.
140
 The Fletcher group 
designed a 1,2-diphenylacetylene scaffold (Figure  1.26b) that mimic the i, i+7 and i+2, i+5 side 
chains on opposite faces of an α-helix, facilitating amphipathic α-helix mimicry.141 The Lim 
group further exploited this approach with the introduction of two-face amphiphilic α-helix 
mimetics based on the triazine-piperazinetriazine scaffold (Figure  1.26c). This class of 
compounds have the potential to generate combinatorial libraries and has already lead to nM 
inhibitors of the Mcl-1/NOXA B and Bcl-xL/Bak interactions.
142
  
 
 
Figure  1.26 Other bifacial scaffolds: (a) Oxopiperazine; (b) 1,2-Diphenylacetylene; (c) 
Triazine-piperazinetriazine. 
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1.4. Project Aims 
 
As illustrated in Chapter 1, the use of small-molecules as PPI modulators is fundamental for 
understanding the mechanisms that govern many diseases as well as to develop new therapeutic 
approaches. Among the wide range of topographies that PPIs display, the α-helix is the most 
common secondary structure in nature and thus represents a good generic template for inhibitor 
design.
1
 The aim of this project was focused on developing a better understanding of the key 
features that play a vital role in modulating protein recognition in order to reproduce the 
functional role of -helices and achieve specificity and selectivity towards different PPIs. 
 
The Wilson group has focused on the inhibition of α-helix mediated PPIs using aromatic 
oligoamide proteomimetics, and most recently constrained peptides, to target different PPIs 
involved in cancer. Building on this previous work, a novel bifacial bis-benzamide scaffold to 
target the ER/co-activator PPI was to be designed and synthesised. Hence, expanding the scope 
of the existing scaffolds and allowing them to target multiple faces of an α-helix mediated PPI. 
 
In addition, the insights of molecular recognition of the recently reported oligobenzmide hybrid 
scaffold were to be further explored using a SAR study in order to achieve more potent and 
selective hybrid compounds against p53/hDM2 and Mcl-1/NOXA B.  
 
Finally, a novel PPI (Asf1/H3) was to be investigated using both stapled peptides and 
proteomimetics to determine advantages and disadvantages of each strategy when applied to the 
same interaction. Moreover, as each class of compound exhibit unique features, both strategies 
could be used to provide a more detailed understanding about the protein-protein interface.  
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Chapter 2. Design, Synthesis and Conformational 
Analyses of Bifacial Benzamide Based Foldamers 
 
The work reported in this chapter formed the basis of the following publication:  
S. Rodriguez-Marin, N. S. Murphy, H. J. Shepherd, A.J. Wilson, RSC Adv., 2015, 5, 104187-
104192.
143
 
 
2.1. Introduction 
 
Most published studies on the development of -helix mimetics to date focus on the design of 
oligobenzamides mimicking the key residues located on one face of the α-helix e.g. at the i, 
i+3/4, i+7/8 positions and so on. However, there are also examples of these scaffolds mimicking 
more than one face, as described in Chapter 1.
139, 144, 145
 In the context of foldamer synthesis and 
structure,
146
 the construction of backbones functionalised with different side-chains on multiple 
faces of the scaffold represents an as yet unrealised approach to achieve control over secondary 
conformation and higher order tertiary/quaternary organisation.  
 
Similarly, there is an obvious need for PPI inhibiting helix mimetics that target more than one 
face of an interaction as shown by Arora and co-workers in their computational analysis of the 
PPIs on the Protein Data Bank (PDB).
5
 This study revealed that helices are present at the 
interface of 62% of known multiprotein complexes, highlighting the importance of α-helices in 
PPIs. Furthermore, within this helical interface subset, 60% interact through residues on a single 
face of the helix, 30% contain hot spot residues on two faces and around 10% require all three 
faces for interaction with the target protein. These results manifest the therapeutic relevance of 
multifaceted helix mimetics to target biological systems e.g. the estrogen receptor (ER) is a 
ligand-activated transcription factor that plays a key role in the development of certain cancers 
and recruits a bifacial helical ligand for co-activation/repression.
147, 148
  
 
2.2. Nuclear hormone receptor superfamily 
 
Nuclear hormone receptors control the development, homeostasis, and metabolism of 
organisms. Their mode of action is based on the functional regulation of their ligands: 
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hormones, such as steroids and thyroids, as well as retinoids and vitamin D. In response to the 
binding with their natural ligands, resulting ligand/receptor dimers undergo structural changes 
that promote interactions with DNA and other molecules, such as cofactors. These interactions 
affect the transcriptional machinery, thereby up- or down-regulating the expression of specific 
genes.
149, 150
 
 
2.2.1.   Estrogen receptor  
 
Estrogen receptor (ER) is a ligand-activated transcription factor that belongs to the nuclear 
hormone receptor superfamily. Its natural ligand is the steroid hormone 17-β-estradiol (E2),151 
and thus it is involved in controlling adolescence and reproductive processes whilst it 
participates in health preservation, such as maintenance of bone density and cholesterol 
levels.
152
 In addition, it has long been implicated in human diseases such as schizophrenia, 
osteoporosis and cancers of the breast, colon and ovarian tissues. In particular, estrogenic 
signalling processes are crucial in the development of breast cancer.
148
 The basis of its 
mechanism involves the binding of a hormone, which initiates changes in the receptor 
conformation and allows the ER to interact with specific DNA binding partners and other 
cellular transcription elements, such as co-regulators (Figure  2.1). These interactions result in 
the activation or repression of target genes.
152
 This receptor was considered as the only ER until 
a second ER was reported by Kuiper et al. in 1996.
153
 These two main groups are known as ERα 
and ERβ and can be detected in a broad spectrum of tissues.  151 
 
 
Figure  2.1 General mode of action of the Estrogen Receptor. 
 
Overall structural features 
 
ERα and ERβ are coded in different genes and are not splice variants. They are formed by six 
structural domains (termed domains A-F) (Figure  2.2). There is a high homology between 
domain C (96%), and domains E/F (53%), whereas domains A, B and hinge D are not that well 
conserved between ERα and ERβ. 
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Figure  2.2 Diagram representing the domain construction of nuclear receptors. The A/B domain 
contains AF-1 site that binds to other transcription factors. The C domain contains the two zinc 
fingers structure that binds to DNA. The E/F domain contains the ligand binding domain and 
the AF-2 site that interacts with peptidic co-activators.
154
 
 
In addition to their structural domains, ERs enclose defined functional domains. An N terminal 
transcriptional activation function (AF-1) domain (NTD) is located in regions A and B. A DNA-
binding domain (DBD) is located in region C and consists of two non-equivalent zinc fingers; 
one is responsible for recognizing the estrogen-responsive element (ERE) and the second 
stabilizes non-specific interactions with DNA segments. Region D is a hinge region and F is a 
variable domain. Region E functions as the ligand binding domain (LBD) and is the basis for 
the second AF domain (AF-2). The majority of co-activators bind the ER at AF-2. This binding 
interaction occurs through short amphipathic α-helix sequences contained in the co-factor 
structure. They contain multiple copies of a signature LXXLL (L = leucine, X = any amino 
acid) motif, also known as nuclear receptor box (NR box). These helical common motifs are 
recognized by a complementary groove formed by four α-helices on the surface of the ER whilst 
a “charge clamp”, involving residues Lys362 and Glu542, stabilizes them. In the co-activator 
helix, the leucine side chains in position i and i+4 are projected into a hydrophobic grove on the 
receptor surface, whereas the leucine side chain at position i+3 is located into an opposite 
hydrophobic pocket. Sequences flanking the core motif LXXLL are also found to be important 
in receptor selectivity (Figure  2.3).148, 151, 152, 155 
A/B C D E F 
AF-1 DNA Ligand AF-2 
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Figure  2.3 Crystal structure of the ER (purple) bound to an LXXLL co-activator motif (red) 
(PDB ID: 2QZO). (a) The co-activator binding grove is shown and the key side chains on the 
helix are highlighted.
156
 (b) The electrostatic interactions between the co-activator and the 
“charge clamp” residues (green) are shown (yellow) and the α-helices forming the binding 
groove are highlighted; the bound estrogen analogue ligand is also shown (orange). 
 
The p160 protein family constitute one of the most relevant family of ER co-activators and 
consists of three members, SRC-1, SRC-2 and SRC-3, all of them containing the common 
LXXLL motif (NR box) in the nuclear receptor interaction domains.
154, 157
 Direct inhibition of 
the receptor/co-activator protein-protein interaction,
137, 158-162
 notably using helix mimetics
137, 161, 
163
 is of potential therapeutic interest as an alternative to the use of competitive inhibitors for the 
ligand binding site.
164
 
 
2.2.2. Androgen receptor 
 
The androgen receptor (AR) is a ligand-dependent transcription factor that belongs to the 
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nuclear hormone receptor superfamily. Its natural ligands are testosterone and 
dihydrotestosterone (DHT) and its main function is the regulation and maintenance of the male 
sexual phenotype. AR has a critical role in prostate cancer development and progression, even 
in the terminal stages of refractory forms of the disease. Ligand binding leads to conformational 
changes in the AR and its translocation from the cytoplasm into the nucleus, where it binds to 
androgen response elements and regulates transcription. This mechanism is analogous to the 
mode of action of the ER (Figure  2.1).147, 165 
 
Overall structural features 
 
AR contains the same structural and functional domains as the other members of the steroid 
hormone receptor family, such as ER (Figure  2.2). In AR, ligand binding induces structural 
modifications that reveal a groove in the AF-2 domain. This region binds short amphipathic 
helical peptides containing the NR box with the common recognition motifs LXXLL and 
FXXFF (L = leucine, F = phenylalanine, X = any amino acid). A distinctive feature of the AR is 
that the interaction can occur either with co-activator proteins (containing the LXXLL or 
FXXFF motifs) or intramolecularly with the FXXLF or WXXLF motifs located in the N-
terminal region of the protein itself. The interaction between the hydrophobic leucine and 
phenylalanine residues from the common helical motif and the AR occur in the same manner as 
in the ER and it also involves the so-called “charge clamp” (residues Lys720 and Glu897) which 
bracket the cleft. Alternatively, AR can interact with the N-terminal motifs via a glutamine-rich 
region rather than the LXXLL NR box motif as in the estrogen receptor.
147
 Nevertheless, the 
interaction of ligand-bound AR with its co-activators is still not fully understood (Figure  2.4). 
147, 166
 
 
 
Figure  2.4 Crystal structure of the AR bound to an FXXFF co-activator motif (PDB ID: 
1T73).
166
 Key side chains on the binding surface of the helix are highlighted. 
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2.3. Design and Synthesis of bifacial proteomimetic scaffolds 
 
In this chapter we introduce two bifacial proteomimetic scaffolds, bis-benzamide and N-(4-
aminophenyl)terephthalamidate (Figure  2.5). The novel foldamers were anticipated as tools to 
(a) enhance our understanding of aromatic oligoamide foldamer conformation and (b) ligands 
that could mimic the key side chains at i, i+3, i+4 positions of -helices that participate in PPIs 
mediated by such a side chain constellation.  
 
The design of these -helix mimetics envisioned the use of the bis-benzamide and N-(4-
aminophenyl)terephthalamidic acid molecules as dimeric backbones which can be 
functionalised at different positions using O-alkylated monomers with the final goal of 
mimicking the key side chains of the co-activator recognition motif LXXLL.  
 
 
Figure  2.5 (a) Bis-benzamide scaffold with the corresponding para-aminobenzoic acid 
constituent building block; (b) N-(4-aminophenyl)terephthalamidic scaffold with the 
corresponding para-phenylenediamine and terephthalate constituent building blocks. 
 
A first generation of bifacial proteomimetic inhibitors, based on the bis-benzamide backbone, 
was synthesised using the work previously developed in the group on the 3-O-alkylated, 2-O-
alkylated and 2,5-O-dialkylated building blocks (Figure  2.5a).122, 126, 127 This work continued the 
synthesis started by a previous member of the group Dr Natasha S. Murphy. Preliminary in 
silico studies performed on modified versions of the bis-benzamide scaffold lead to a second 
generation of inhibitors. The novel scaffold was designed based on a N-(4-
aminophenyl)terephthalamidic acid backbone, where the central amide bond is inverted in 
comparison with the bis-benzamide scaffold. This modification made necessary the 
development of novel synthetic routes to the para-phenylenediamine and terephthalate building 
blocks together with new monomer coupling conditions (Figure  2.5b). 
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2.3.1. Synthesis of the first generation of a bifacial proteomimetic 
scaffold 
 
2.3.1.1. Bis-benzamide monomer building blocks synthesis 
 
The synthesis for the bis-benzamide monomer building blocks used methods previously 
developed in the group (Scheme  2.1).122 Fisher esterification of the commercially available 2.1 
and 2.2 followed by alkylation using isobutyl bromide generated intermediates 2.5 and 2.6 in 
excellent yields. The alkylated products were then either reduced to the amino derivatives 2.9 
and 2.10 using tin (II) chloride or hydrolysed to the acid product 2.7 and 2.8 in basic conditions. 
The synthetic route to the dialkylated building blocks 2.15 and 2.16 added a prior 
dihydroxylation reaction, which follows a procedure described by the Ahn group 
(Scheme  2.1b).139  
 
Scheme  2.1 Synthesis of 3-O, 2-O, 2,5-O alkylated p-aminobenzoic acid monomers for bis-
benzamide derived foldamers. 
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2.3.1.2. Bis-benzamide dimers synthesis  
 
The synthesis of the bis-benzamide dimers followed the same synthetic strategy previously 
developed in the group (Scheme  2.2). The nitro-acid monomers 2.7 and 2.15 were reacted with 
thionyl chloride or Ghosez’s reagent to form the corresponding acyl chloride before coupling 
them with an appropriate aniline partner 2.16, 2.9 or 2.10. Subsequent reduction of the nitro 
compounds 2.17, 2.18, 2.23 and 2.24 to the corresponding amine 2.19, 2.20, 2.25 or 2.26 with 
Pd catalysed hydrogenation followed by basic ester hydrolysis gave the final foldamers 2.21, 
2.22, 2.27 and 2.28.  
 
 
Scheme  2.2 Synthesis of the bis-benzamide foldamers. 
 
The regioisomer of compound 2.21 could not be obtained due to unsuccessful coupling between 
methyl 4-amino-2,5-diisobutoxybenzoate 2.16 and 4-amino-2-isobutoxybenzoic acid 2.8 under 
multiple conditions. The tetrasubstituted scaffold 2.22 was also synthesised to explore the role 
of a 4
th
 side chain in helix mimicry (Figure  2.6). 
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2.3.2. Synthesis of the second generation of a bifacial proteomimetic 
scaffold 
 
A novel second generation scaffold was designed based on a N-(4- 
aminophenyl)terephthalamidic acid backbone. The dimer is formed from a para-
phenylenediamine monomer linked to a terephthalate monomer through an amide bond and the 
backbone can be functionalized at different positions using a variety of O-alkylated monomers 
(Figure  2.7).  
 
 
Figure  2.7 Building blocks for the N-(4- aminophenyl)terephthalamidic scaffold. 
 
2.3.2.1. Disubstituted di-acid and di-amine monomer synthesis 
 
For the disubstituted di-acid monomer, double alkylation of the commercially available diethyl 
2,5-dihydroxyterephthalate 2.29 with isobutyl or benzyl bromide gave access to intermediates 
2.30 and 2.31 containing isobutyl and phenyl side-chains respectively. Subsequent base-
catalysed hydrolysis of the esters provided the final di-acid building blocks 2.32 and 2.33 in 
excellent yields (Scheme  2.3). 
 
Figure  2.6 Bis-benzamide foldamers comprising 3-O, 2-O, 2,5-O alkylated p-aminobenzoic 
acid monomers. 
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The initial synthetic strategy to obtain the disubstituted di-amine building block consisted of 
forming the isocyanate intermediate derived from 2.32, which could then be hydrolysed to the 
desired amine or trapped with alcohols to afford the corresponding carbamate 2.35.
167
 Three 
different rearrangement reactions were investigated (Scheme  2.4): 
 
Hofmann rearrangement:
168
 The acyl chloride intermediate 2.38, resulting from the reaction of 
2.32 with thionyl chloride, was reacted without further purification with an aqueous ammonia 
solution to afford the desired primary carboxamide 2.39 in excellent yield. Subsequent 
conversion into the corresponding carbamates 2.35 was attempted using N-bromosuccinimide 
(NBS) as a bromine source and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) as a base, either 
under reflux or microwave conditions. Unfortunately, formation of the expected product 2.35 
was not observed.  
 
Lossen rearrengement:
169
 Compound 2.32 was reacted with 1,1'-carbonyldiimidazole (CDI) and 
hydroxylammonium hydrochloride to afford the desired hydroxamic acid 2.37 in moderate 
yield. The rearrangement into its corresponding carbamate 2.35 was attempted using 1,1'-
carbonyldiimidazole (CDI) and tert-butanol under reflux. Unfortunately, formation of the 
expected product 2.35 was not observed. 
 
Curtius rearrengement:
170
 Monomer 2.32 was reacted with diphenylphosphoryl azide (DPPA) 
under basic conditions to afford the desired di-isocyanate 2.34 in moderate yield. Surprisingly, 
the acyl azide intermediate 2.36 was not isolated as expected, which suggests that it 
decomposed at low temperature (ca. 30 C). Low temperature Curtius rearrangements are 
unusual; however, some examples are described in the literature.
171, 172
 The di-isocyanate 2.34 
was treated with tert-butanol in toluene affording the corresponding carbamate 2.35 in good 
yield. The corresponding unprotected di-amine building block was found to be unstable upon 
exposure to air and/or aqueous media, possibly due to polymerization and oxidation 
processes.
173
  
Scheme  2.3 Synthesis of disubstituted di-acid and di-amine monomers for N-(4-
aminophenyl)terephthalamidic derived foldamers. 
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Scheme  2.4 Synthetic routes investigated from monomer 2.32 to 2.35. Different types of 
rearrengment reactions are highlighted. 
 
2.3.2.2. Monosubstituted di-amine monomer synthesis 
 
A noteworthy feature of the monosubstituted di-amine monomer synthesis is the use of the 
common starting material 2.40 to construct two different classes of building blocks: compounds 
2.41 and 2.42; and compounds 2.45 and 2.46, which are suitable for the assembly of 
regioisomeric foldamers (Scheme  2.5). Alkylation of the commercially available compound 
2.40 with isobutyl or benzyl bromide provided monomers 2.41 and 2.42 respectively. 
Subsequent Fmoc protection of the amino group followed by the reduction of the nitro group to 
the corresponding amine with tin (II) chloride gave access to the regioisomers 2.45 and 2.46. 
 
 
Scheme  2.5 Synthesis of monosubstituted di-amine monomers for N-(4-
aminophenyl)terephthalamidic derived foldamers. 
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2.3.2.3. Monosubstituted di-acid monomer synthesis 
 
For the synthesis of monosubstituted alkoxy derivatives of 2-hydroxyterephthalic acid 2.47 
(Scheme  2.6), double Fisher esterification followed by alkylation gave intermediate 2.49 in high 
yield. It was then necessary to perform a sequence of protecting group manipulations; selective 
hydrolysis of the most electron-deficient ethyl ester in compound 2.49 yielded the 
monosubstituted di-acid building block 2.50. Subsequent tert-butyl esterification of the free 
carboxylic acid lead to compound 2.51. 
 
 
Scheme  2.6 Synthesis of monosubstituted di-acid monomers for N-(4-
aminophenyl)terephthalamidic derived foldamers. 
 
2.3.2.4. N-(4- aminophenyl)terephthalamidic dimer synthesis  
 
To effect amide bond formation, the acyl chloride of the di-acid monomer 2.32 and 2.33 was 
obtained using thionyl chloride before coupling to its amino-monomer partners 2.45, 2.46 and 
2.41 (Scheme  2.7c and d). By using an excess of the di-acid 2.32 and 2.33 it was possible to 
bias the product distribution towards the monoamide. The final products 2.56, 2.54 and 2.55 
were obtained by hydrogentation of the nitro group or hydrolysis of the Fmoc group 
respectively.  
 
Due to the oxidation upon exposure to air as mentioned above, the di-amine derivative of 
compound 2.35 was obtained through in situ Boc deprotection and direct reaction with the acid 
chloride derivative of 2.50, which was obtained by in situ activation using Ghosez’s reagent 
(Scheme  2.7a). Alternatively, the ethyl ester of compound 2.51 was selectively hydrolysed in 
basic conditions and directly transformed to the acid chloride by in situ activation using 
Ghosez’s reagent before coupling to the di-amine derivative of compound 2.35 (Scheme  2.7b). 
Again, the monoamide product was biased by using the starting di-amine 2.35 in excess. The 
final compounds 2.52 and 2.53 were obtained after appropriate deprotection sequences 
(Scheme  2.7a and b) either basic or acid hydrolysis, respectively.  
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Despite numerous efforts, we were unable to obtain the dimer derived from 2.42 and 2.33. The 
amide formation was performed successfully; however, the following reduction step to 
transform the nitro to the amino group was ineffective and cleavage of the side chains was 
observed under forcing conditions, such as high temperatures and long reaction times. The 
synthetic route for the tetrasubstituted foldamer derived from 2.32 and 2.35 was proven 
successful following the above described methodology. Unfortunately, the dimer was unstable 
upon air exposure and could not be isolated. 
 
 
Scheme  2.7 Synthesis of N-(4-aminophenyl)terephthalamidic foldamers. 
  
40 
2.4. Conformational analyses 
 
2.4.1. 2D NMR studies 
 
Previous studies performed in the group on 2- and 3-O-alkylated trimers and model dimers on 
the oligobenzamide scaffold revealed intramolecular pseudo-six- or five-membered rings 
hydrogen bonding between the NH and adjacent O-alkyl group (Figure  2.8).127, 128 This resulted 
in restricted rotation around one of the Ar-CO or Ar-NH bonds leaving the other free to rotate. 
The conformation of such scaffolds can be further restricted by introduction of a second alkoxy 
group leading to a “bifurcated” hydrogen bonding interaction, where the NH is located between 
two phenolic oxygens from adjacent monomers forming pseudo-six- and five-membered 
rings.
126, 174, 175
 
 
In principle, the set of compounds discussed here can display a similar array of conformations 
as those described above. Therefore, structural and conformational analyses were performed on 
each compound using NMR spectroscopy. In particular, 
1
H-
1
H NOESY analyses were used to 
determine their preferred conformation in solution by identifying the interactions of the dimer 
amide NH with the adjacent aromatic protons. 
 
Compounds 2.21 and 2.52 formed pseudo five-membered hydrogen bonded rings, whilst 
compounds 2.28, 2.54 and 2.55 formed pseudo six-membered hydrogen bonded rings, as 
expected in each case, as the NH could only form a single type of intramolecular hydrogen 
bond. A representative example is shown in Figure  2.9 for compound 2.21. The amide NH 
displays nOe correlations with the adjacent aromatic protons 1-H2 and 1-H6 suggesting free 
rotation around the Ar-CO axis, whereas absence of cross peaks with the aromatic proton 2-H3 
indicated that rotation was constrained around the Ar-NH axis. Thus, confirming that the amide 
proton was locked in an S(5) intramolecular H-bonded ring. 
Figure  2.8 Illustration of the types of intramolecular hydrogen bonding interactions on the 
oligobenzamide scaffold. 
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Figure  2.9 
1
H-
1
H NOESY (500 MHz, CDCl3) spectra of dimer 2.21 at 5 mM. Structures and 
1
H 
proton assignments are shown and relevant nOe signals are highlighted. 
 
More interestingly, compounds 2.27, 2.22, 2.53, 2.56 could potentially display either isolated 
S(5) and S(6) or “bifurcated” S(5)/S(6) hydrogen bonding systems. Compound 2.27 was 
indicative of both pseudo-five- and six-membered hydrogen-bonded rings being populated in 
solution. The absence of nOe correlations between the amide and the adjacent aromatic protons 
1-H6 and 2-H3 suggested that rotation was constrained around both the Ar-CO and Ar-NH axes 
(Figure  2.10a). An X-ray crystal structure of compound 2.27 previously obtained by Dr 
Natasha. S. Murphy support this result with NH to O distances of 2.007 and 2.223 Å for the 
S(6) and S(5) H-bonded rings respectively (Figure  2.10b).143 
 
Figure  2.10 (a) 
1
H-
1
H NOESY (500 MHz, CDCl3) spectra of dimer 2.27 at 5 mM. Structures 
and 
1
H proton assignments are shown and relevant nOe signals are highlighted; (b) X-ray 
structure of 2.27, H-bonding distances (Å) are shown in red. 
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Intriguingly, compounds 2.22, 2.53 and 2.56 showed evidence of only pseudo-six-membered 
intramolecular hydrogen bonded ring formation in solution. A representative example is shown 
in Figure  2.11 for compound 2.56. The amide displays nOe correlations with the adjacent 
aromatic proton 1-H6 suggesting free rotation around the Ar-NH axis, whereas absence of cross 
peaks with the aromatic proton 2-H6 and nOe signals with the side chain proton 2-Hα proposed 
that rotation was constrained around the Ar-CO axis. Thus, confirming that the amide proton 
was locked into an S(6) intramolecular H-bonded ring. 
 
Figure  2.11 
1
H-
1
H NOESY (500 MHz, CDCl3) spectra of dimer 2.56 at 5 mM. Structures and 
1
H proton assignments are shown and relevant nOe signals are highlighted. 
 
Initially, DMSO was chosen as an appropriate solvent model for comparison with the aqueous 
media in biological systems. Unfortunately, the complete conformational analysis of the 
compounds in DMSO proved problematical due to indistinguishable peaks and weak signals. 
Nevertheless, the results that were obtained in DMSO were comparable to those obtained in 
CDCl3. 
 
 
2.4.2. H/D Exchange studies 
 
H/D exchange studies were performed to further characterise the hydrogen bonding interactions 
involved in controlling the conformation of our set of compounds. It is worth noting that the 
relative rates of this exchange depend on different factors, such as the acidity of the NH proton, 
which will be affected by its electronic environment; the steric accessibility of the NH group 
and the strength of the hydrogen bonding. The H atoms are anticipated to exchange more 
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rapidly the more acidic they are, the less steric hindrance they present and the weaker hydrogen 
bonds they form.
176
 Nevertheless, the correlation of the rate of exchange with the strength of the 
hydrogen bonding can be used to obtain additional information about these interactions.  
 
The H/D exchange experiments were performed on compounds 2.27, 2.21 and 2.56, as models 
of the three different types of hydrogen bonding interactions. A 10% CD3OD/CDCl3 system was 
used to ensure pseudo first order kinetics. A distinct non-exchanging signal was used as an 
internal integration reference in order to minimize variability. The rate constant was determined 
from the slope of a non-linear least squares fit to the graph following Equation 1 and the half-
life of the H/D exchange determined using Equation 2. 
 
 
 
 
 
 
 
The resulting graph is shown in Figure  2.12. The extracted kH/D and t½ values for compounds 
2.27, 2.21 and 2.56 are listed in Table  2.1, together with the values for two other previously 
reported compounds 2.57 and 2.58 from our group for comparison (Figure  2.13).
127, 128
 The 
order of magnitude for the amide proton exchange rate constants suggest the presence of a S(5), 
S(6) and bifurcated S(5)/S(6) H-bonding for compounds 2.21, 2.56 and 2.27 respectively. These 
values are consistent with previous studies
128
 and propose a (S)6 hydrogen bond with greater 
stability than its (S)5 analogue, the stabilization is even higher in the “bifurcated” S(6)/S(5) 
system. Importantly, these results are in agreement with the proposed conformations from the 
1
H-
1
H NOESY analyses (See section  2.4.1).  
Equation 1      At = Ao e
-kt
  At : Integral of amide proton at time t  
     Ao : Integral of amide proton at time zero (fixed at 1) 
     k  : reaction rate coeficient 
Equation 2      𝑡½ =  
ln 2
𝑘
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Figure  2.12 H/D exchange kinetics of compounds 2.27, 2.21 and 2.56 at 10 mM in 10% 
CD3OD/CDCl3. 
Table  2.1 Kinetic constants and t1/2 based on H/D exchange in 10% CD3OD/CDCl3. 
 kH/D (min
-1
) t½ (min) H bonding 
2.56 0.00305 ± 0.00005 228 ± 3 S(6) 
2.27 6.7857 x 10
-4
 ± 0.0000093 1021.5 ± 14 S(5)/S(6) 
2.21 0.01485 ± 0.00017 46.7 ± 0.5 S(5) 
2.57 (1-NH) 0.00176 ± 0.00005 394 ± 12 S(6) 
2.57 (2-NH) 0.00230 ± 0.00005 301 ± 6 S(6) 
2.58 (1-NH) 0.0212 ± 0.0004 32.7 ± 0.6 S(5) 
2.58 (2-NH) 0.0225 ± 0.0005 30.8 ± 0.7 S(5) 
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Figure  2.13 Reported reference compounds 2.57 and 2.58, intramolecular hydrogen bonding 
interactions are shown.
127, 128
 
 
 
2.5. Molecular modelling  
 
A conformational search was performed on the entire set of compounds. The structure was 
minimised performing a full Monte Carlo search with the MMFFs method and using the 
software Macromodel
®
.
177
 Water was chosen as implicit solvent and free rotation around the 
amide bonds was allowed in order to increase the accuracy of the conformational search. All the 
conformations within 1.5 kJ/mol of the lowest energy conformation were selected for further 
analysis. In the lowest energy conformation all the compounds adopt an extended structure, 
where the amide bond is trans. Importantly, the conformations for each compound are 
consistent with those that are accessible in solution phase according to the NOESY data and 
H/D exchange experiments (Figure  2.14).  
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Figure  2.14 Preferred conformation and intramolecular hydrogen-bonding interactions of the 
compounds 2.21, 2.27, 2.28 and 2.52 to 2.56 supported by molecular modelling, 2D NMR 
studies and H/D exchange experiments. Distances and angles between side chains (green and 
black respectively), H-bonds (dashed black line) and free rotation axes (red arrow) are shown. 
 
 
The nature of the structure permits the superimposition in both parallel and antiparallel N-to-C 
orientation with respect to an α-helical peptide.125 Accordingly, both alignments were analysed 
using an ERα co-activator sequence (PDB ID: 2QZO). The match was assessed on the basis of 
the RMSD between α-carbons on the helix and oxygen atoms on the foldamer together with an 
evaluation on the quality of the backbone orientation with respect to the helical axis of the 
peptide.  
 
The overlay of the first generation of foldamers with the native co-activator peptide is shown in 
Figure  2.15. Compounds 2.21, 2.27 and 2.28 present a good overlay, where the three side chains 
overlap reasonably well with the leucine residues at positions i, i+3 and i+4 of the co-activator 
helix and the distances between the oxygens of the dimers match the distance between the α-CH 
of these residues. 
 
  
47 
 
 
The overlay of the second generation of foldamers with the native co-activator peptide is shown 
in Figure  2.16. Compounds 2.52 and 2.54 present a good overlay, where the three side chains 
overlap reasonably well with the leucine residues at positions i, i+3 and i+4 of the co-activator 
helix and the distances between the oxygens of the dimers match the distance between the α-CH 
of these residues. Compounds 2.53 and 2.56, matched less well in terms of alignment with the 
helical backbone. 
 
 
Figure  2.15 Overlay of the first generation of foldamers with the native co-activator peptide. 
Co-activator residues are in dark colours and helix mimetic residues are in light colours. Parallel 
(right) and antiparallel (left) alignment with the peptide dipole moment are shown (RMSD 
values are given for both alignments and the best alignment shown in a box): (a) compound 
2.27; (b) compound 2.21; (c) compound 2.28. 
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The results of the molecular modelling analyses for the full set of helix mimetic analogues are 
summarised in Table  2.2. The best alignment with the native helical peptide and the 
corresponding RMSD value are shown for each compound. It is worth noting that in some cases 
the aligment (parallel or antiparallel) with the lowest RMSD value was not chosen as the best 
overlay, as the backbone of the compounds did not match the helical axis of the peptide. 
Figure  2.16 Overlay of the second generation of foldamers with the native co-activator peptide. 
Co-activator residues are in dark colours and helix mimetic residues are in light colours. Parallel 
(right) and antiparallel (left) alignment with the peptide dipole moment are shown (RMSD 
values are given for both alignments and the best alignment shown in a box): (a) compound 
2.52; (b) compound 2.53; (c) compound 2.56; (d) compound 2.54. 
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Table  2.2 Summary of Molecular Modelling Analyses 
 alignment
a 
RMSD 
2.27 Antiparallel 1.322 
2.21 Parallel 1.625 
2.28 Antiparallel 2.084 
2.52 Antiparallel 1.038 
2.53 no good alignment 1.622 
2.56 no good alignment 1.027 
2.54 Parallel 2.046 
 
a 
where N and C termini of the benzamide and helix match, they are defined as being parallel 
and where they oppose, they are defined as being antiparallel. 
 
2.6. Docking studies 
 
To ascertain the extent to which the set of foldamers might act as ERα/co-activator inhibitors, 
the lowest energy conformations within 1.5 kJ/mol of each compound were docked with the 
crystal structure of ERα (PDB ID: 2QZO) using the software Glide®. The results from the 
docking analyses reveal binding poses that display favourable interaction of all the foldamers 
2.21, 2.27, 2.28 and 2.52 to 2.56  with the co-activator binding groove. Shown in Figure  2.17a is 
a good pose for 2.52; the three hydrophobic side chains of the foldamer occupy the hydrophobic 
space normally occupied by the co-activator peptide as shown in Figure  2.17b. 
 
 
Figure  2.17 (a) Proposed binding mode of compound 2.52 in the ER co-activator binding 
groove (b) Native co-activator helix in the ER co-activator binding cleft. 
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Furthermore, the docking studies also show electrostatic interactions for both termini of the 
foldamer with the ER surface residues; however, in most cases only one of these involves the 
precise “charge clamp” residues from ER exploited by co-activator ligands (Figure  2.18a). A 
representative example is shown in Figure  2.18b, where the terminal carboxylic acid and aniline 
groups of dimer 2.52 are suitably positioned to form electrostatic interactions in the region of 
the “charge clamp”. In particular, these interactions occur between i) the N terminus of the 
foldamer and the Glu
542
 from the ER native “charge clamp”; and ii) the C terminus of the 
foldamer and the Lys
362
 from the ER native “charge clamp”, or the Gln372, which is a 
neighbouring residue. This behaviour is reproduced for the other compounds. 
 
 
Figure  2.18 (a) Proposed hydrogen bonding interactions between compound 2.52 and ER 
“charge clamp” residues (b) Hydrogen bonding interactions between the native co-activator and 
ER “charge clamp” residues.  
 
2.7. Biophysical assays 
 
To perform a preliminary assessment of the ability of our set of helix mimetics to act as PPI 
inhibitors, we carried out fluorescence polarization competition assays against three nuclear 
receptor/co-activator interactions (ERα/SrcBox2, ERβ/Src1B2 and RXRα/D22) in the 
laboratory of Prof. Luc Brunsveld (Technische Universiteit Eindhoven). Brundsveld and co 
workers
161
 recently reported a family of molecules with potential to change their activity as 
agonist and/or antagonist over small chemical modifications, thus generating opposite effects in 
the receptor biological functions. Accordingly, our set of proteomimetic compounds were 
screened in agonistic (binding at the ligand binding pocket) and antagonistic mode (binding at 
the coactivator binding grove) as shown in Figure  2.19. Unfortunately, our compounds were not 
sufficiently potent to show a significant effect in these assays. 
 
  
51 
 
Figure  2.19 Mode of action of the Nuclear Receptor (NR) agonist dependent coactivator 
peptide recruitment assay.  
 
2.8. Summary and future work 
 
In summary, the design and syntheses of two new bifacial proteomimetic scaffolds based on bis-
benzamide and N-(4-aminophenyl)terephthalamidic backbones have been described. A 
complete structural analysis in combination with in silico studies revealed that different 
combinations of monomers leads to a plethora of side chain spatial relationships, which 
effectively mimic the intended side-chains on an α-helix. Significant conformational knowledge 
has been gained and added to the already existing data on aromatic oligoamide foldamers. 
Unfortunately, preliminary evaluation of the new scaffolds against nuclear receptor/co-activator 
interactions was not able to show binding of our helix mimetics to the protein surface, 
highlighting the complex relationship between helix mimetic conformation and molecular 
recognition. Taking into account the flexible nature of the coactivator binding grove in the ER 
surface, we hypothesise that the rigidity of our scaffolds, introduced by the discussed 
intramolecular H-bonding (See section 2.4), might be unfavourable for the interaction and final 
binding to the protein surface. 
 
To study this hypothesis, future work will focus on the assessment of more flexible compounds 
containing just two side chains and without intramolecular H-bonding constraints. In addition, 
to increase the binding of our proteomimetics to the protein targets, polar groups (i.e. alkyl 
amines or alkyl carboxylic acids) will be introduced at the N and/or C terminus of the scaffold 
to enhance the electrostatic interactions with the residues of the ER “charged clamp”. Finally, 
the synthesis of libraries bearing different side-chain arrays will be required in order to exploit 
the potential of the scaffold to target other PPIs containing essential residues in more than one 
face of an α-helix. 
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Chapter 3. Optimization of the hybrid oligoamide 
proteomimetic scaffold 
3.1. Introduction 
 
The design and synthesis of proteomimetic scaffolds that target PPIs with high potencies and 
are amenable to library assembly has advanced significantly in the last few years.
125, 142
 
However, the next main breakthrough in the field seems to be pointing towards molecules with 
enhanced pharmacokinetic properties and that permit greater control over target selectivity. 
Commonly, structural constraints involving covalent or non-covalent interactions have been 
introduced in the proteomimetic scaffold backbone in order to reproduce the topography of the 
“hot spot” residues from the native -helix and thus favour bioactive conformations. However, 
many studies to date have underlined the complex relationships between molecular rigidity, 
target plasticity and activity, which all participate in surface recognition processes.
8, 70
 
 
In that context, the Wilson group recently reported the design and synthesis of a hybrid 
oligobenzamide -helix mimetic formed by a combination of previously reported aryl building 
blocks and natural amino acids.
135
 This scaffold is capable of reproducing the side chains at i, 
i+4 and i+7 positions of an α-helix and shows high functional group tolerance combined with a 
simple synthetic route. In particular, the scaffold was based on modifications of the O-alkylated 
oligobenzamide previously reported by the group (Figure  3.1). In this case the structural rigidity 
of the oligobenzamide backbone
127
 was broken through substitution of the central aryl-unit with 
an -amino acid residue.  
 
Figure  3.1 Design of the hybrid oligobenzamide -helix mimetic by modification of the 3-O-
alkylated oligobenzamide scaffold. 
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This modification generated a different intramolecular hydrogen bonding arrangement with 
hydrogen bonds at the top and bottom of the sequence, which maintain the potential to adopt 
well-defined conformations. Importantly, the irregular nature of the backbone increased the 
degree of flexibility and gave access to a wider conformational space, thus perhaps facilitating 
an induce-fit type of interaction with the target protein. This fact was illustrated by early studies 
where the energy of the different scaffold structures 3.1 and 3.2 was minimised in Macromodel 
and the conformers within 1.5 kJ/mol were superimposed without further manipulation 
(Figure  3.2). These simulations also highlighted the increased conformational plasticity of the 
new hybrid scaffold over the original 3-O-alkylated oligobenzamide scaffold.
135
 Importantly, 
previous work also discovered that switching the side chain of the bottom aryl unit from the 3-O 
position to the 2-O position, as in compound 3.2, increases the binding affinity of the scaffold to 
the target proteins, in most cases.
135, 136
 Therefore, all the work of this chapter focusses on 
hybrid compounds incorporating these modifications. 
 
Figure  3.2 Illustrations of the accessible conformational space (shown as a shaded 3D object) 
highlighting the orientation of the side-chains
135
 (shown in CPK format): (a) Structure of the 3-
O-alkylated trimer model 3.1 and corresponding side (top) and top (bottom) view; (b) Structure 
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of the hybrid trimer model 3.2 and corresponding side (top) and top (bottom) view. Energy 
minimisation by Macromodel and superimposition of the conformers within 1.5 kJ/mol. 
 
Furthermore, SAR
136
 studies identified M inhibitors of the p53/hDM2 and Mcl-1/NOXA B 
interactions, which are highly involved in cancer development. Nevertheless, the most 
important feature displayed by the hybrid oligobenzamide -helix mimetic was the 
unprecedented stereodependent selectivity imported by the chiral nature of the scaffolds. In 
particular, the substitution of the central L-amino acid by its D-enantiomer switched the 
selectivity of the scaffold from hDM2 only to both hDM2 and Mcl-1 proteins. This attribute 
permitted the synthesis of chiral structures that can be tuned to achieve enantioselective 
recognition by the protein partner.  
 
 
3.2. Interactions of interest 
 
3.2.1. p53/hDM2-hDMX 
 
The p53 tumour suppressor stimulates the intrinsic apoptosis pathway, in response to severe 
cellular stresses, such as DNA damage or hypoxia. Therefore, its activity is vital for the 
maintenance of the genomic integrity of the cell. Inactivation of p53 occurs due to mutations in 
over half of all cancer cases; whilst in most of the remaining cases it is mediated by genomic 
amplification of the hDM2 oncoprotein (Figure  3.3). In normal cells, hDM2 down-regulates 
p53, which modulates its growth-suppressing activity. Alternatively, when DNA is damaged, 
p53 levels increase and activate the expression of hDM2. The hDM2 protein can, in turn, bind 
to the transactivation domain of p53 and inhibit further activity of p53 as a transcription factor. 
In tumours, gene amplification and other processes can lead to hDM2 amplification and 
consequently p53 inhibition.
14, 178
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Figure  3.3 Diagram of the apoptotic pathway regulated by p53 in normal and tumor cells. 
 
Overall structural features 
 
The interacting region of mDM2 (hDM2 homolog protein from mouse) consists of a structural 
domain located in its N-terminal part. Alternatively, the p53 recognition motif involves a short, 
linear sequence of 11 amino acids (residues 17 to 27), which comprises one of the conserved 
regions of p53 and contains sequences responsible for transactivation (Figure  3.4).178 
 
The mDM2 domain is divided in two structurally similar parts with low sequence similarity. 
The two halves form a small globular structure with a hydrophobic core. When the two repeats 
are joined across their hydrophobic side, they form a cleft at their interface. The cleft is about 25 
Å long, 10 Å wide near the surface but narrowing toward the bottom, and up to 10 Å deep. It is 
asymmetric and is composed of two helices forming the sides, two short helices making the 
bottom and a pair of three-stranded β-sheets capping each end. The p53 peptide forms an 
amphipathic α-helix of about 2.5 turns, which is followed by an extended region of three 
residues. The α-helix has a hydrophobic face formed by three hydrophobic key amino acids 
(Phe
19
, Trp
23
, Leu
26
), at i, i+4 and i+7 positions, that interact with the protein cleft through a 
sequence of van der Waals contacts.
178
 
 
The p53/mDM2 interface has an area of 1498 Å
2
 and is mostly hydrophobic in nature. The 
position of the p53 helix allows Phe
19
, Trp
23
 and Leu
26
 residues to sit deep inside the mDM2 
cleft in a complementary fashion. The van der Waals contacts at the interface are augmented 
only by two intermolecular hydrogen bonds. One occurs between the Phe
19
 backbone amide of 
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p53 and the Gln
72
 side chain of mDM2 at the entrance of the cleft; the second is between the 
p53 Trp
23
 indole group and the mDM2 Leu
54
 carbonyl, deep inside the cleft.
178
 
 
Figure  3.4 Crystal structure of p53/mDM2 PPI (PDB ID: 1YCR). Key side chains on the 
binding surface of the helix are highlighted. 
 
3.2.2. Bcl-2 family 
 
The members of the B-cell lymphoma 2 (Bcl-2) family play a central role as regulators of 
apoptotic cell death, in response to a wide variety of stimuli (Figure  3.5). These molecules can 
be combined with themselves or other family members to form homo-dimers and hetero-dimers, 
and produce several pro-apoptotic and/or anti-apoptotic entities. For example, Bcl-2, Bcl-xL and 
Mcl-1 inhibit programmed cell death, and Bak and Bax (Bcl-2 homologous antagonist killers) 
can promote apoptosis.
179
 Consistently, members that inhibit apoptosis are over expressed in 
many cancers and contribute to tumour initiation, progression and resistance to therapy.
62
 
 
Figure  3.5 Diagram of the apoptotic pathway regulated by Bcl-2 family members in the 
mitochondria in normal and tumor cells. 
  
57 
Overall structural features 
 
All the Bcl-2 family members are formed by up to four conserved Bcl-2 homology (BH) 
domains, all of which include α-helical segments ( Table  3.1). Anti-apoptotic proteins exhibit 
conservation of the sequence in all BH domains. Conversely, pro-apoptotic proteins are divided 
into multi-domain members that are formed by the BH1, BH2 and BH3 domains, such as Bax 
and Bak; and BH3-only members, such as Bid and Bad. There is a common region in the BH3 
α-helical domain, which binds to the hydrophobic groove formed by the structural connection of 
BH1, BH2 and BH3 domains of anti-apoptotic multidomain members. This common helical 
segment is necessary for the promotion of cell death.
46
  
 
 
 Table  3.1 Members of the Bcl-2 family
180, 181
 
Multidomain 
Anti-apoptotic proteins 
Multidomain 
Pro-apoptotic proteins 
BH3-only 
Pro-apoptotic proteins 
Bcl-2 Bak BID 
Bcl-xL Bax BIM 
Mcl-1  NOXA B 
Bcl-w  PUMA 
  BAD 
 
 
The structural insights of the recognition process between these protein families were first 
reported by Fesik and co-workers with the structure of the Bcl-xL/Bak peptide complex 
(Figure  3.6).179 The structure of the Bcl-xL protein consists of two central hydrophobic α-helices 
surrounded by five amphipathic helices. The Bak peptide binds in a hydrophobic cleft formed 
by the BH1, BH2 and BH3 domains of Bcl-xL, where the N-terminal residues interact with the 
BH1 region, whereas the C-terminal end interacts mostly with the BH2 and BH3 domains. In 
the Bak helix, the hydrophobic face is projected into the hydrophobic cleft, stabilizing the 
complex, whilst the charged side chains are close to oppositely charged residues of the Bcl-xL 
protein.
179
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Figure  3.6 Crystal structure of Bcl-xL/Bak PPI (PDB ID: 1BXL). Key side chains on the 
binding surface of the helix are highlighted. 
 
Another member of the Bcl-2 family is Mcl-1, which has a central and non-redundant role in the 
maintenance of progenitor and stem cells (Figure  3.7). Its overexpression has been related to the 
development of a variety of resistant cancers, including multiple myeloma, acute myeloid 
leukemia, melanoma and poor-prognosis breast cancer.
34
 Mcl-1 is neutralized by the BH3-only 
proteins NOXA, Puma, Bim and Bak.
34, 63
 Certain residues within the Mcl-1 protein sequence 
are determinant for its binding activity; the conserved amino acids Leu
213
, Arg
214
, Gly
217
 and 
Asp
218
, which are shared among many BH3 domains, and the discrete residue Val
220
, which is 
responsible for the selectivity (Fig. 10).
63
 
 
Figure  3.7 Crystal structure of Mcl-1/NOXA B PPI (PDB ID: 2JM6). Key side chains on the 
binding surface of the helix are highlighted. 
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3.3. Description of the scaffold 
 
The results obtained using the hybrid oligobenzamide -helix mimetic represented a good 
starting point to further investigate the rules that govern molecular recognition and work into 
establishing guidelines for the synthesis of functional proteomimetics. Therefore, in this chapter 
an attempt to further study and optimize the hybrid oligobenzamide scaffold towards more 
potent and selective inhibitors of PPIs is presented.  
 
In particular, compound 3.3 (Figure  3.8) was chosen as initial template for the optimization 
process for the following reasons: 
- It was one of the most potent analogues of the family against p53/hDM2 with an IC50 of 
11.9 M. 
- It was selective for hDM2 over Mcl-1 (IC50 >100 M). 
- Selectivity for Mcl-1 could be tuned by changing the stereochemistry of the central aa: 
L- (IC50 >100 M) compound 3.3, whilst D- (IC50 27.1 M) compound 3.4. 
- It was formed using some of the most accessible building blocks.  
 
 
Figure  3.8 Structures and inhibitory activity against p53/hDM2 and Mcl-1/NOXA B of hybrids 
3.3 (L-Phe) and 3.4 (D-Phe). 
Subsequently, five modification sites (Figure  3.9) were selected to introduce a series of 
chemical changes into the structure: the N terminus, the top  bottom aryl building blocks, the 
central amino acid, and the C terminal amino acid. Each manipulation was selected to change 
the size, shape, flexibility and/or solubility of the compounds, which should lead to a better 
understanding of the SAR of these molecules.  
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Figure  3.9 Scaffold optimization process schematics. Modification sites of compound 3.3 are 
highlighted. 
 
3.4. Synthesis of the hybrid  -helix mimetic scaffold 
 
The synthesis of the hybrid -helix mimetic scaffold was based on an Fmoc (9-
fluorenylmethyloxycarbonyl) solid phase peptide synthesis (SPPS) strategy to enable library 
generation and reduce the preparation time.
135
 
 
3.4.1. Monomer synthesis 
 
The synthesis of the 2-O-alkylated and the 3-O-alkylated Fmoc-protected monomers followed a 
synthetic route previously described by the group (Scheme  3.1).125, 127 It consisted of an initial 
alkylation step, followed by reduction of the nitro to the amino group. Subsequent hydrolysis of 
the ester and final Fmoc-protection produced the monomers in good yields.  
 
 
Scheme  3.1 Synthetic route to 2-O and 3-O Fmoc-protected building blocks 
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3.4.2. General synthetic scheme for oligomers 
 
The hybrid -helix mimetics were synthesised using an adapted version of the microwave-
assisted automated SPPS (Scheme  3.2) originally developed by Dr V. Azzarito.135 It consisted 
of a series of deprotection and coupling steps, using Fmoc-aa- (where aa can be any amino acid) 
preloaded Wang resins as solid support and HATU as a coupling reagent for the protected 
monomers.  
 
 
Scheme  3.2 Solid phase synthetic route for the hybrid -helix mimetics. 
 
3.4.3. Side chain diversification 
 
The methodology described above (Scheme 3.2) was used to synthesise a library of hybrid 
compounds (3.27 to 3.48). The design behind the multitude of modifications that were 
introduced is detailed in the following sections 3.4.3.1 to 3.4.3.5. 
3.4.3.1. Modification of the top aryl unit 
 
The benzyl substituent of compound 3.3 mimicked the original phenylalanine residue from the 
p53 -helix. The modifications incorporated here (Table  3.2, Figure  3.10) mainly focused on 
studying the effect of:  
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- para- substituted phenyl rings to improve interactions with the Phe hydrophobic 
binding pocket, compounds 3.27 to 3.29. 
- Extended aromatic ring systems to improve interactions with the Phe hydrophobic 
binding pocket, compound 3.30. 
- Aliphatic side chains to investigate the effect of different hydrophobic groups, 
compounds 3.31 to 3.33. 
 
Table  3.2 Library of hybrid -helix mimetics with modifications on the top aryl unit illustrating 
side-chain sequence. 
Hybrid R1 aa R3 resin 
3.27 3-O-p-Cl-Bn L-Phe 2-O-iPr Gly 
3.28 3-O-p-CF3-Bn L-Phe 2-O-iPr Gly 
3.29 3-O-p-tBu-Bn L-Phe 2-O-iPr Gly 
3.30 3-O-2-Nph L-Phe 2-O-iPr Gly 
3.31 3-O-sBu L-Phe 2-O-iPr Gly 
3.32 3-O-(MeS-3-Pr) L-Phe 2-O-iPr Gly 
3.33 3-O-Methylcyclopropane L-Phe 2-O-iPr Gly 
 
 
Figure  3.10 Side chains incorporated in the top aryl unit of the hybrid proteomimetics. The 3-
O-alkylated monomers used in the synthesis of the oligomers 3.27 to 3.33 were provided by Dr 
N. S. Murphy. 
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3.4.3.2. Modification of the central amino acid 
 
The Phe aa in compound 3.3 mimicked the original Trp residue from the p53 -helix. The 
modifications incorporated here (Table  3.3, Figure  3.11) mainly focused on studying the effect 
of: 
- Extended aromatic ring systems to improve interactions with the deep Trp hydrophobic 
binding pocket, compounds 3.34 and 3.35. 
- Different aa enantiomers to exploit further the stereodependent selectivity of the 
scaffold, compounds 3.34 and 3.35. 
 
 
Table  3.3 Library of hybrid -helix mimetics with modifications on the central aa illustrating 
side-chain sequence. 
Hybrid R1 aa R3 resin 
3.34 3-O-Bn L-2-Nal 2-O-iPr Gly 
3.35 3-O-Bn D-2-Nal 2-O-iPr Gly 
 
 
Figure  3.11 Aa side chains incorporated in the central position of the hybrid proteomimetics. 
 
Structural modifications were also explored by the introduction of the following building blocks 
in the central position of the hybrid scaffold (Table  3.4, Figure  3.12): 
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- α,α’-Disubstituted amino acids182 3.37 and 3.38 to study the restriction of 
conformational freedom of side chains and the introduction of a complementary side 
chain. 
- β-Amino acids183 3.39 and 3.40 to study the access to a new group of different 
pharmacophores with distinct flexibility on the central backbone. 
- N-methylated Phe to study the effect of potential new bioactive conformations, 
compound 3.36. 
 
Table  3.4 Hybrid -helix mimetic with structural modifications on the central aa illustrating 
side-chain sequence. 
Hybrid R1 aa R3 resin 
3.36 3-O-Bn N-Me-Phe 2-O-iPr Gly 
 
 
 
Figure  3.12 (a) N-Me aa incorporated in the central position of the hybrid proteomimetic; (b) 
Different α,α’-disubstituted and β-amino acid residues which failed to be incorporated in the 
central position of the hybrid oligomers. 
 
The incorporation of the aa residues 3.37 to 3.40, which were used as test substrates 
(Figure  3.12), and the aryl building block 3.26 proved unsuccessful using the standard synthetic 
methodology for the hybrids (Scheme  3.2). In order to increase their reactivity the acid chlorides 
from the corresponding monomers were pre-formed and then coupled to the growing chain 
(Scheme  3.3). Unfortunately, this methodology only permitted incomplete coupling of the 
monomers, even after repeated coupling cycles. The poor reactivity of these monomers might be 
due to the steric hindrance of the α,α’-disubstituted amino acids. Alternatively, the β-amino acid 
residues may have adopted unreactive conformations where the free amine was inaccessible for 
coupling, as indicated by subsequent ineffective acetylations attempts using acetic anhydride. 
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Scheme  3.3 Acid chloride based methodology for the incorporation of challenging building 
blocks. 
 
3.4.3.3. Modification of the bottom aryl unit 
 
The iPr side chain in compound 3.3 mimicked the original Leu residue from the p53 -helix. 
The modifications incorporated here (Table  3.5, Figure  3.13) mainly focused on studying the 
effect of: 
 
- Different aliphatic side chains to assess the effect of size and shape of the aliphatic 
substituents in the Leu binding site, compounds 3.41 to 3.43. 
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Table  3.5 Library of hybrid -helix mimetics with modifications on the bottom aryl unit 
illustrating side-chain sequence. 
Hybrid R1 aa R3 resin 
3.41 3-O-Bn L-Phe 2-O-iBu Gly 
3.42 3-O-Bn L-Phe 2-O-sBu Gly 
3.43 3-O-Bn L-Phe 2-O-Me Gly 
 
 
Figure  3.13 Side chains incorporated in the bottom aryl unit of the hybrid proteomimetics. The 
2-O-alkylated monomer used in the synthesis of the oligomer 3.41 was provided by Dr V. 
Azzarito. 
 
3.4.3.4. Modification of the N-terminus 
 
One of the main disadvantages of this type of proteomimetics is their limited solubility in 
aqueous media.
126
 In order to address this issue, solubilising groups could be attached onto the 
scaffold; however, the site of modification had to be chosen carefully as it could disrupt the 
activity of the compound. The N-terminus of the molecule was anticipated to allow further 
modification of the scaffold without altering the key binding side chains. Furthermore, the intra-
molecular hydrogen bond between the NH and the alkoxy group of the top monomer would 
position the N-linked side chain towards the solvent exposed face of the compounds 
(Figure  3.14). 
 
 
Figure  3.14 Possible projection of the N-linked side chain towards the solvent exposed face of 
the hybrid compounds. 
 
Accordingly, a new modification strategy was developed based on a reductive amination 
reaction on resin (Scheme  3.4). The reaction provided the modified hybrid in good yields. An in 
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situ oxidation of the alcohol to the corresponding aldehyde was performed when necessary. The 
advantages of this reaction are: i) reduction of preparation time and potential for library 
generation resulting from the nature of a late stage derivatization; ii) solid phase chemistry 
permits the use of a large excess of reagents, which results in high modification yields. 
 
The modifications incorporated at the N-terminus (Table  3.6, Figure  3.15) are mainly focused 
on the introduction of polar side chains to increase the water solubility of the analogues.  
 
 
Scheme  3.4 Reductive amination on resin of the hybrids N-terminus. 
 
Table  3.6 Library of hybrid -helix mimetics with modifications on the N-terminus illustrating 
side-chain sequence. 
Hybrid R1 aa R3 R4 resin 
3.44 3-O-Bn L-Phe 2-O-iPr 4-N-3-NH2-Pr Gly 
3.45 3-O-Bn L-Phe 2-O-iPr 4-N-2-MeNH-Et Gly 
3.46 3-O-Bn L-Phe 2-O-iPr 4-N-3-Pyridyl Gly 
3.47 3-O-Bn L-Phe 2-O-iPr 4-N-2-Furanyl Gly 
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Figure  3.15 Side chains incorporated in the N-terminus of the hybrid protomimetics.  
The N-terminal modification of compounds 3.44 and 3.45 was performed with Boc protected 
building blocks (Scheme 3.4): the Boc protected amino alcohols were oxidised to the 
corresponding Boc protected amino aldehydes, before being used in the reductive amination 
reaction. The subsequent cleavage and deprotection step in acidic conditions removed the Boc 
group to yield the final compounds 3.44 and 3.45. 
 
3.4.3.5. Modification of the C-terminal amino acid 
 
The aa at the C-terminal position of the hybrid compounds was also modified in order to 
increase the solubility of the proteomimetics in aqueous media. In particular, the standard 
glycine residue was substituted by a lysine aa in compound 3.48, introducing an extra polar 
amino group into the scaffold (Table  3.7). 
 
 
Table  3.7 Hybrid -helix mimetics with modifications on the C-terminal aa illustrating side-
chain sequence. 
Hybrid R1 aa R3 resin 
3.48 3-O-Bn L-Phe 2-O-iPr Lys 
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3.5. Biophysical testing: Fluorescence Anisotropy Competition 
Assays 
 
The use of fluorescence anisotropy (FA) to determine binding constants is well established 
within the Wilson group.
123, 124, 132, 134, 135
 Consequently, to test the potential of the new hybrid 
analogues to selectively inhibit the p53/hDM2 and Mcl-1/NOXA B PPIs, their activity was 
tested in a FA competition assay targeting those PPIs, as shown in Figure  3.16.  
 
 
Figure  3.16 Mode of action of the fluorescence anisotropy competition assay. 
 
In the FA competition assay the protein in complex with the corresponding peptide tracer, a 
binding peptide bearing a fluorophore group, is titrated with an increasing concentration of 
proteomimetic compound. Initially, the peptide tracer is bound to the protein and tumbles 
slowly in solution due to the big size of the peptide-protein complex, which produces a high 
anisotropy signal. This interaction can be disrupted by the binding of the proteomimetic 
compounds to the protein, which displace the peptide tracer from the protein surface to the 
solution. This process results in a decrease of anisotropy due to the fast tumble of the peptide 
now in solution.  
 
It is worth noting that this assay was used to determine the binding affinities of our benchmark 
compound 3.3, which displayed an IC50 of 11.9 M for p53/hDM2 and >100 M for Mcl-
1/NOXA B (shown in Figure  3.8). 
 
3.5.1. Modification of the top aryl unit 
 
The FA competition assay targeting the p53/hDM2 and Mcl-1/NOXA B PPI for the top aryl 
modified series of hybrids and the corresponding IC50 values are shown in Figure  3.17. 
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Figure  3.17 Top aryl modifications series: Dose-response curves against the p53/hDM2 (left) 
and Mcl-1/NOXA B (right) PPI (40 mM phosphate buffer pH 7.50, 200 mM sodium chloride, 
0.02 mg mL
- 1
 BSA). 
 
The results illustrate that the para substitution of the benzene ring with -Cl and -CF3 groups in 
compounds 3.27 (11.0 ± 0.5 M) and 3.28 (14.6 ± 0.7 M) respectively, and the replacement by 
a naphtyl side chain in compound 3.30 (8.0 ± 0.3 M) did not have a significant effect on the 
binding affinity for hDM2. However, a slight improvement on potency of two fold was 
achieved with the introduction of a tBu group in the para-Bn position in compound 3.29, 
resulting in the most potent hybrid obtained to date against hDM2 with an IC50 of 5.0 ± 0.4 M.  
 
Unfortunately, all the changes resulted in compounds with binding affinities for Mcl-1 
throughout the low M range, thus eliminating the selectivity towards hDM2 from the original 
compound 3.3. Furthermore, the substitution of the aromatic system by aliphatic side chains, 
compounds 3.31 to 3.33, resulted in a decrease of binding affinity to >100 M for both hDM2 
and Mcl-1 proteins. This result highlights the importance of the aromatic ring in the top 
position. 
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3.5.2. Modification of the central amino acid 
 
The FA competition assay targeting the p53/hDM2 and Mcl-1/NOXA B PPI for the central aa 
modified series of hybrids and the corresponding IC50 values are shown in Figure  3.18. 
 
 
 
Figure  3.18 Central aa modifications series: Dose-response curves against the p53/hDM2 (left) 
and Mcl-1/NOXA B (right) PPI (40 mM phosphate buffer pH 7.50, 200 mM sodium chloride, 
0.02 mg mL
-1
 BSA). 
 
The results showed how the substitution of the central Phe ring from the original compound 3.3 
by a naphtyl system, compounds 3.34 and 3.35, did not produce more potent hybrids, and hence 
did not improve contacts with the deep Trp binding pocket on the hDM2 surface as envisioned 
when they were designed. 
 
Furthermore, both L- and D- enantiomers were obtained, compounds 3.34 and 3.35 respectively. 
However, surprisingly the enantiomer dependent selectivity towards Mcl-1 shown by the 
original compounds 3.3 and 3.4 was not retained in this case.  
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Additionally, the introduction of an N-methyl group on the central Phe aa in compound 3.36 
resulted in a decrease of binding affinity to >100 M for both hDM2 and Mcl-1 proteins.  
 
3.5.3. Modification of the bottom aryl unit 
 
The FA competition assay targeting the p53/hDM2 and Mcl-1/NOXA B PPI for the bottom aryl 
modified series of hybrids and the corresponding IC50 values are shown in Figure  3.19. 
 
 
Figure  3.19 Bottom aryl modifications series: Dose-response curves against the p53/hDM2 
(left) and Mcl-1/NOXA B (right) PPI (40 mM phosphate buffer pH 7.50, 200 mM sodium 
chloride, 0.02 mg mL
-1
  BSA). 
 
Interestingly, the results showed that reducing the size of the aliphatic side chain on the bottom 
aryl unit in compound 3.43, with just a methyl group on that position, allowed the selectivity 
towards hDM2 over Mcl-1 of the original compound 3.3 to be retained. However, this 
modification also caused a loss of potency. Conversely, the increase in size of the aliphatic 
chain on the same position in compounds 3.41 and 3.42, which display an iBu and sBu groups 
respectively, resulted in complete loss of the afore mentioned selectivity. This result could 
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contribute to the elucidation of the factors that drive the selectivity in this family of 
proteomiemtics. 
3.5.4. Modifications of the N-terminus and C-terminal amino acid 
 
The FA competition assay targeting the p53/hDM2 and Mcl-1/NOXA B PPI for the C-terminal 
aa modified hybrid 3.48 showed IC50 values >100 µM, indicating that the substitution of the 
glycine by a lysine residue decreased the binding of the hybrid compound to both protein 
targets. Unfortunately, due to time constraints the testing of the N-terminal modified hybrids 
was not performed.    
 
3.5.5. Investigation of additive effects 
 
The ultimate goal of the SAR study was to identify factors that increase the potency and/or 
selectivity of the hybrid and combine these modifications into a new generation of PPI 
inhibitors. Therefore, it was necessary to investigate if a combination of different substitutions 
on an individual compound would result in additive effects in activity and/or selectivity. 
 
In this context, it is important to highlight some SAR features observed in a selection of hybrid 
compounds:  
i) Previously, the hybrids halo-substituted at the p-Bn position of the central aa were 
identified as inhibitors of the Mcl-1/NOXA B PPI. In particular, the p-bromo 
functionalised hybrid 3.49 was shown to be the best inhibitor with an IC50 of 13.0 ± 0.6 
M (Figure  3.20).136 
 
Figure  3.20 Structure and inhibitory activity against Mcl-1/NOXA B of p-bromo functionalised 
hybrid 3.49. 
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ii) The stereochemistry of the central Phe aa in compounds 3.3 and 3.4 dictates the 
selectivity towards the Mcl-1 protein (See Figure  3.8). 
iii) The functionalization of the top aryl unit with a p-tBu group in compound 3.29 increase 
in 2-fold its binding affinity towards hDM2 (See Figure  3.17). 
 
Subsequently, compounds 3.50 and 3.51, which share a combination of substitutions were 
obtained (Figure  3.21). The FA competition assay targeting the p53/hDM2 and Mcl-1/NOXA B 
PPI for these hybrids and the corresponding binding affinities are shown in Figure  3.21. 
 
 
Figure  3.21 Combined modifications series: Dose-response curves against the p53/hDM2 (left) 
and Mcl-1/NOXA B (right) PPI (40 mM phosphate buffer pH 7.50, 200 mM sodium chloride, 
0.02 mg mL
-1
 BSA). 
 
Unfortunately, the resulting enantiomeric compounds 3.29 and 3.50 did not retain any 
selectivity between the p53/hDM2 and Mcl-1/NOXA B interactions, as shown by their similar 
binding affinities to both proteins. Furthermore, the combination of the p-bromo in the central 
aa and the p-tert-butyl group on the top aryl unit in compound 3.51 did not result in the 
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expected increase in potency towards any of the PPI of interest. Therefore, this set of 
compounds does not appear to show an additive SAR.  
 
3.6. Conclusions and future directions 
 
A new set of hybrid compounds derived from the benchmark compound 3.3 has been 
successfully synthesised allowing a SAR study of its interaction with hDM2 and Mcl-1. The 
existing synthetic strategy for this scaffold has been modified when required and also a novel 
methodology has been developed (i.e. reductive amination on resin) to customize the hybrid 
proteomimetics adequately. 
 
Unfortunately, among the set of hybrid analogues synthesised and tested here inhibtors that 
display a significant increase on their binding affinity towards hDM2 or Mcl-1 were not 
identified. However, the most potent hybrid to date against hDM2, compound 3.29 with an IC50 
of 5.0 ± 0.4 M, was obtained through the introduction of a tBu group in the para-Bn position 
of the top aryl unit of the original compound 3.3. However, the enantioselectivity from the 
original compound 3.3 was not reproduced by compound 3.29 or any of the other chiral 
compounds investigated. Interestingly, the size of the aliphatic substituent at the bottom unit 
was found to be important for the selectivity between the p53/hDM2 and Mcl-1/NOXA B 
interactions. Finally, early studies on the SAR features within the hybrid compound library 
revealed that these features did not have an additive effect when combined in the same 
proteomimetic structure. 
 
The next step will be to test the hybrids with modifications at the N-terminus and in the C-
terminal aa against the PPIs of interest. In parallel, a quantitative analysis of the aqueous 
solubility of the compounds by HLPC will also be performed to determine the variations 
produced by the N-terminal and C-terminal aa modifications. Unfortunately, due to time 
constraints these experiments could not be performed. Finally, the synthetic methodology needs 
to be further explored to incorporate other monomers of interest, such as the already described β 
and α,α-disubstituted amino acids, which could lead to a plethora of novel bioactive molecules. 
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Chapter 4. Design, synthesis and evaluation of 
inhibitors for the Asf1/H3 PPI 
4.1. Introduction 
 
Advancements in the understanding of PPIs have led to them becoming more attractive 
therapeutic targets.
184
 There are already available drugs on the market aimed at treating a 
multitude of diseases linked to PPIs and an increasing number in clinical trials.
92, 185
 Therefore, 
PPIs are one of the key targets for intervention in biological systems directly related to disease. 
However, the ubiquitous nature of PPIs makes challenging the complete understanding of their 
complex organizations. In that context, continuing investigations towards the modulation of 
unexplored PPIs is vital in the design of new targeted therapeutics.
184
 
 
4.2. Interaction of interest: Asf1/H3 
 
Chromatin - nucleosome - histones 
 
The fundamental structural unit of chromatin is the nucleosome, which is formed by 147 base 
pairs of DNA wound 1.7 times around the outside of a histone octamer core.
186, 187
 The histone 
octamer comprises two units of each of the histone proteins H2A, H2B, H3 and H4, where two 
H2A/H2B dimers are tethered to each side of one (H3/H4)2 tetramer.
186-188
 Nucleosome 
assembly and disassembly is a vital process that allows rapid access to specific DNA sequence 
during transcription, replication, repair and recombination. Hundreds of proteins regulate the 
folding and unfolding of chromatin allowing the DNA to be exposed and organised for each 
specific function.
188
 
 
Histone chaperones are proteins that regulate the association of basic histone proteins with the 
DNA strand.
189, 190
 Histones and DNA fail to self-assemble into nucleosomes under 
physiological conditions due to the strong tendency of histones to associate non-specifically 
with DNA and form aggregates.
191
 Therefore, the assistance of chaperones permits the 
nucleosome to form in an ordered and controlled manner. 
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Asf1/H3 PPI 
 
Histone chaperone anti-silencing function 1 (Asf1) is a highly conserved histone chaperone 
involved in both nucleosome assembly and disassembly.
192-195
 In particular, the interaction 
between Asf1 and the H3 and H4 histone proteins forms Asf1-(H3/H4) complexes (Figure  4.1), 
which can either supply histones to the nucleosome assembly proteins chromatin assembly 
factor 1 (CAF-1) and histone regulator A (HIRA)
193, 196, 197
 or can interact directly with the 
DNA.
198, 199
 The primary role of Asf1 is to shield H3/H4 dimers from unfavorable interactions 
with the DNA whilst assisting the formation of positive histone–DNA contacts, which leads to 
disome [(H3/H4)-DNA] assembly.
200
 Furthermore, Asf1 binds the H3/H4 dimer enveloping the 
C-terminus of histone H3 and physically blocking formation of the (H3/H4)2 tetramer.
196
  
 
Figure  4.1 Diagram illustrating Asf1 (purple) function in nucleosome assembly by depositing 
an H3/H4 histone dimer (red and yellow respectively) onto DNA-complexed with the 
nucleosome assembly protein CAF- 1 (green).
201
 
 
Overall structural features 
 
The Asf1 protein comprises a conserved N-terminal domain of 156 amino acids, which is 
essential for its function in vivo, and a divergent unstructured C-terminal domain, which is 
believed not to be necessary for the protein function.
195, 202
 The structure of the Asf1 comprises 
an elongated  sandwich core with three α-helices in the loops between the  strands.  
 
The contacts between H3 and Asf1 are extensive and result in a buried surface area of 909 Å
2
. 
The histone H3 binding site is located in the concave face of Asf1 (Figure  4.2) and involves  
strands 3, 4, and 6-9.195, 196, 202 Interestingly, this region of the sequence is highly conserved 
across species and has a distinctly negative charged nature. The main interactions occur through 
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the C-terminal helix of H3 (residues 122–134), where the key residues Leu126 and Ile130 form a 
hydrophobic clamp with the hydrophobic region of Asf1. Additionally, there is a network of 
electrostatic interactions within the PPI interface, such as the the salt bridge between Arg
129
 
from H3 and Asp
54
 from Asf1.
203
 
 
Figure  4.2 NMR structure of Asf1/H3 PPI (PDB ID: 2IIJ). Key side chains on the binding 
surface of the helix are highlighted. 
 
Furthermore, the Asf1-H3/H4 structure also shows extensive contacts between Asf1 and histone 
H4.
196
 This interface has two parts: the globular core of Asf1 interacts with the C-terminal tail of 
H4 to form a strand-swapped dimer and the C-terminal tail of Asf1 binds to the histone fold 
region of histone H4.  
 
4.3. Inhibition of Asf1/H3 as a PPI of therapeutic interest 
 
The histone chaperone Asf1 has emerged as a promising target for therapeutic intervention for 
multiple cancers.
188, 200, 204, 205
 The binding of Asf1 to H3/H4 dimers promotes the acetylation of 
the Lys
56
 residue from histone H3.
206
 This acetylation process is directly related to genomic 
stability, DNA replication and repair, whereas decreased acetylation levels seem to sensitize the 
cells to DNA damaging agents. Consequently, the development of compounds able to modulate 
this PPI could play a key role in the development of therapeutics to treat cancer.  
 
The NMR structure of the conserved N-terminal Asf1 histone-binding domain with the histone 
H3 C-terminal peptide was used as a model for the complex between Asf1 and the entire H3/H4 
complex. In particular, we envisioned the C-terminal α-helix peptide of H3 as a template for the 
design of molecules able to disrupt the PPI. In order to directly compare and contrast different 
inhibitor designs when targeting the same PPI, two different approaches were utilised: the 
proteomimetic strategy and the hydrocarbon stapling peptide strategy.  
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4.3.1. Proteomimetic approach 
 
The proteomimetic approach has been extensively used within the Wilson group to modulate 
PPIs. Among the different scaffolds available, the 3-O-alkylated oligobenzamide scaffold 
(Figure  4.3a) was chosen in this case as the proteomimetic approach for the following reasons: 
- Proven ability to reproduce the side chains of residues located on one face of an α-
helix.
120, 123 
- Effective inhibition of α-helix mediated PPI.123, 126 
- Accessible synthetic route amenable to library generation.125  
 
Initially, we assessed the potential of the 3-O-alkylated scaffold to reproduce the key binding 
residues of the C-terminal H3 peptide by minimising the energy of a model scaffold structure 
in Macromodel. The lowest energy conformations within 1.5 kJ/mol of the model compound 
adopted an extended structure where the amide bonds are trans. Subsequently, these structures 
were superimposed onto the native α-helix of histone H3, as shown in Figure  4.3b. The match 
was assessed on the basis of the overlapping between α-carbons on the helix and oxygen atoms 
on the foldamer. As anticipated, the scaffold projects the side chains in a similar orientation to 
the native peptide, as evidenced by their overlay (RMSD = 0.70). 
 
                            
Figure  4.3 (a) structure of the 3-O-alkylated oligobenzamide scaffold. (b) Overlay of a model 
proteomimetic scaffold (grey) and the native H3 α-helix (red) with key binding residues 
highlighted (green). 
 
(a) (b) 
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4.3.2. Synthesis  
 
The synthesis of the 3-O-alkylated oligobenzamide -helix mimetic scaffold was based on an 
Fmoc (9-fluorenylmethyloxycarbonyl) solid phase peptide synthesis (SPPS) strategy previously 
developed in the Wilson group.
125
 It comprises the synthesis of the monomeric units followed 
by their assembly in a sequential manner.  
 
4.3.2.1. Monomer synthesis 
 
The synthesis of the 3-O-alkylated protected monomers followed a synthetic route previously 
described by the group (Scheme  3.1).122, 125 It consisted of an initial alkylation step, followed by 
reduction of the nitro to the amino group. Subsequent hydrolysis of the ester and final Fmoc-
protection produced the desired 3-O alkylated Fmoc-protected monomers in high yields. 
 
 
Scheme  4.1 Synthetic route to 3-O alkylated Fmoc-protected building blocks. Monomer 4.4 was 
provided by Dr N. S. Murphy. 
 
4.3.2.2. General synthetic scheme 
 
The 3-O-alkylated -helix mimetics were synthesised through a microwave-assisted automated 
SPPS (Scheme  3.2) developed by Dr N. S. Murphy.125 It consisted of a series of deprotection 
and coupling steps, using Fmoc-aa- (where aa can be any amino acid) preloaded Wang resins as 
solid support; and the pre-formed acid chlorides from the Fmoc- monomers as building blocks. 
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Scheme  4.2 Solid phase synthetic route for assembly of the 3-O-alkylated -helix mimetics. 
 
It is worth noting that the coupling of monomers bearing protected polar side chains was found 
to be more challenging than the coupling of hydrophobic monomers. As a result of this, double 
coupling steps were required for these building blocks. Using the described synthetic route, a set 
of proteomimetics was obtained (Figure  4.4). In order to investigate the potential of the 3-O-
alkylated scaffold to mimic the H3 -helix, the compounds that were obtained displayed the 
following characteristics: 
 
- Native sequence mimetic, compound 4.5. The side chains from the H3 key binding 
residues Lys
122
, Leu
126
 and Ile
130
 (see Figure  4.2) are mimicked by a propylamine, iso-
butyl and a sec-butyl groups respectively. 
- Exchange of the hydrophobic side chains, compound 4.6. The hydrophobic Leu126 and 
Ile
130
 mimetics are swapped in this compound to study the subtle differences in the 
shape of their side chains.   
- Antiparallel mimetic of the native sequence, compound 4.7. The nature of the structure 
permits the superimposition in parallel and antiparallel N-to-C orientation with respect 
to an α-helical peptide.125 In this case, the H3 key binding residues Lys122, Leu126 and 
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Ile
130
 (See Figure  4.2) are mimicked by an ethylamine, iso-butyl and a sec-butyl groups 
respectively in an antiparallel orientation. 
- Negative control, compound 4.8. The three side chains displayed by this mimetic are 
hydrophobic sec-butyl groups. It is intended to be a poor mimetic of the native H3 
helix. 
- Control dimers, compounds 4.9 and 4.10. These proteomimetics were generated from 
two building blocks bearing hydrophobic side chains and were expected to bind less 
tightly to the protein targets.  These compounds would highlight the importance of the 
third side chain in the recognition process and in particular the need for an amino group 
to mimic the electrostatic interactions of the Lys
122
 residue.   
 
 
 
Figure  4.4 Set of 3-O-alkylated oligobenzamides 4.5 to 4.10 as C-terminal H3 -helix 
proteomimetics. 
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4.3.3. Hydrocarbon stapled peptide approach 
 
One of the methodologies used in the Wilson group to inhibit PPIs is with hydrocarbon stapled 
peptides. In recent years, Dr D. Yeo introduced a monosubstituted alkenyl amino acid 4.11 
(Figure  4.5) to prepare hydrocarbon staples at i and i+4 positions of a peptide sequence. These 
type of stapled peptides showed an increased propensity to adopt an -helical conformation and 
effectively disrupted PPIs.
69, 70
 
 
 
Figure  4.5 Structure of the monosubstituted alkenyl amino acid 4.11. 
 
In order to further expand this approach to other families of α-helix mediated PPI, the 
stapled variant of the C-terminal H3 peptide was designed. The sites to incorporate the 
monosubstituted amino acids within the peptide sequence were selected taking into account 
the following factors: 
 
- The space between residues should be suitable to form a crosslink (usually i and i+4 
positions). 
- The hydrocarbon bridge should be located in a position that does not interfere in the 
protein-protein interface and should not modify the orientation of the key 
interacting residues. 
- The substitutions should not replace any other key residues, such as charged 
residues involved in stabilizing salt bridges or peptide solubility. 
 
Based on that criteria, the Met(120) and Ile(124) residues of the H3 peptide sequence 
(Figure  4.6) were substituted by the monosubstituted amino acid 4.11.  
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Figure  4.6 C-terminal H3 peptide showing the key binding residues (green) and the new 
stapling positions (yellow). Side (left) and top (right) views are given. 
 
4.3.3.1. Amino acid Synthesis 
 
The monosubstituted alkenyl amino acid incorporated in the stapled peptides was obtained 
using a synthetic route reported by the Wilson group (Scheme  4.3).69 It involves a six steps 
synthesis and exploits a chiral ligand to provide the desired stereochemistry in the final Fmoc-
protected amino acid. The synthetic route starts with reductive amination between L-proline 
4.12 and benzyl aldehyde 4.13 to give N-benzyl proline 4.14, followed by in situ formation of 
the corresponding acyl chloride and coupling to 4.15 provides the final chiral ligand 4.16. The 
complexation reaction between glycine 4.17, the chiral ligand 4.16 and Ni(II) yields complex 
4.18, which is then enantioselectively alkylated in the -position under basic conditions to give 
compound 4.20. Final decomplexation under acid conditions followed by Fmoc-protection leads 
to the desired Fmoc-monosubstituted alkenyl amino acid 4.11. 
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Scheme  4.3 Reaction scheme of the synthesis of Fmoc-protected monosubstituted alkenyl 
amino acid 4.11.
69
 
 
4.3.3.2. Peptide Synthesis 
 
The peptides were synthesised on Rink Amide MBHA resin as solid support, in order to obtain 
C-terminal amidated peptides comparable to the C-terminal domain of H3 (Scheme  4.4). Low 
loading resin was used in order to reduce clustering of the growing peptide chain and hence aid 
the coupling and deprotection steps. 
 
The synthesis was performed using Fmoc solid phase peptide synthesis (SPPS), with HCTU as 
activating reagent and DIPEA as base for peptide elongation. Double couplings were required 
for the coupling of the ARRIR region, after small scale test cleavages had revealed these 
couplings to be incomplete after 2 hours. The monosubstituted unnatural amino acid 4.11 was 
incorporated using HATU as a coupling reagent, with the Kaiser test being conclusive for their 
couplings.
207
 
 
The alkenyl side chains of the unnatural amino acids were metathesized using the first 
generation Grubbs catalyst. The cleavage and side chain deprotection of the peptide from the 
resin was carried out with Reagent K, which contains ethanedithiol, thioanisole and phenol as 
scavengers to prevent the irreversible modification of nucleophilic side chains by carbocations, 
such as tert-butyl, and the oxidation of sensitive residues, such as methionine. The deprotection 
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times needed to be extended to 2-4 hour washes due to the multiple arginine residues bearing 
Pbf protecting groups, which had proven challenging to remove in this particular sequence.   
 
 
 
 
Scheme  4.4 Synthetic route to the stapled peptides. 
 
Purification of the stapled and unstapled H3 peptides was performed using reverse phase 
preparative HPLC. This process proved challenging, as the alternating polar and hydrophobic 
regions in the peptide sequence are prone to aggregate. This resulted in poor yields of 11% and 
5% of pure stapled and unstapled peptide respectively. 
 
 
4.3.4. Circular Dichroism (CD) 
 
Circular dichroism (CD) was used to evaluate the effectiveness of the hydrocarbon crosslink to 
promote an -helical secondary structure and hence to reduce the peptide conformational 
freedom in aqueous solution. CD is a technique that provides distinct spectral profiles 
depending on the secondary structure present on a species (Figure  4.7). In particular, -helical 
conformations of peptides and peptidomimetics are identified and quantified using the 
amplitude of the spectrum at 222 nm.
208, 209
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Figure  4.7 Representative example of a CD spectra of an unstructured random coil peptide 
(green) and an α-helical peptide (blue). 
 
 
The helical character of the unstapled and stapled 1 H3 peptide variants was investigated using 
CD as shown in Figure  4.8. Unfortunately, the results show a predominantly unstructured 
random coil character for both stapled 1 and native peptide sequences, suggesting that the 
introduction of the hydrocarbon staple at these positions did not increased the helicity of the 
peptide. Additionally, trifluoroethanol (TFE) was used as a cosolvent due to its ability to 
promote α-helical conformations in short peptides,210, 211 and thus providing a benchmark for the 
maximum helicity of the particular peptide sequence. In these conditions, both stapled 1 and 
native peptide showed an almost identical change in their CD profiles, matching an -helical 
secondary structure. The highly similar results for both peptides also suggest that in this case the 
hydrocarbon staple does not interfere with the conformational flexibility of the peptide. 
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Figure  4.8 CD spectra of the native (black) and stapled 1 (red) H3 peptides in 40 mM 
phosphate buffer, pH 7.5 (solid line) and in 30% TFE (dash line). 
 
4.3.5. Redesign of the stapled peptide 
 
In order to further investigate the potential of the hydrocarbon stapling strategy to increase the 
helicity of the C-terminal H3 peptide, a different stapling position was selected (Figure  4.9). In 
this case, a more central position within the sequence was chosen, replacing the Asp(123) and 
Ala(127) residues, in the belief that it would aid the helical conformation promotion.   
 
In addition, the extra three residue fragment GCA was added at the C-terminus of the peptide 
sequence. This additional section was introduced as a future conjugation handle via the 
nucleophilic thiol of the cysteine residue. 
 
The new stapled 2 peptide was synthesised following the same procedure as described in section 
4.3.3.2 and obtained in 3% yield. The CD measurements show a significant increase in the 
helicity of the stapled 2 peptide when compared with the unstructured unstapled variant 
(Figure  4.10), suggesting the hydrocarbon staple successfully promotes a more helical 
conformation in the peptide. Again, both peptides increased their -helical structure when TFE 
was used, however on this occasion the stapled 2 variant showed a smaller increase in helicity 
  
89 
than the native sequence. This observation may be due to a reduction of the peptide 
conformational flexibility caused by the hydrocarbon cross-linkage. 
 
 
Figure  4.9 C-terminal H3 peptide showing the key binding residues (green) and the new 
stapling positions (pink). Side (left) and top (right) views are given. 
 
 
Figure  4.10 CD spectra of the native (black) and stapled 2 (red) H3 peptides in 40 mM 
phosphate buffer, pH 7.5 (solid line) and in 30% TFE (dash line). 
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4.4. Biophysical testing - Isothermal Titration Calorimetry 
(ITC) 
 
The set of proteomimetic compounds and the stapled peptides were sent to our collaborators in 
the Ochsenbein group at the Institute of Biology and Technology of Saclay (iBiTec-S) to assess 
their ability to act as PPI inhibitors. The PhD student May Baikal used Isothermal Titration 
Calorimetry (ITC) to study the binding of the compounds to the Asf1 protein.  
 
Isothermal titration calorimetry (ITC) is a technique used to study the thermodynamic 
parameters of interacting  bimolecular systems.
212
 In particular, this method allows 
determination of the thermodynamic contributions of binding events through the calculation of 
the Kd and H values. The technique consists of measuring small heat variations in a cell as one 
species is titrated into another. The thermal changes reflect the enthalpy changes of the system 
and they decrease upon saturation of the binding sites. The main advantage of ITC compared to 
other biophysical techniques is that labelled substrates are not required, which avoids additional 
non-target interactions and equilibria.  
 
Unfortunately, our 3-O-alkylated oligobenzamide proteomimetics compounds were not 
sufficiently potent at low concentrations to be detected using ITC; however, increasing the 
concentration was problematic due to the low solubility and aggregation of the compounds.  
 
Conversely, the native and stapled 1 peptide provided clear binding curves when titrated into the 
Asf1 protein (Figure  4.11), displaying a 1 to 1 stoichiometry in both cases. The thermodynamic 
parameters extracted from the curves (Table  4.1) show marginal differences in the binding 
constant (KD), and the enthalpic (ΔH) and entropic (ΔS) contributions. These results are in 
agreement with the previously discussed CD studies (See section 4.3.4), proposing that the 
hydrocarbon staple at this position did not affect the peptide conformation, and hence it did not 
change the binding of the peptide to the Asf1 protein. Unfortunately, we are still awaiting the 
ITC results for the second variant of stapled peptide. 
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Figure  4.11 ITC thermograms for the (a) native and (b) stapled 1 H3 peptides and Asf1 protein. 
       
Table  4.1 ITC data for the native and stapled 1 H3 peptides and Asf1 protein. 
 
 
4.5. NMR studies – 
1
H-
15
N HSQC 
 
In order to confirm the binding mode of the stapled peptide, the PhD student May Baikal from 
the Ochsenbein group performed 
1
H-
15
N HSQC perturbation shifts studies.
213
 This method 
involves acquisition of the HSQC spectra for both the 
15
N-labelled protein only and the 
15
N-
labelled protein in the presence of the ligand of interest. Then, the complexation-induced shifts 
on certain residues can be identified and mapped onto the protein structure. 
 
Distinct complexation-induced shifts were observed upon addition of the stapled 1 H3 peptide. 
Peptide KD (µM) ΔG (kcal.M
-1
) N ΔH (kcal.M
-1
) -TΔS (kcal.M
-1
) 
Native 1.48 (±0.46) -7.41 (±0.17) 1.02 (±0.02) -13.44 (±0.30) 6.03 (±0.47) 
Stapled 1 0.86 (±0.11) -7.71 (±0.07) 0.97 (±0.01) -15 (±0.96) 7.28 (±1.03) 
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Once mapped onto the structure of Asf1/H3 (PDB ID: 2IIJ), the study showed that shift changes 
were induced in the same area of the protein to those induced by the C-terminal H3 peptide, as 
shown in Figure  4.12. These results further confirm that the stapled 1 variant interact with Asf1 
in the same region and in the same manner to the native C-terminal H3 peptide. Interestingly, 
the two main amino acids which shift differently between the stapled and the unstapled peptides 
are Glu
49
 and Glu
51
, which are located in the histone binding site and face the expected position 
of the staple (indicated with green stars). 
 
Figure  4.12 
1
H-
15
N HSQC chemical shift perturbation mapping onto the structure of Asf1/H3 
(PDB ID: 2IIJ) highlighting the shift changes of the residues on a red (major movement) to 
yellow (minor movement) gradient, grey (no movement). The position of the Glu
49
 and Glu
51
 
residues are shown in magenta. The C-terminal H3 peptide is represented in blue (left structure) 
and the expected position of the staple is indicated with green stars. 
 
4.6. Conclusions and future directions 
 
Two different approaches for inhibition of PPIs have been used to target the Asf1/H3 
interaction. The proteomimetic approach utilised the 3-O-alkylated oligobenzamide scaffold to 
synthesise a set of inhibitors, which mimic the key side chain residues of the C-terminal H3 
helix. Unfortunately, in the biophysical assays performed by the Ochsenbein group using ITC 
the proteomimetic compounds did not reproducibly show binding to the Asf1 protein. These 
results might be due to a low binding affinity combined with low solubility and aggregation of 
the proteomimetics. 
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The hydrocarbon stapled peptide approach exploited the monosubstituted alkenyl amino acid 
methodology existing in the group to synthesise a first stapled variant of the C-terminal H3 
peptide. CD analysis revealed that the staple did not increase the helicity of the peptide when 
compared to the native H3 sequence. Consistently, the ITC studies confirmed a 1 to 1 
stoichiometry in both cases and show marginal differences in the thermodynamic parameters for 
the constrained peptide, such as binding constant (KD), and the enthalpic (ΔH) and entropic (ΔS) 
contributions. 
1
H-
15
N HSQC perturbation shifts studies further suggested a similar binding 
mode of the stapled and unstapled peptides to the Asf1 protein. Subsequently, a second stapled 
peptide was synthesised bearing a novel stapling position. In this case, the promising results 
from the CD analysis showed a significant increase in the helical character of the stapled 
peptide when compared to the native H3 sequence. Unfortunately, the results from the binding 
studies of the second stapled peptide to the Asf1 protein have yet not been received from our 
colleagues in the Ochsenbein group. 
 
The future work includes the use of other scaffolds available in the Wilson group, such as the N-
alkylated oligobenzamide scaffold or the hybrid scaffold, with more soluble profiles. 
Furthermore, the introduction of polar groups, such as a guanidino functionality as an arginine 
mimetic, could be introduced on the top of the sequence to improve solubility and add a further 
binding group. 
 
Regarding the hydrocarbon stapling strategy, ongoing work in the Ochsenbein group points 
towards the possibility of working with longer H3 based peptides bearing optimised sequences 
that bind Asf1. This opens the door to a multitude of options for stapled peptides variants, 
including the assessment of new stapling positions and the effect of hydrocarbon linker length. 
Finally, the conjugation of the H3 stapled peptides to cell penetrating peptides (CPP) using the 
additional GCA fragment incorporated at the C-terminus of the stapled peptide 2 could aid the 
study of our PPI inhibitors in cells. 
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Chapter 5. Thesis summary  
 
Protein-protein interactions (PPIs) play a central role in the mediation of regulatory pathways 
and control essential cellular processes.
3, 4
 Therefore, the use of small-molecules to modulate 
PPIs is important for the development of new therapeutic approaches, as well as to gain further 
insight into biological systems.
1
 Since the α-helix is the most common secondary structure in 
nature, significant efforts have focused on targeting α-helix mediated PPIs.5 Some of the most 
relevant approaches in this field are the proteomimetic approach, which recapitulate the key 
binding residues of an α-helix on a non-peptidic scaffold; and the constrained peptides; which 
pursue to reproduce the helical structure by stabilising the helical peptide. Both approaches have 
generated potent inhibitors of a great diversity of α-helix mediated PPIs. 
 
Over 40 % of the α-helix mediated PPIs involve key binding residues located on more than one 
face of the helix. However, there are very few scaffolds designed to mimic multiple faces of the 
putative helix. In Chapter 2, we introduced the design and synthesis of two bifacial 
proteomimetic scaffolds, bis-benzamide and N-(4-aminophenyl)terephthalamidic, to target the 
ER/co-activator PPI by mimicking the key side chains of the co-activator recognition motif 
LXXLL. Subsequent structural analysis, involving 2D NMR techniques and H/D exchange 
experiments, in combination with in silico studies revealed a plethora of different side chain 
spatial relationships, some of which effectively mimic the intended side-chains of the co-
activator α-helix. Significant conformational knowledge has been gained and added to the 
already existing data on aromatic oligoamide foldamers. Unfortunately, fluorescence 
polarization assays of the new scaffolds against nuclear receptor/co-activator interactions did 
not show binding of the compounds to the protein surface, highlighting the complex relationship 
between helix mimetic conformation and molecular recognition. 
 
Another major challenge towards the effective modulation of PPIs are molecules with enhanced 
control over target selectivity. The complex relationships between molecular rigidity, target 
plasticity and activity all participate in surface recognition processes. Recently, the Wilson 
group reported a new hybrid scaffold, which reproduced the side chains at i, i+4 and i+7 
positions of an α-helix, showed increased conformational plasticity over the original 3-O-
alkylated oligobenzamide scaffold, and most importantly presented stereodependent target 
selectivity. In Chapter 3 we attempted to further study and optimize the hybrid oligobenzamide 
scaffold towards more potent and selective inhibitors of the p53/hDM2 and the Mcl-1/NOXA B 
PPIs. 
  
95 
 
SAR analysis was performed on the new set of hybrid compounds obtained through 
modification of the N termini, the top or bottom aryl building blocks, the central amino acid, 
and the C terminal amino acid of the original scaffold. As a result, the most potent hybrid to 
date against hDM2, with an IC50 of 5.0 ± 0.4 M, was obtained. Interestingly, the selectivity of 
the compounds between the p53/hDM2 and Mcl-1/NOXA B interactions seemed to be affected 
by the size of the aliphatic substituent at the bottom unit of the scaffold. However, the 
enantioselectivity from the original benchmark compounds was not reproduced by any of the 
chiral compounds investigated. In addition, the SAR features observed within the hybrid 
compound library did not have an additive effect when combined in the same proteomimetic 
structure. 
 
Finally, it is essential to continue expanding the scope of PPI inhibition as a therapeutic tool by 
developing new modulators that target unexplored PPIs related with disease. In that context, the 
histone chaperone Asf1 has emerged as a promising target for therapeutic intervention for 
multiple cancers.
188, 200, 204
 In Chapter 4 we designed inhibitors of the Asf1/H3 interaction using 
the C-terminal α-helix peptide of H3 as a template. Two different approaches were used, the 
proteomimetic strategy and the hydrocarbon stapling peptide strategy, in order to compare the 
different inhibitor designs when targeting the same PPI.  
 
The proteomimetic approach exploited the 3-O-alkylated oligobenzamide scaffold to synthesise 
a set of inhibitors. Unfortunately in the biophysical assays performed by the Ochsenbein group 
using ITC, the proteomimetic compounds did not show binding to the Asf1 protein. These 
results might be due to a low binding affinity combined with low solubility and aggregation of 
the proteomimetics. The hydrocarbon stapled peptide approach exploited the monosubstituted 
alkenyl amino acid methodology existing in the group to synthesise two stapled variants of the 
C-terminal H3 peptide. Circular Dichroism (CD) revealed that the first stapled variant did not 
increase the helical character of the peptide in solution when compared with the native 
sequence. This fact consistently resulted in identical binding affinities and binding modes to the 
Asf1 protein, which was determined by the Ochsenbein group using ITC and HSQC studies 
respectively. Promisingly, a second re-designed stapled variant did produce a peptide with an 
increased helical secondary structure when compared to the native helix. Unfortunately, the 
effect of this increased helical character on the binding affinity to Asf1 has still to be determined 
as we are awaiting the results from the Ochsenbein group.  
 
During this PhD, two different approaches to inhibit PPIs have been used, the proteomimetic 
and the constrained peptide strategies. Three different scaffolds (bifacial, 3-O-alkylated and 
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hybrid scaffolds) and two stapled peptides have been explored to target a multitude of PPIs 
(ER/co-activator, hDM2/p53, Mcl-1/NOXAB, Asf1/H3). Both approaches have helped address 
key questions regarding helix mimetic conformation and molecular recognition, and selectivity 
between different targets. The addition of these results to the existing knowledge in the filed 
could aid the generation of more potent and selective PPI inhibitors in the future.  
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Chapter 6. Experimental Section  
 
6.1. General experimental points 
All commercial solvents were purchased and used without further purification unless stated 
otherwise. Commercially available starting materials and reagents were obtained from Sigma-
Aldrich, Alfa Aesar or Fisher Scientific. Amino acid derivatives, coupling reagents and resins 
were purchased from Novabiochem. Purification by column chromatography was carried out 
using silica gel (40-63 μm mesh size). Analytical thin layer chromatography (TLC) was 
conducted using Merck 0.2 mm silica gel 60 F254 pre-coated aluminium sheets. 
1
H and 
13
C NMR 
spectra were measured using a Bruker DRX 500 series spectrometer. Chemical shifts are 
expressed as parts per million using solvent as internal standard and coupling constants (J) are 
reported to the nearest 0.1 Hz. The following abbreviations are used: s for singlet, d for doublet, 
t for triplet, q for quartet and m for multiplet. High resolution mass spectrometry (HRMS) was 
carried out using a Bruker MicroTOF mass spectrometer or a Bruker Maxis impact mass 
spectrometer, in both cases under electro-spray ionisation (ESI) conditions. Infra-red spectra 
were recorded using a Perkin-Elmer Spectrum One FT-IR spectrophotometer. Elemental 
combustion analyses were performed by the School of Chemistry Microanalysis facility using a 
Carlo Erba Elemental Analyser MOD 1106 instrument and the found composition is reported to 
the nearest 0.05%. LC-MS experiments were run on a Bruker Daltonics HTCUltra
TM
 series 
spectrometer and were run through a C18 column on a methanol/water gradient (0-95% MeCN 
over 3 minutes). Analytical HPLC experiments were run on an Agilent 1290 Infinity LC series 
spectrometer. Mass-directed preparative HPLC experiments were run using an Agilent 1260 
Infinity Preparative system and analysed by a 6120 Quadrupole detector. 
 
6.2. Numbering system for proteomimetic scaffolds  
To simplify the numbering and NMR assignment of the different proteomimetic scaffolds, a 
sequential nomenclature and numbering system has been created, where each of the monomer 
building blocks is considered separately. Assignment is as follows: 
 
- The naming proceeds from N to C terminus. Following this order, each monomer is 
assigned a number corresponding to its position on the chain. This number will be added as 
a prefix to the individual carbon number for differentiation. 
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- In the 3-O-alkylated and hybrid scaffolds the O-alkylated monomers are named as 
[R-(n-HABA)], where R is the alkoxy side-chain, n- indicates the position of the alkoxy 
moiety on the aromatic ring (e.g. for a 2-O-alkylated monomer n = 2) and HABA is the 
acronym for Hydroxy Amino Benzoic Acid. 
- Each alkylated monomer is numbered using the standard system, where the substituents are 
assigned to the lowest number, in the case of originally symmetrical monomers one of the 
side chains is differentiated with an apostrophe () after the carbon number. Side-chain 
assignment follows a peptide nomenclature pattern in which the carbon attached to the 
alkoxy oxygen is assigned as Cα and the numbering of the aliphatic part of the side chain 
continues with Cβ, etc. In the case of aromatic side chains, the aromatic carbons are 
numbered CAr1, CAr2, etc. The Fmoc carbons are differentiated by the prefix F; the CH2 
group is numbered as CFα, the neighbouring CH is CFβ, and the aromatic positions go 
from CF-Ar2 to CF-Ar5.  
- Amino acids are numbered using the standard convention. 
- The numbering of the protons is based on the carbon numbering system.  
 
Examples of the numbering system for the proteomimetic scaffolds and monomer building 
blocks are given below (Figure  6.1). 
 
Figure  6.1 Numbering system (a) Bifacial scaffold (b) 3-O-alkylated scaffold (c) Hybrid 
scaffold (d) Monomer building blocks 
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6.3. Design, synthesis and conformational analyses of Bifacial 
Benzamide Based Foldmers (Chapter 2)  
6.3.1. Monomer syntheses and characterisation  
 
Methyl-2-hydroxy-4-nitrobenzoate (2.4)
127
 
A stirred solution of 2-hydroxy-4-nitro benzoic acid 2.2 (10.0 g, 54.6 mmol) and 
concentrated sulfuric acid (1.0 mL, 18.8 mmol) in anhydrous methanol (200 mL) 
under an nitrogen atmosphere was heated at reflux. After 96 h stirring, the 
reaction mixture was concentrated to leave a pale yellow solid, which was 
poured into ethyl acetate, washed with water (2 × 100 mL) and the organic layer was dried over 
anhydrous Na2SO4. The organic solvent was removed under reduced pressure to leave the pure 
product 2.4 (10.6 g, 53.8 mmol, 98%) as a pale yellow powder; RF  0.51 (30% ethyl acetate in 
cyclohexane); H (300 MHz, MeOD) 7.97 (d, J = 5.4 Hz, 1H, H6), 7.65 (s, 1H, H3), 7.62 (d, J = 
5.4 Hz, 1H, H5), 3.91 (s, 3H, CO2CH3); C (75 MHz, CDCl3) 170.7, 163.2, 153.8, 133.09, 
119.36, 114.9, 113.8, 53.9; νmax/cm
-1
 (solid state) 3627, 2965, 1733, 1661, 1665, 1558, 1440, 
1387, 1237; ESI-HRMS found m/z 196.0253 [M-H]
-
, C8H6NO5 requires 197.0324; Found: C, 
49.05; H, 3.65; N, 7.00; C8H7NO5 requires: C, 48.74; H, 3.58; N, 7.10 %. 
 
Methyl 2-isobutoxy-4-nitrobenzoate (2.6)
127
 
To a stirred solution of methyl-2-hydroxy-4-nitrobenzoate 2.4 (3.6 g, 18.3 
mmol) and potassium carbonate (7.6 g, 54.8 mmol) in DMF (100 mL), 
isobutyl bromide (2.8 mL, 25.6 mmol) was added and the resulting mixture 
stirred at 50 °C during 20 h under a nitrogen atmosphere. The resultant 
suspension was allowed to cool, poured into water and extracted with ethyl acetate (3 × 150 
mL). The combined organic fractions were washed with water (2 × 250 mL) and brine (4 × 300 
mL) before being dried over MgSO4. The organic solvent was evaporated resulting in an orange 
solid which was purified by column chromatography (Stationary Phase: Silica; Mobile Phase: 
ethyl acetate) to afford the product 2.6 (4.15 g, 16.4 mmol, 90%) as a bright yellow oil; RF 0.86 
(30% ethylacetate in dichloromethane); H (500 MHz, MeOD) 7.77 (d, J = 8.5 Hz, 1 H, H6), 
7.75 (s, 1 H, H3), 7.72 (d, J = 8.5 Hz 1 H, H5), 3.90 (s, 3 H, CO2CH3), 3.87 (d, J = 6 Hz, 2 H, 
H), 2.14 – 2.09 (quin, J = 6 Hz, 1 H, H), 1.07 (d, J = 6 Hz, 6H, H); C (126 MHz, MeOD) 
167.1 , 159.9, 152.1, 132.8, 127.5, 115.7, 108.8, 76.9, 53.0, 29.5, 19.6; νmax/cm
-1
 (solid state) 
3120, 2961, 1737, 1709, 1616, 1589, 1530 1489; ESI-HRMS found m/z 276.0853 [M+Na]
+
, 
C12H15NNaO5 requires 276.0842; Found: C, 57.15; H, 6.05; N, 5.45; C12H15NO5 requires C, 
56.91; H, 5.97; N, 5.53 %. 
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Methyl 4-amino-2-isobutoxybenzoate (2.10)
127
 
 A solution containing methyl 2-isobutoxy-4-nitrobenzoate 2.6 (3.86 g, 15.2 
mmol) in methanol (120 mL) and palladium on carbon (10 wt. %) was 
evacuated and flushed with nitrogen (3 times) and left under vacuum. 
Hydrogen was drawn into the flask and the reaction was left stirring at rt 
overnight. On completion, the reaction mixture was filtered through a celite pad and washed 
with methanol. The organic solvent was evaporated to dryness to yield the target product 2.10 
(3.4 g, 15.2 mmol, quant.) as a grey gel; RF 0.56 (30% ethylacetate in dichloromethane); H (500 
MHz, CDCl3) 7.75 (d, J = 8.5 Hz, 1 H, H6), 6.21 (s, 1 H, H3), 6.18 (d, J = 8.5 Hz 1 H, H5), 4.10 
(br, 2 H, NH2), 3.84 (s, 3 H, CO2CH3), 3.72 (d, J = 6.5 Hz, 2 H, H), 2.19 – 2.11 (quin, J = 6.5 
Hz, 1 H, H), 1.04 (d, J = 6.5 Hz, 6 H, H); C (126 MHz, CDCl3) 166.6, 161.3, 152.1, 134.2, 
109.2, 106.3, 98.7, 75.0, 51.3, 28.3, 19.3; νmax/cm
-1
 (solid state) 3635, 3445, 2977, 1732, 1433, 
1395, 1221; ESI-HRMS found m/z 246.1107 [M+Na]
+
, C12H15NNaO5 requires 246.1101. 
 
Methyl 3-hydroxy-4-nitrobenzoate (2.3)
122
 
Sulphuric acid (conc) (1.10 mL, 20.4 mmol) was added to a solution of 3-hydroxy-
4-nitrobenzoic acid 2.1 (10.0 g, 54.6 mmol) in MeOH (100 mL) and the resulting 
mixture heated at reflux overnight under a nitrogen atmosphere. The reaction 
mixture was allowed to cool to rt and the resulting precipitate collected via 
filtration to afford the desired product 2.3 (10.37 g, 52.6 mmol, 96%) as a yellow solid; RF: 0.61 
(dichloromethane); δH (500 MHz, CDCl3) 10.51 (s, 1 H, OH), 8.19 (d, J = 9.0 Hz, 1 H, H5), 
7.84 (d, J = 1.5 Hz, 1 H, H2), 7.63 (dd, J = 9.0, 1.5 Hz, 1 H, H6), 3.98 (s, 3 H, CO2CH3); δC 
(125 MHz, CDCl3) 164.9, 154.7, 138.0, 135.8, 125.3, 121.7, 120.6, 52.9; νmax/cm
-1
 (solid state) 
= 3317, 2962, 1722, 1587, 1436, 1223, 743; ESI-HRMS found m/z 196.0253 [M-H]
-
, C8H6NO5 
requires 197.0324; Found: C, 48.80; H, 3.60; N, 6.90; C8H7NO5 requires: C, 48.74; H, 3.58; N, 
7.10 %. 
 
Methyl 3-isobutoxy-4-nitrobenzoate (2.5)
122
 
To a stirred solution of methyl-3-hydroxy-4-nitrobenzoate 2.3 (2.00 g, 10.2 
mmol) and potassium carbonate (3.52 g, 25.5 mmol) in DMF (30 mL), 
isobutyl bromide (1.40 mL, 12.5 mmol) was added and the resulting mixture 
stirred at 50 °C overnight under a nitrogen atmosphere. The reaction was 
incomplete, so a further aliquot of isobutyl bromide (600 μL, 5.34 mmol) was added. After 20 h 
stirring, the resultant suspension was allowed to cool, poured into water and extracted with ethyl 
acetate (3 × 50 mL); the combined organic fractions were washed with water (2 × 150 mL) and 
brine (4 × 200 mL) before being dried over MgSO4. The organic solvents were evaporated 
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resulting in an orange solid 2.5 (2.09 g, 8.26 mmol, 81%); RF: 0.65 (dichloromethane); δH (500 
MHz, CDCl3) 7.82 (d, J = 8.5 Hz, 1 H, H5), 7.73 (d, J = 1.5 Hz, 1 H, H2), 7.67 (dd, J = 8.5, 1.5 
Hz, 1 H, H6), 3.97 (s, 3 H, CO2CH3), 3.93 (d, J = 6.5 Hz, 2 H, H), 2.20 – 2.14 (m, 1 H, H), 
1.07 (d, J = 7.0 Hz, 6 H, H) ; δC (125 MHz, CDCl3) 165.3, 152.1, 142.5, 134.7, 125.2, 121.1, 
115.4, 76.0, 52.8, 28.2, 19.0; νmax/cm
-1
 (solid state) = 3100, 2957, 1726, 1608, 1524, 1307, 1236, 
750; ESI-HRMS found m/z 276.0841 [M+Na]
+
, C12H15NNaO5 requires 276.0842. 
 
Methyl 4-amino-3-isobutoxybenzoate (2.9)
122
 
A solution containing methyl 3-isobutoxy-4-nitrobenzoate 2.5 (1.99 g, 7.86 
mmol) in a 1:1 mixture of methanol : tetrahydrofuran (40 mL) and palladium 
on carbon (10 wt. %) was evacuated and flushed with nitrogen (3 times) and 
left under vacuum. Hydrogen was drawn into the flask and the reaction was 
left stirring at rt overnight. On completion, the reaction mixture was filtered through a celite pad 
and washed with methanol and tetrahydrofuran. The organic solvents were evaporated to 
dryness to yield the target product  2.9 (1.66 mg, 7.44 mmol, 95%) as a beige solid; δH (500 
MHz, CDCl3) 7.54 (dd, J = 1.8, 8.0 Hz, 1 H, H6), 7.44 (d, J = 1.8 Hz, 1 H, H2), 6.67 (d, J = 8.0 
Hz, 1 H, H5), 4.22 (s, broad, 2 H, NH2), 3.87 (s, 3 H, CO2CH3), 3.83 (d, J = 6.5 Hz, 2 H, H), 
2.17 – 2.11 (m, 1 H, H), 1.06 (d, J = 6.5 Hz, 6 H, H); δC (125 MHz, CDCl3) 167.4, 145.6, 
141.3, 123.9, 119.5, 113.1, 112.1, 74.7, 51.7, 28.3, 19.3; νmax/cm
-1
 (solid state) = 3461, 3343, 
3201, 2951, 1687, 1622, 1270, 766; ESI-HRMS found m/z 224.1281 [M+H]
+
, C12H18NO3 
requires 224.1281. 
 
3-Isobutoxy-4-nitrobenzoic acid (2.7)
122
  
 
A solution of 10% aqueous sodium hydroxide (21 mL) was added to a solution 
of methyl 3-isobutoxy-4-nitrobenzoate 2.5 (3.50 g, 13.8 mmol) in a 1:1 
mixture of methanol : tetrahydrofuran (90 mL). On completion, the organic 
solvents were removed under reduced pressure and the remaining solution was 
poured in water (100 mL) and acidified via addition of hydrochloric acid (conc) to pH 1. The 
resulting suspension was extracted with dichloromethane (4 × 100 mL), the organic fractions 
were combined and washed with water (2 × 200 mL) followed by brine (200 mL) and dried over 
MgSO4. The organic solvents were evaporated to yield the target material 2.7 (3.15 g, 13.5 
mmol, 95%) as a yellow solid; δH (300 MHz, DMSO-d6) 7.96 (d, J = 8.3 Hz, 1 H, H3), 7.74 (d, 
J = 1.3 Hz, 1 H, H6), 7.63 (dd, J = 1.3, 8.3 Hz, 1 H, H2), 4.01 (d, J = 6.4 Hz, 2 H, H), 2.03 (m, 
1 H, H), 0.98 (d, J = 6.7 Hz, 6 H, H); δC (75 MHz, DMSO-d6) 166.1, 151.4, 142.5, 136.0, 
125.3, 121.5, 115.6, 75.5, 28.0, 19.0; νmax/cm
-1
 (solid state) = 3088, 2531, 2342, 1817, 1693, 
1310, 1015, 748; ESI-HRMS found m/z 238.0721 [M-H]
-
, C11H12NO5 requires 238.0721; Found 
C, 55.05; H, 5.45; N, 5.80%. C11H13NO5 requires C, 55.23; H, 5.48; N, 5.86%. 
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2,5-Dihydroxy-4-nitrobenzoic acid (2.12) 
 
To a stirred solution of 3-hydroxy-4-nitrobenzoic acid 2.11 (40.00 g, 218.4 
mmol) in 2 N aqueous sodium hydroxide solution (800 mL) was added 
dropwise a solution of potassium persulfate (59.00 g, 218.4 mmol) in water 
(1200 mL). The resulting solution was stirred at rt for 14 days. The reaction 
mixture was acidified via the addition of sulphuric acid (conc) to pH 1 and the resulting 
precipitate was removed by filtration. The aqueous solution was refluxed for 1 h. After cooling 
to rt the resulting precipitate was collected via filtration to yield the title compound 2.12 (16.11 
g, 80.9 mmol, 37%) as gold microcrystals; δH (300 MHz, DMSO-d6) 7.49 (s, 1 H, H6), 7.37 (s, 
1 H, H3); δC (75 MHz, DMSO-d6) 170.1, 152.3, 143.1, 141.7, 119.7, 119.1, 112.5; νmax/cm
-1
 
(solid state) = 3533, 3400, 2000, 1690, 1598, 1442, 1244, 760, 627; ESI-HRMS found m/z 
198.0049 [M-H]
-
, C7H4NO6 requires 198.0044; Found C, 42.05; H, 2.35; N, 6.80%. C7H5NO6 
requires C, 42.22; H, 2.53; N, 7.03%. 
 
Methyl 2,5-dihydroxy-4-nitrobenzoate (2.13)  
 
To a stirred solution of 2,5-dihydroxy-4-nitrobenzoic acid 2.12 (5.00 g, 25.1 
mmol) in methanol (200 mL) was added slowly concentrated sulphuric acid (2 
mL) and the resulting solution was stirred at reflux overnight. The reaction 
mixture was allowed to cool to rt and sodium bicarbonate was added until 
carbon dioxide evolution ceased. The mixture was added to water (250 mL) and extracted with 
ethyl acetate (3  100 mL) and the combined organic fractions were washed with brine (100 
mL). The organic solvent was removed by reduced pressure and the resulting orange solid was 
crystallised with chloroform to yield the title compound 2.13 (5.33 g, 25.0 mmol, quant.) as 
orange crystals; δH (300 MHz, CDCl3) 10.19 (s, 1 H, 5-OH), 9.75 (s, 1H, 2-OH), 7.71 (s, 1 H, 
H3), 7.69 (s, 1 H, H6), 4.02 (s, 3 H, CO2CH3); δC (75 MHz, CDCl3) 168.9, 153.5, 146.7, 137.5, 
121.4, 120.8, 112.8, 53.7; νmax/cm
-1
 (solid state) = 3359, 1695, 1440, 1220, 790; ESI-HRMS 
found m/z 212.0207 [M-H]
-
, C8H6NO6 requires 212.0273; Found C, 45.15; H, 3.25; N, 6.45%. 
C8H7NO6 requires C, 45.08; H, 3.31; N, 6.57%. 
 
Methyl 2,5-diisobutoxy-4-nitrobenzoate (2.14)  
 
To a stirred solution of methyl 2,5-dihydroxy-4-nitrobenzoate 2.13 
(4.00 g, 18.8 mmol) and potassium carbonate (13.00 g, 93.8 mmol) 
in DMF (200 mL), isobutyl bromide (6.5 mL, 56.3 mmol) was added 
and the resulting mixture stirred at 50 °C overnight under a nitrogen 
atmosphere. On completion, the resulting suspension was allowed to cool to rt, poured into 
water and extracted with ethyl acetate (3 × 150 mL); the combined organic fractions were 
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washed with water (2 × 250 mL) and brine (4 × 300 mL) before being dried over MgSO4. The 
organic solvent was evaporated resulting in the title compound 2.14 (4.41 g, 13.6 mmol, 72%) 
was yielded as a yellow oil; δH (500 MHz, CDCl3) 7.47 (s, 1 H, H3), 7.39 (s, 1 H, H6), 3.94 (s, 3 
H, CO2CH3), 3.85 (d, J = 6.4 Hz, 2 H, H2), 3.79 (d, J = 6.4 Hz, 2 H, H5), 2.11 – 2.17 (m, 2 
H, H2, H5), 1.04 – 1.07 (m, 12 H, H2, H5); δC (75 MHz, CDCl3) 165.6, 151.6, 145.7, 
141.7, 125.3, 118.0, 110.3, 76.6, 76.2, 52.5, 28.3, 28.3, 19.1, 19.0; νmax/cm
-1
 (solid state) = 2960, 
1739, 1529, 1392, 1217, 1024, 793; ESI-HRMS found m/z 348.1417 [M+Na]
+
, C16H23NNaO6 
requires 348.1418. 
 
 
2,5-Diisobutoxy-4-nitrobenzoic acid (2.15) 
 
A solution of 10% aqueous sodium hydroxide (13 mL) was added to 
a solution of methyl 2,5-diisobutoxy-4-nitrobenzoate 2.14 (2.16 g, 
8.0 mmol) in a 1:1 mixture of methanol : tetrahydrofuran (50 mL). 
On completion, the organic solvents were removed under reduced 
pressure and the remaining solution was poured into water (100 mL) and acidified via addition 
of hydrochloric acid (conc) to pH 1. The resulting suspension was extracted with 
dichloromethane (4 × 100 mL), the organic fractions were combined and washed with water (2 
× 200 mL) and brine (200 mL) before being dried over MgSO4. The organic solvent was 
evaporated to yield the target material 2.15 (2.13 g, 6.84 mmol, 97%) as an amorphous yellow 
solid; δH (500 MHz, CDCl3) 7.90 (s, 1 H, H6), 7.50 (s, 1 H, H3), 4.04 (d, J = 6.4 Hz, 2 H, H2), 
3.91 (d, J = 6.4 Hz, 2 H, H5), 2.25 (m, 1 H, H2), 2.14 (m, 1 H, H5), 1.12 (m, 6 H, H2), 
1.05 (m, 6 H, H5); δC (125 MHz, CDCl3) 163.7, 150.3, 146.9, 142.4, 121.9, 119.5, 110.1, 77.6, 
76.6, 28.2, 28.1, 19.1, 19.0; νmax/cm
-1
 (solid state) = 3229, 2961, 1747, 1525, 1203, 1003, 803; 
ESI-HRMS found m/z 334.1267 [M+Na]
+
, C15H21NNaO6 requires 334.1261. 
 
 
Methyl 4-amino-2,5-diisobutoxybenzoate (2.16)  
 
To a stirred solution of methyl 2,5-diisobutoxy-4-nitrobenzoate 2.14 
(2.24 g, 6.89 mmol) in ethyl acetate (50 mL), tin(II) chloride 
dihydrate (9.32 g, 41.33 mmol) was added and the resulting mixture 
stirred at 50 °C overnight under a nitrogen atmosphere. On 
completion, the reaction mixture was allowed to cool and poured over ice. The solution was 
basified to pH 8 by addition of a saturated sodium bicarbonate solution and the resulting 
mixture was allowed to stir for an hour. The aqueous mixture was extracted with ethyl acetate (3 
× 100 mL) and the organic fractions were combined, washed with water (3 × 250 mL) and brine 
(2 × 250 mL), dried over MgSO4 and the organic solvents were evaporated to afford the desired 
product 2.16 (1.83 g, 6.2 mmol, 90%) as a light brown solid; δH (500 MHz, CDCl3) 7.33 (s, 1 H, 
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H6), 6.29 (s, 1 H, H3), 3.85 (s, 3 H, CO2CH3), 3.76 (d, J = 6.4 Hz, 2 H, H2), 3.71 (d, J = 6.4 
Hz, 2 H, H5), 2.07 – 2.15 (m, 2 H, H2, H5), 1.03 – 1.06 (m, 12 H, H2, H5); δC (75 MHz, 
CDCl3) 166.8, 155.7, 142.2, 139.7, 114.8, 107.7, 100.0, 76.0, 75.2, 51.5, 28.5, 28.4, 19.4, 19.3; 
νmax/cm
-1
 (solid state) = 3492, 3368, 2957, 1704, 1621, 1523, 1445, 1252, 1210, 1035, 780; ESI-
HRMS found m/z 318.1675 [M+Na]
+
, C16H25NNaO4 requires 318.1676. 
 
Diethyl 2,5-diisobutoxyterephthalate (2.30)  
To a stirred solution of diethyl 2,5-dihydroxyterephthalate 2.29 (2.02 
g, 7.95 mmol) and potassium carbonate (5.00 g, 36.2 mmol) in DMF 
(50 mL), isobutyl bromide (2.12 mL, 18.9 mmol) was added and the 
resulting suspension stirred at 90 °C under a nitrogen atmosphere. 
After 18 h the reaction was shown to be incomplete, so a further aliquot of isobutyl bromide (1 
mL, 8.91 mmol) was added. After 40 h stirring, the resulting suspension was poured into water 
and extracted with ethyl acetate (3 × 60 mL). The combined organic fractions were washed with 
water (2 × 140 mL) and brine (4 × 140 mL), then dried over MgSO4. The solvent was removed 
under reduced pressure and the resulting oil purified by column chromatography (Stationary 
Phase: Silica; Mobile Phase: dichloromethane) to afford the desired product 2.30 (1.98 g, 5.41 
mmol, 68%) as a colourless solid; RF: 0.47 (dichloromethane); H (500 MHz, CDCl3) 7.34 (s, 2 
H, H2), 4.39 (q, J = 7.5 Hz, 4 H, CO2CH2), 3.78 (d, J = 6.5 Hz, 4 H, H), 2.14 – 2.09 (m, 2 H, 
H), 1.40 (t, J = 7.5 Hz, 6 H, CO2CH2CH3), 1.05 (d, J = 6.5 Hz, 12 H, H); δC (125 MHz, 
CDCl3) 166.3, 151.7, 124.6, 116.4, 76.0, 61.2, 28.4, 19.2, 14.3; νmax/cm
-1
 (solid state) = 3069, 
2953, 2496, 1694, 1422, 1216, 1022, 781; ESI-HRMS found m/z 389.1953 [M+Na]
+
, 
C20H30NaO6 requires 389.1935; Found: C, 65.55; H, 8.30; C20H30O6 requires: C, 65.55; H, 8.25 
%. 
 
Diethyl 2,5-bis(benzyloxy)terephthalate (2.31) 
To a stirred solution of diethyl 2,5-dihydroxyterephthalate 2.29 
(4.00 g, 15.7 mmol) and potassium carbonate (10.00 g, 72.4 
mmol) in DMF (80 mL), benzyl bromide (4.50 mL, 37.7 mmol) 
was added and the resulting suspension stirred at 90 °C under a 
nitrogen atmosphere overnight. The resulting suspension was 
poured into water and extracted with ethyl acetate (3 × 100 mL). The combined organic 
fractions were washed with water (2 × 300 mL) and brine (4 × 300 mL) before being dried over 
MgSO4. The solvent was removed under reduced pressure to afford the desired product 2.31 
(6.80 g, 15.7 mmol, quant.) as a colourless solid; H (500 MHz, CDCl3) 7.50 – 7.49 (m, 6 H, 
H2, HAr2), 7.41 – 7.31 (m, 6 H, HAr3, HAr4), 5.15 (s, 4 H, H), 4.39 (q, J = 7.0 Hz, 4 H, 
CO2CH2), 1.35 (t, J = 7.0 Hz, 6 H, CO2CH2CH3); δC (125 MHz, CDCl3) 165.8, 151.7, 136.6, 
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128.5, 127.9, 127.3, 125.2, 117.6, 71.8, 61.4, 14.2; (νmax/cm
-1
 (solid state) = 2979, 1687, 1477, 
1454, 1216, 1199, 1015, 738, 694; ESI-HRMS found m/z 435.1806 [M+H]
+
, C26H27O6 requires 
435.1802. 
 
2,5-Diisobutoxyterephthalic acid (2.32) 
Diethyl 2,5-diisobutoxyterephthalate 2.30 (501 mg, 1.37 mmol) was 
dissolved in a 1:1 mixture of methanol : tetrahydrofuran (30 mL), a 
10% sodium hydroxide solution (5 mL) was added and the resulting 
solution was stirred at rt overnight. The organic solvents were 
removed under reduced pressure and the remaining solution was poured into water (50 mL) and 
acidified via addition of hydrochloric acid (conc) to pH 1. The resulting suspension was 
extracted with dichloromethane (4 × 50 mL) and the organic fractions were combined and 
washed with water (2 × 150 mL), followed by brine (150 mL), and dried over MgSO4. The 
organic solvents were evaporated to yield the target material 2.32 (365 mg, 1.18 mmol, 86%) as 
a colourless solid; δH (500 MHz, CDCl3) 11.12 (s, broad, 2 H, CO2H), 7.89 (s, 2 H, H2), 4.09 (d, 
J = 6.5 Hz, 4 H, H), 2.27 – 2.22 (m, 2 H, H), 1.11 (d, J = 6.5 Hz, 12 H, H); δC (125 MHz, 
CDCl3) 164.1, 151.8, 122.7, 117.4, 77.4, 28.1, 19.1; νmax/cm
-1
 (solid state) = 2970, 1737, 1366, 
1443, 1227, 1032, 760; ESI-HRMS found m/z 309.1360 [M-H]
-
, C16H21O6 requires 309.1344; 
Found: C, 62.20; H, 7.10; C16H22O6 requires: C, 61.92; H, 7.15 %. 
 
 
2,5-Bis(benzyloxy)terephthalic acid (2.33)  
Diethyl 2,5-diisobutoxyterephthalate 2.31 (6.0 g, 13.7 mmol) was 
dissolved in a 1:1 mixture of methanol : tetrahydrofuran (200 
mL) and a 10% sodium hydroxide solution (50 mL) was added, 
the resulting solution was stirred at rt overnight. The organic 
solvents were removed under reduced pressure and the remaining solution was poured into 
water (200 mL) and acidified via addition of hydrochloric acid (conc) to pH 1. The resulting 
suspension was extracted with tetrahydrofuran (4 × 150 mL); the organic fractions were 
combined and washed with brine (3 × 200 mL) before being dried over MgSO4. The organic 
solvents were evaporated to yield the target material 2.33 (4.25 g, 11.2 mmol, 82%) as a 
colourless solid; δH (500 MHz, DMSO) 7.48 (d, J = 7.5 Hz, 4 H, HAr2), 7.42 (s, 2 H, H2), 7.39 
(app t, J = 7.5 Hz, 4 H, HAr3), 7.32 (d, J = 7.5 Hz, 4 H, HAr4), 5.17 (s, 4 H, H); δC (125 MHz, 
DMSO) 166.7, 150.3, 137.0, 128.3, 127.7, 127.2, 125.7, 116.1, 70.5; νmax/cm
-1
 (solid state) = 
2859, 2644, 2528, 1673, 1444, 1378, 1220, 1021, 736; ESI-HRMS found m/z 377.1035 [M-H]
-
, 
C22H17O6 requires 377.1031. 
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1,4-Diisobutoxy-2,5-diisocyanatobenzene (2.34) 
To a stirred solution of 2,5-diisobutoxyterephthalic acid 2.32 (125 
mg, 0.40 mmol) in anhydrous toluene (30 mL), triethylamine (125 
μL, 0.90 mmol) followed by diphenylphosphoryl azide (163 μL, 
0.76 mmol) were added and the resulting solution was stirred for 
2 h at rt under a nitrogen atmosphere, then the reaction mixture 
was left overnight without stirring. Ethyl acetate was added and the resulting solution was 
washed with a saturated sodium bicarbonate solution and brine before being dried over MgSO4. 
The solvent was removed under reduced pressure and the resulting dark purple oil purified by 
column chromatography (Stationary Phase: Silica; Mobile Phase: ethyl acetate/hexane, 3:1) to 
afford the desired product 2.34 (50 mg, 0.41 mmol, 41%) as a dark solid; H (500 MHz, CDCl3) 
6.55 (s, 2 H, H2), 3.74 (d,  J = 6.5 Hz, 4 H, H), 2.18 – 2.12 (m, 2 H, H), 1.05 (d,  J = 7.0 Hz, 
12 H, H); δC (125 MHz, CDCl3) 147.0, 130.9, 120.8, 107.5, 75.8, 28.2, 19.2; νmax/cm
-1
 (solid 
state) = 2957, 2254 (N=C=O stretch), 1540, 1450, 1220, 859. 
 
tert-Butyl 2,5-diisobutoxy-1,4-phenylenedicarbamate (2.35) 
A solution of 1,4-diisobutoxy-2,5-diisocyanatobenzene 2.34 (45 mg, 
0.15 mmol) was dissolved in anhydrous tert-butanol (10 mL) and 
heated to reflux overnight under a nitrogen atmosphere. The solvent 
was evaporated under reduced pressure and the resulting oil purified 
by column chromatography (Stationary Phase: Silica; Mobile Phase: 
ethyl acetate/hexane, 1:3) to afford the desired product 2.35 (53 mg, 
0.12 mmol, 79%) as a brown solid; δH (500 MHz, CDCl3) 7.75 (s, 2 
H, H2), 6.98 (s, 2 H, NH), 3.78 (d, J = 6.5 Hz, 4 H, H), 2.13 – 2.05 (m, 2 H, H), 1.53 (s, 18 
H, NHCO2C(CH3)3), 1.04 (d, J = 6.5 Hz, 12 H, H); δC (125 MHz, CDCl3) 152.9, 140.9, 122.6, 
103.3, 80.1, 75.8, 28.4, 28.4 19.4; νmax/cm
-1
 (solid state) = 3442, 2963, 1724, 1541, 1428, 1232, 
1153, 1052, 861; ESI-HRMS found m/z 453.2970 [M+H]
+
, C24H41N2O6 requires 453.2959. 
 
2,5-Diisobutoxyterephthaloyl dichloride  (2.38) 
To a stirred solution of 2,5-diisobutoxyterephthalic acid 2.32 (414 
mg, 1.34 mmol) in dichloromethane (40 mL), thionyl chloride (500 
μL, 6.89 mmol) was added and the resulting mixture was stirred at 
reflux overnight under a nitrogen atmosphere. The organic solvent 
and the thionyl chloride were co-evaporated under a nitrogen flow, this was repeated 3 times 
with the corresponding addition of further portions of dichloromethane, to yield a yellow solid 
2.38; δH (500 MHz, CDCl3) 7.48 (s, 2 H, H2), 3.84 (d, J = 6.5 Hz, 4 H, H), 2.19-2.13 (m, 2 H, 
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H), 1.07 (d, J = 6.5 Hz, 12 H, H); δC (125 MHz, CDCl3) 163.6, 151.2, 128.3, 116.9, 76.2, 
28.3, 19.1; νmax/cm
-1
 (solid state) = 3127, 2963, 2875, 1770, 1492, 1386, 1226, 1154, 783. 
Found: C, 55.60; H, 5.75; Cl, 20.20; C16H20Cl2O4 requires: C, 55.34; H, 5.81; Cl, 20.42 %. 
 
2,5-Diisobutoxyterephthalamide  (2.39) 
2,5-Diisobutoxyterephthaloyl dichloride 2.38 (279 mg, 0.81 mmol) 
was dissolved in diethyl ether (30 mL) and the resulting solution was 
cooled down to 0 
o
C in an ice bath. A 35% aqueous ammonia 
solution was added dropwise to the solution until the product 
precipitated, which was then collected via filtration to afford the desired product 2.39 as a 
colourless solid (951 mg, 2.20 mmol, 92%); δH (500 MHz, DMSO-d6) 7.82 (s, broad, 2 H, NH), 
7.66 (s, broad, 2 H, NH), 7.51 (s, 2 H, H2), 3.89 (d, J = 6.5 Hz, 4 H, H), 2.11-2.09 (m, 2 H, 
H), 1.00 (d, J = 6.5 Hz, 12 H, H); δC (125 MHz, DMSO-d6) 165.1, 150.0, 125.0, 115.0, 75.4, 
27.4, 18.5; νmax/cm
-1
 (solid state) = 3409, 3184, 2954, 1645, 1435, 1217, 1036; ESI-HRMS 
found m/z 309.1810 [M+H]
+
, C16H25N2O4 requires 309.1809.   
 
N1, N4-Dihydroxy-2,5-diisobutoxyterephthalamide  (2.37) 
To a solution of 2,5-diisobutoxyterephthalic acid 2.32 (250 mg, 0.81 
mmol) in DMF (30 mL), 1,1'-carbonyldiimidazole (522 mg, 3.22 
mmol) was added and the resulting solution stirred for 30 min at rt. 
Hydroxylammonium hydrochloride (448 mg, 6.45 mmol) was added 
and the reaction stirred overnight. Water (750 mL) was added to the 
reaction mixture and the resulting solution was stirred for 2 h. The precipitate was collected via 
filtration, washed with water and dried under vacuum to yield the target product  2.37 (130 mg, 
0.38 mmol, 47%) as a beige solid;  δH (500 MHz, DMSO-d6) 10.53 (s, 2 H, OH), 9.19 (s, 2 H, 
NH), 7.20 (s, 2 H, H2), 3.80 (d, J = 6.5 Hz, 4 H, H), 2.06-2.00 (m, 2 H, H), 0.97 (d, J = 7.0 
Hz, 12 H, H); δC (125 MHz, DMSO-d6) 162.4, 149.6, 125.3, 114.4, 75.3, 27.6, 19.0; νmax/cm
-1
 
(solid state) = 3340, 2943, 1614, 1391, 1207, 1023, 805; ESI-HRMS found m/z 341.1711 
[M+H]
+
, C16H25N2O6 requires 341.1707; Found: C, 56.50; H, 7.15; N, 8.10; C16H24N2O6 
requires: C, 56.46; H, 7.11; N, 8.23 %. 
 
2-Isobutoxy-4-nitroaniline (2.41) 
A solution of 2-amino-5-nitrophenol 2.40 (499 mg, 3.25 mmol) and 
potassium carbonate (1.12 g, 8.13 mmol) in DMF (15 mL) was stirred at 50 
°C for 1 h. Isobutyl bromide (330 μL, 2.93 mmol) was added dropwise and 
the reaction was allowed to stir overnight, leading to complete conversion. 
The resulting suspension was poured into water and extracted with ethyl acetate (3 × 100 ml). 
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The combined organic fractions were washed with water (3 × 100 ml), brine (5 × 100 ml), and 
then dried over MgSO4. The solvent was evaporated under reduced pressure and the resulting 
orange solid was dissolved in chloroform, filtered and purified by column chromatography 
(Stationary Phase: Silica; Mobile Phase: ethyl acetate) to afford the desired product 2.41 (430 
mg, 2.05 mmol, 70%) as an orange solid; RF: 0.71 (ethyl acetate); H (500 MHz, CDCl3) 7.81 
(dd, J = 2.0, 8.8 Hz, 1 H, H5), 7.66 (d, J = 2.0 Hz, 1 H, H3), 6.65 (d, J = 8.8 Hz, 1 H, H6), 4.54 
(s, broad, 2 H, NH2), 3.86 (d, J = 6.5 Hz, 2 H, H), 2.21 – 2.13 (m, 1 H, H), 1.08 (d, J = 7.0 
Hz, 6 H, H); δC (125 MHz, CDCl3) 145.0, 143.3, 138.8, 119.0, 111.8, 106.7, 75.1, 28.2, 19.3; 
νmax/cm
-1
 (solid state) = 3505, 3392, 2915, 1615, 1312, 1235, 745; ESI-HRMS found m/z 
211.1078 [M+H]
+
, C10H15N2O3 requires 211.1077; Found: C, 57.15; H, 6.55; N, 13.45; 
C10H14N2O3 requires: C, 57.13; H, 6.71; N, 13.33 %. 
 
2-(benzyloxy)-4-nitroaniline (2.42) 
A solution of 2-amino-5-nitrophenol 2.40 (2.50 g, 16.2 mmol) and 
potassium carbonate (5.60 g, 40.5 mmol) in DMF (50 mL) was stirred at 
50 °C for 1 h. Benzyl bromide (1.73 mL, 14.6 mmol) was added 
dropwise and the reaction was allowed to stir overnight. The resulting 
suspension was poured into water and extracted with ethyl acetate (3 × 150 ml); the combined 
organic fractions were washed with water (3 × 150 ml) and brine (5 × 150 ml) before being 
dried over MgSO4. The solvent was evaporated under reduced pressure to afford the desired 
product 2.42 (3.60 g, 14.6 mmol, quant.) as an orange solid; RF: 0.69 (ethyl acetate); H (500 
MHz, CDCl3) 7.82 (dd, J = 2.0, 9.0 Hz, 1 H, H5), 7.78 (d, J = 2.0 Hz, 1 H, H3), 7.47 – 7.39 (m, 
5 H, HAr), 6.66 (d, J = 9.0 Hz, 1 H, H6), 5.16 (s, 4 H, H), 4.58 (s, broad, 2 H, NH2); δC (125 
MHz, CDCl3) 144.5, 143.5, 138.7, 135.8, 128.8, 128.6, 127.9, 119.4, 112.0, 107.3, 70.9; 
νmax/cm
-1
 (solid state) = 3481, 3357, 1620, 1478, 1272, 1221, 1006, 754; ESI-HRMS found m/z 
245.0920 [M+H]
+
, C13H13N2O3 requires 245.0921. 
 
(9H-Fluoren-9-yl)methyl 2-isobutoxy-4-nitrophenylcarbamate (2.43) 
A solution of 2-isobutoxy-4-nitroaniline 2.41 (505 mg, 2.40 mmol) and 
sodium bicarbonate (425 mg, 5.06 mmol) in tetrahydrofuran (50 mL) was 
stirred at reflux under a nitrogen atmosphere. A solution of 1-(9-
fluorenyl)methylchloroformate (952 mg, 3.68 mmol) in tetrahydrofuran (10 
mL) was added dropwise and the reaction allowed to stir at reflux overnight. 
The sodium bicarbonate was removed via hot filtration and the reaction 
mixture was allowed to cool to rt, concentrated under reduced pressure and 
the resulting precipitate collected via filtration to afford the desired product 2.43 (761 mg, 1.76 
mmol, 74%) as a colourless solid; RF: 0.86 (dichloromethane); H (500 MHz, CDCl3) 8.18 (s, 
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broad, 1 H, NH), 7.89 (d, J = 8.0 Hz, 1 H, H6 ), 7.80 (d, J = 7.5 Hz, 2 H, FHAr5), 7.74 (m, 1 H, 
H5), 7.62 (d, J = 7.5 Hz, 2 H, FHAr2), 7.53 (s, 1 H, H3), 7.45 – 7.42 (m, 2 H, FHAr4), 7.36 – 
7.33 (m, 2 H, FHAr3), 4.56 (d, J = 6.8 Hz, 2 H, FH), 4.34 (t, J = 6.8 Hz, 1 H, FH), 3.93 (d, J 
= 6.5 Hz, 2 H, H), 2.28 – 2.20 (m, 1 H, H), 1.12 (d, J = 7.0 Hz, 6 H, H); δC (125 MHz, 
CDCl3) 152.7, 146.5, 143.5, 142.7, 141.4, 133.9, 128.0, 127.2, 125.0, 120.2, 117.6, 116.8, 
106.2, 75.7, 67.7, 47.0, 28.1, 19.2; νmax/cm
-1
 (solid state) = 3095, 2958, 1713, 1587, 1504, 1344, 
1246, 734; ESI-HRMS found m/z 433.1767 [M+H]
+
, C25H25N2O5 requires 433.1758; Found: C, 
69.35; H, 5.50; N, 6.35; C25H24N2O5 requires: C, 69.43; H, 5.59; N, 6.48 %. 
 
(9H-fluoren-9-yl)methyl 2-(benzyloxy)-4-nitrophenylcarbamate (2.44) 
A solution of 2-(benzyloxy)-4-nitroaniline 2.42 (1.00 g, 4.09 mmol) and 
sodium bicarbonate (687 mg, 8.18 mmol) in tetrahydrofuran (90 mL) was 
stirred at reflux under a nitrogen atmosphere. A solution of 1-(9-
fluorenyl)methylchloroformate (1.60 mg, 6.14 mmol) in tetrahydrofuran 
(20 mL) was added dropwise and the reaction allowed to stir at reflux 
overnight. The sodium bicarbonate was removed via hot filtration and the 
reaction mixture was allowed to cool to rt and concentrated under reduced 
pressure. The resulting precipitate was collected via filtration to afford the desired product 2.44 
(1.54 g, 3.30 mmol, 81%) as a colourless solid; H (500 MHz, DMSO) 8.25 (s, broad, 1 H, NH), 
7.91 (d, J = 7.5 Hz, 2 H, FHAr5), 7.88 – 7.83 (m, 2 H, H6, H5, H3), 7.76 (d, J = 7.5 Hz, 2 H, 
FHAr2), 7.45 – 7.31 (m, 9 H, HAr, FHAr4, FHAr3), 5.36 (s, 2 H, H), 4.49 (d, J = 7.0 Hz, 2 H, 
FH), 4.34 (t, J = 7.0 Hz, 1 H, FH); δC (125 MHz, DMSO) 153.3, 148.1, 143.6, 142.7, 140.8, 
136.1, 134.4, 128.5, 128.1, 127.7, 127.6, 127.1, 125.2, 120.2, 120.2, 116.9, 107.7, 70.4, 66.6, 
46.4; νmax/cm
-1
 (solid state) = 3362, 1715, 1551, 1489, 1339, 1216, 1029, 734; ESI-HRMS found 
m/z 467.1600 [M+H]
+
, C28H23N2O5 requires 467.1601. 
 
(9H-Fluoren-9-yl)methyl 4-amino-2-isobutoxyphenylcarbamate (2.45) 
To a stirred solution of (9H-fluoren-9-yl)methyl 2-isobutoxy-4-
nitrophenylcarbamate 2.43 (528 mg, 1.22 mmol) in ethyl acetate (15 mL) 
and tetrahydrofuran (3 mL), tin(II) chloride dihydrate (1.80 g, 7.04 mmol) 
was added and the resulting mixture stirred at 50 °C overnight under a 
nitrogen atmosphere. The reaction mixture was allowed to cool and poured 
over ice. The solution was basified to pH 8 by addition of a saturated 
sodium bicarbonate solution and the resulting basic mixture was allowed to 
stir for an hour. The aqueous mixture was extracted with ethyl acetate (3 × 100 mL) and the 
organic fractions were combined, washed with water (3 × 250 mL) and brine (2 × 250 mL) 
before being dried over MgSO4. The organic solvents were evaporated and the resulting dark 
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solid purified by column chromatography (Stationary Phase: Silica; Mobile Phase: 
dichloromethane to 1:1 dicholomethane / ethyl acetate) to afford the desired product 2.45 (378 
mg, 0.94 mmol, 77%) as a purple solid; H (500 MHz, CDCl3) 7.80 – 7.78 (m, 3 H, FHAr5 and 
H6), 7.64 (d, J = 5.5 Hz, 2 H, FHAr2),  7.44 – 7.41 (m, 2 H, FHAr4), 7.34 – 7.31 (m, 2 H, 
FHAr3), 7.02 (s, broad, 1 H, NH), 6.32 – 6.29 (m, 2 H, H5 and H3), 4.46 (d, J = 6.8 Hz, 2 H, 
FH), 4.33 (t, J = 6.8 Hz, 1 H, FH), 3.76 (d, J = 6.5 Hz, 2 H, H), 3.61 (s, broad, 2 H, NH2), 
2.19 – 2.14 (m, 1 H, H), 1.08 (d, J = 6.5 Hz, 6 H, H); δC (125 MHz, CDCl3) 153.7, 148.9, 
144.0, 142.8, 141.4, 127.7, 127.1, 125.2, 120.4, 120.0, 119.1, 107.1, 99.8, 74.9, 67.0, 47.2, 28.3, 
19.3; νmax/cm
-1
 (solid state) = 3312, 2960, 1705, 1534, 1448, 1224, 738; ESI-HRMS found m/z 
403.2019 [M+H]
+
, C25H27N2O3 requires 403.2016; Found: C, 74.20; H, 6.40; N, 6.80; 
C25H26N2O3 requires: C, 74.60; H, 6.51; N, 6.96 %. 
 
 
(9H-fluoren-9-yl)methyl 4-amino-2-(benzyloxy)phenylcarbamate (2.46) 
Tin(II) chloride dihydrate (3.28 g, 12.8 mmol) was added to a stirred 
solution of (9H-fluoren-9-yl)methyl 2-(benzyloxy)-4-nitrophenylcarbamate 
2.44 (1.00 g, 2.14 mmol) in 1:1 mixture of ethyl acetate : tetrahydrofuran 
(100 mL) and the resulting mixture stirred at 50 °C overnight under a 
nitrogen atmosphere. The reaction mixture was allowed to cool to rt and 
poured over ice. The solution was basified to pH 8 by addition of a saturated 
sodium bicarbonate solution and the resulting basic mixture was allowed to 
stir for an hour. The aqueous suspension was extracted with ethyl acetate (3 × 100 mL) and the 
organic fractions were combined, washed with water (3 × 250 mL) and brine (2 × 250 mL) 
before being dried over MgSO4. The organic solvent was evaporated and the resulting dark solid 
purified by column chromatography (Stationary Phase: Silica; Mobile Phase: 
dichloromethane/ethyl acetate, 9:1) to afford the desired product 2.46 (335 mg, 0.77 mmol, 
36%) as a purple solid; H (500 MHz, CDCl3) 7.80 – 7.77 (m, 3 H, FHAr5 and H6), 7.61 (d, J = 
6.0 Hz, 2 H, FHAr2),  7.43 – 7.28 (m, 9 H, HAr, FHAr4, FHAr3), 7.01 (s, broad, 1 H, NH), 
6.35 – 6.32 (m, 2 H, H5 and H3), 5.09 (s, 2 H, H), 4.45 (d, J = 7.0 Hz, 2 H, FH), 4.30 (t, J = 
7.0 Hz, 1 H, FH), 3.57 (s, broad, 2 H, NH2); δC (125 MHz, CDCl3) 153.7, 148.7, 144.0, 142.9, 
141.3, 136.6, 128.8, 128.3, 127.7, 127.4, 127.1, 125.2, 120.9, 120.0, 119.3, 107.7, 100.3, 70.8, 
67.0, 47.2; νmax/cm
-1
 (solid state) = 3300, 3030, 1690, 1531, 1222, 1041, 730; ESI-HRMS found 
m/z 437.1868 [M+H]
+
, C28H25N2O3 requires 437.1860. 
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Diethyl 2-hydroxyterephthalate (2.48) 
p-Toluenesulfonic acid (200 mg, 1.05 mmol) was added to a stirred solution of 
2-hydroxyterephthalic acid 2.47 (2.00 g, 10.98 mmol) in anhydrous ethanol 
(125 mL) and the resulting solution refluxed at 90 °C under a nitrogen 
atmosphere. After 3 days the reaction was incomplete, so a further portion of p-
toluenesulfonic acid (50 mg, 0.26 mmol) and anhydrous ethanol (50 mL) were added. After 3 
more days, the organic solvent was evaporated under reduced pressure, the solid residue was 
redisolved in water and the resulting mixture basified with a saturated solution of NaHCO3 to 
pH 8. The solution was extracted with ethyl acetate (3 × 60 mL); the combined organic fractions 
were washed with water (2 × 60 mL) and brine (1 × 60 mL) before being dried over MgSO4. 
The solvent was removed under reduced pressure to afford the desired product 2.48 (2.25 g, 
9.45 mmol, 86%) as light brown oil; H (500 MHz, CDCl3) 10.85 (s, 1 H, OH), 7.91 (d, J = 8.5 
Hz, 1 H, H6), 7.65 (d, J = 1.5 Hz, 1 H, H3), 7.53 (dd, J = 1.5, 8.5 Hz, 1 H, H5), 4.45 (q, J = 7.0 
Hz, 2 H, CO2CH2 meta), 4.39 (q, J = 7.0 Hz, 2 H, CO2CH2 ortho), 1.45 (t, J = 7.0 Hz, 3 H, 
CO2CH2CH3 meta), 1.41 (t, J = 7.0 Hz, 3 H, CO2CH2CH3 ortho); δC (125 MHz, CDCl3) 169.6, 
165.6, 161.4, 136.7, 130.0, 119.6, 118.8, 115.9, 61.9, 61.5, 14.2, 14.2; νmax/cm
-1
 (solid state) = 
3139, 2983, 1722, 1675, 1294, 1203, 1099, 754; ESI-HRMS found m/z 237.0727 [M-H]
-
, 
C12H13O5 requires 237.0768.
 
 
Diethyl 2-isobutoxyterephthalate (2.49) 
Isobutyl bromide (566 µL, 5.04 mmol) was added to a stirred solution of 
diethyl 2-hydroxyterephthalate 2.48 (1.00 g, 4.20 mmol) and potassium 
carbonate (1.28 g, 9.24 mmol) in DMF (20 mL), and the resulting 
suspension stirred at 50 °C overnight under a nitrogen atmosphere. The 
reaction was incomplete, so a further aliquot of isobutyl bromide (200 µL, 1.78 mmol) was 
added. After 15 h stirring, the resulting suspension was poured into water and extracted with 
ethyl acetate (3 × 60 mL); the combined organic fractions were washed with water (2 × 140 mL) 
and brine (4 × 140 mL) before being dried over MgSO4. The solvent was removed under 
reduced pressure to afford the desired product 2.49 (1.17 g, 3.98 mmol, 94%) as a yellow oil; H 
(500 MHz, CDCl3) 7.78 (d, J = 8.0 Hz, 1 H, H6), 7.62 (dd, J = 1.5, 8.0 Hz, 1 H, H5), 7.59 (d, J 
= 1.5 Hz, 1 H, H3), 4.40 (q, J = 7.0 Hz, 2 H, CO2CH2 meta), 4.39 (q, J = 7.0 Hz, 2 H, CO2CH2 
ortho), 3.87 (d, J = 6.5 Hz, 2 H, H), 2.20 – 2.12 (m, 1 H, H), 1.42 (t, J = 7.0 Hz, 3 H, 
CO2CH2CH3 meta), 1.40 (t, J = 7.0 Hz, 3 H, CO2CH2CH3 ortho), 1.08 (d, J = 6.5 Hz, 6 H, H); 
δC (125 MHz, CDCl3) 166.3, 165.9, 158.1, 134.5, 131.2, 124.9, 120.9, 113.6, 75.3, 61.4, 61.2, 
28.4, 19.2, 14.3 (2 C); ESI-HRMS found m/z 295.1538 [M+H]
+
, C16H23O5 requires 295.1540. 
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4-(Ethoxycarbonyl)-3-isobutoxybenzoic acid (2.50) 
Lithium hydroxide monohydrate (286 mg, 6.82 mmol) was dissolved in 
the minimum quantity of water and added to a solution of diethyl 2-
isobutoxyterephthalate 2.49 (2.23 g, 7.58 mmol) in tetrahydrofuran (50 
mL). The reaction was stirred at rt for 18 h; further portions of lithium 
hydroxide monohydrate were added to achieve completion. The mixture was acidified with a 
10% solution of potassium bisulphate to pH 4 and was extracted with ethyl acetate (3 × 60 mL); 
the combined organic fractions were washed with water (2 × 60 mL) and brine (1 × 60 mL) 
before being dried over MgSO4. The solvent was removed under reduced pressure and the solid 
residue subjected to high pressure liquid chromatography [(50-95% MeCN:water and 0.01% 
Formic acid) t = 8 min, XBridge Prep C18 column] to isolate the title compound 2.50 (1.00 g, 
3.76 mmol, 50%) as a colourless solid; H (500 MHz, CDCl3) 7.81 (d, J = 8.0 Hz, 1 H, H6), 
7.71 (dd, J = 1.0, 8.0 Hz , 1 H, H5), 7.59 (d, J = 1.0 Hz, 1 H, H3), 4.40 (q, J = 7.0 Hz, 2 H, 
CO2CH2), 3.87 (d, J = 6.5 Hz, 2 H, H), 2.21 – 2.13 (m, 1 H, H), 1.41 (t, J = 7.0 Hz, 3 H, 
CO2CH2CH3), 1.08 (d, J = 7.0 Hz, 6 H, H); δC (125 MHz, CDCl3) 171.1, 166.3, 158.1, 133.1, 
131.3, 125.9, 121.6, 114.0, 75.3, 61.3, 28.4, 19.2, 14.3; (νmax/cm
-1
 (solid state) = 2979, 2952, 
2872, 1718, 1687, 1243, 1080, 764; ESI-HRMS found m/z 265.1085 [M-H]
-
, C14H17O5 requires 
265.1081. 
 
4-tert-butyl 1-ethyl 2-isobutoxyterephthalate (2.51) 
Under nitrogen atmosphere, a 20% solution of Ghosez’s reagent in 
anhydrous chloroform (1.12 mL, 1.70 mmol) was added to a solution of 
4-(ethoxycarbonyl)-3-isobutoxybenzoic acid 2.50 (300 mg, 1.13 mmol) 
in anhydrous chloroform (30 mL). The reaction was stirred at 50 °C for 3 
h before tert-butanol (540 µL, 5.68 mmol) was added. The resulting 
mixture was stirred at 50 °C overnight. The organic solvents were evaporated and the resulting 
oil purified by column chromatography (Stationary Phase: Silica; Mobile Phase: hexane / 
chloroform / ethyl acetate, 75:25:5 ) to afford the desired product 2.51 (215 mg, 0.67 mmol, 
59%) as a yellow oil; H (500 MHz, CDCl3) 7.76 (d, J = 7.5 Hz, 1 H, H6), 7.56 (d, J = 1.0 Hz, 1 
H, H3), 7.55 (dd, J = 7.5, 1.0 Hz , 1 H, H5), 4.38 (q, J = 7.0 Hz, 2 H, CO2CH2), 3.85 (d, J = 6.5 
Hz, 2 H, H), 2.11 – 2.19 (m, 1 H, H), 1.61 (s, 9 H, CO2C(CH3)3), 1.39 (t, J = 7.0 Hz, 3 H, 
CO2CH2CH3), 1.06 (d, J = 6.5 Hz, 6 H, H); δC (125 MHz, CDCl3) 166.4, 165.1, 158.2, 136.4, 
131.1, 124.4, 120.7, 113.5, 81.7, 75.2, 61.1, 28.3, 28.1, 19.2, 14.3; (νmax/cm
-1
 (solid state) = 
2960, 2931, 2882, 1713, 1367, 1241, 1145, 962, 745; ESI-HRMS found m/z 323.1855 [M+H]
+
, 
C18H27O5 requires 323.1853. 
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6.3.2. Dimer Syntheses and Characterisation  
 
4-(4-amino-2,5-diisobutoxybenzamido)-3-isobutoxybenzoic acid (2.27) 
Under a nitrogen atmosphere, thionyl chloride (348 μL, 4.8 mmol, 
5 equiv) was added to a stirred solution of 2,5-diisobutoxy-4-
nitrobenzoic acid 2.15 (299 mg, 0.96 mmol, 1 equiv) in anhydrous 
dichloromethane (50 mL / g), and the resulting mixture was stirred 
at reflux overnight. The organic solvent and the excess thionyl 
chloride were co-evaporated under a nitrogen flow; this was 
repeated 3 times with further additions of dichloromethane to yield 
a yellowish solid. The resulting 2,5-diisobutoxy-4-nitrobenzoyl chloride (318 mg, 0.96 mmol, 1 
equiv) was dissolved in anhydrous chloroform (50 mL / g) and methyl 4-amino-3-
isobutoxybenzoate 2.9 (214 mg, 0.96 mmol, 1 equiv) was added. The resulting mixture was 
stirred at reflux under a nitrogen atmosphere. The organic solvent was evaporated under reduced 
pressure and the solid residue dissolved, without further isolation of compound 2.23, in a 1:1 
mixture of methanol : tetrahydrofuran (30 mL / g) and palladium on carbon (10 wt. %). The 
flask was evacuated and flushed with nitrogen (3 times) and left under vacuum, then hydrogen 
was drawn into the flask and the reaction was left stirring at rt overnight. On completion, the 
reaction mixture was filtered through a celite pad and washed with methanol and 
tetrahydrofuran. The resulting solid was reacted, without further purification of compound 2.25, 
with a 10% sodium hydroxide solution (10 mL / g) in tetrahydrofuran (100 mL / g) at rt. On 
completion, the organic solvent was evaporated under reduced pressure and the solid residue 
subjected to HPLC [(50-95% MeCN:water and 0.1% Formic acid) t = 8 min, 20 mL min
-1
, 
XBridge Prep C18 column]  to yield the target dimer 2.27 (53% overall yield) as a beige 
amorphous solid; H (500 MHz, CDCl3) 10.4 (s, broad, 1 H, 2-NH), 8.72 (d, 1 H, J = 7.5 Hz, 2-
H5), 7.80 (dd, J = 1.5, 7.5 Hz, 1 H, 2-H6), 7.66 (s, 1 H, 1-H6), 7.62 (d, J = 1.5 Hz, 1 H, 2-H2), 
6.40 (s, 1 H, 1-H3), 3.93 (d, J = 6.5 Hz, 2 H, 2-H), 3.92 (d, J = 7.0 Hz, 2 H, 1-H’), 3.84 (d, J 
= 6.5 Hz, 2 H, 1-H), 2.23 – 2.09 (m, 3 H, 1-H, 1-H’, 2-H), 1.04 (d, J = 6.5 Hz, 6 H, 2-H), 
1.03 (d, J = 7.0 Hz, 6 H, 1-H), 0.98 (d, J = 6.5 Hz, 6 H, 1-H’); δC (125 MHz, CDCl3) 164.3, 
152.7, 147.5, 146.1, 141.1, 139.4, 134.3, 131.2, 124.2, 123.1, 120.0, 119.2, 114.1, 112.6, 75.6, 
75.6, 75.2, 28.3, 28.0, 27.8, 19.3, 19.3, 19.2; νmax/cm
-1
 (solid state) = 3490, 3328, 2957, 2872, 
1587, 1519, 1261, 1206, 1030, 768; ESI-HRMS found m/z 473.2663 [M-H]
-
, C26H35N2O6 
requires 473.2646. 
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4-(4-amino-2,5-diisobutoxybenzamido)-2-isobutoxybenzoic acid (2.28) 
Under a nitrogen atmosphere, Ghosez’s reagent (120 μL, 0.91 
mmol, 0.95 equiv) was added to a solution containing 2,5-
diisobutoxy-4-nitrobenzoic acid 2.15 (299 mg, 0.96 mmol, 1 
equiv) in chloroform (40 mL / g) and the resulting mixture was 
refluxed for 3 h. Methyl 4-amino-2-isobutoxybenzoate 2.10 (214 
mg, 0.96 mmol, 1 equiv) was subsequently added and heated at 
reflux overnight. The solvents were removed under reduced 
pressure and the resulting mixture dissolved, without further isolation of compound 2.24, in a 
1:1 mixture of methanol : tetrahydrofuran (30 mL / g) and palladium on carbon (10 wt. %). The 
flask was evacuated and flushed with nitrogen (3 times) and left under vacuum, then hydrogen 
was drawn into the flask and the reaction was left stirring at rt overnight. On completion, the 
reaction mixture was filtered through a celite pad and washed with methanol and 
tetrahydrofuran. The resulting solid was reacted, without further purification of compound 2.26, 
with a 10% sodium hydroxide solution (10 mL / g) in tetrahydrofuran (100 mL / g) at rt. On 
completion, the organic solvent was evaporated under reduced pressure and the solid residue 
subjected to HPLC [(50-95% MeCN:water and 0.1% Formic acid) t = 8 min, 20 mL min
-1
, 
XBridge Prep C18 column] to isolate the title compound 2.28 (35% overall yield) as a light 
brown amorphous solid; H (500 MHz, CDCl3) 10.34 (s, broad, 1 H, 2-NH), 8.31 (d, J = 1.5 Hz, 
1 H, 2-H3), 8.11 (d, J = 8.5, 1 H, 2-H6), 7.66 (s, 1 H, 1-H6), 6.71 (dd, J = 1.5, 8.5 Hz, 1 H, 2-
H5), 6.45 (s, 1 H, 1-H3), 4.10 (d, J = 7.5 Hz, 2 H, 2-H), 3.91 (d, J = 6.5 Hz, 2 H, 1-H), 3.84 
(d, J = 7.0 Hz, 2 H, 1-H’), 2.32 – 2.21 (m, 2 H, 2-H, 1-H), 2.17 – 2.09 (m, 1 H, 1-H’), 1.15 
(d, J = 7.0 Hz, 6 H, 1-H), 1.11 (d, J = 7.0 Hz, 6 H, 2-H), 1.04 (d, J = 6.5 Hz, 6 H, 1-H’); δC 
(125 MHz, CDCl3) 165.3, 164.4, 158.9, 153.0, 145.3, 142.1, 140.9, 134.1, 113.8, 112.1, 111.9, 
109.4, 103.6, 98.5, 76.4, 76.4, 75.3, 28.6, 28.3, 28.2, 19.5, 19.3, 19.3; νmax/cm
-1
 (solid state) = 
3466, 3341, 2959, 2874, 1722, 1581, 1514, 1223, 1015, 760; ESI-HRMS found m/z 473.2659 
[M+H]
+
, C26H37N2O6 requires 473.2646. 
 
 
4-(4-amino-2,5-diisobutoxybenzamido)-2,5-diisobutoxybenzoic acid (2.22) 
Under a nitrogen atmosphere, Ghosez’s reagent (66 μL, 0.50 mmol, 
1 equiv) was added to a solution containing 2,5-diisobutoxy-4-
nitrobenzoic acid 2.15 (155 mg, 0.50 mmol, 1 equiv) in chloroform 
(40 mL / g) and the resulting mixture was refluxed for 3 h. Methyl 
4-amino-2,5-diisobutoxybenzoate 2.16 (148 mg, 0.50 mmol, 1 
equiv) was subsequently added and heated at reflux overnight. The 
solvents were removed under reduced pressure and the resulting 
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mixture dissolved, without further isolation of compound 2.18, in a 1:1 mixture of methanol : 
tetrahydrofuran (30 mL / g) and palladium on carbon (10 wt. %). The flask was evacuated and 
flushed with nitrogen (3 times) and left under vacuum, then hydrogen was drawn into the flask 
and the reaction was left stirring at rt overnight. On completion, the reaction mixture was 
filtered through a celite pad and washed with methanol and tetrahydrofuran. The resulting solid 
was reacted, without further purification of compound 2.20, with a 10% sodium hydroxide 
solution (10 mL / g) in tetrahydrofuran (100 mL / g) at rt. On completion, the organic solvent 
was evaporated under reduced pressure and the solid residue subjected to HPLC [(50-95% 
MeCN:water and 0.1% Formic acid) t = 8 min, 20 mL min
-1
, XBridge Prep C18 column] to 
isolate the title compound 2.22 (11% overall yield) as a brownish amorphous solid; H (500 
MHz, CDCl3) 10.52 (s, broad, 1 H, 2-NH), 8.62 (s, 1 H, 2-H3), 7.66 (s, 1 H, 2-H6), 7.61 (s, 1 H, 
1-H6), 6.43 (s, 1 H, 1-H3), 4.09 (d, J = 7.0 Hz, 2 H, 2-H), 3.97 (d, J = 7.0 Hz, 2 H, 1-H), 
3.89 (d, J = 7.0 Hz, 2 H, 2-H’), 3.83 (d, J = 6.5 Hz, 2 H, 1-H’), 2.27 – 2.09 (m, 4 H, 1-H, 1-
H’, 2-H, 2-H’), 1.09 (d, J = 6.5 Hz, 6 H, 2-H), 1.04 (d, J = 6.5 Hz, 6 H, 1-H’), 1.02 (d, J = 
6.5 Hz, 6 H, 2-H’), 0.97 (d, J = 7.0 Hz, 6 H, 1-H); δC (125 MHz, CDCl3) 166.7, 164.6, 152.8, 
152.7, 142.5, 141.4, 135.1, 114.6, 113.8, 110.5, 105.0, 100.6, 77.2, 76.9, 76.0, 75.3, 28.3, 28.3, 
28.0, 27.7, 19.3, 19.3, 19.2, 19.2 (two quaternary carbons were not observed); νmax/cm
-1
 (solid 
state) = 3489, 3329, 2958, 2872, 1587, 1582, 1259, 1199, 1025, 765; ESI-HRMS found m/z 
545.3237 [M-H]
-
, C30H44N2O7 requires 545.3221. 
 
 
4-(4-amino-3-isobutoxybenzamido)-2,5-diisobutoxybenzoic acid (2.21)  
Under a nitrogen atmosphere, Ghosez’s reagent (145 μL, 1.08 mmol, 
0.95 equiv) was added to a solution containing 3-isobutoxy-4-
nitrobenzoic acid 2.7 (250 mg, 1.12 mmol, 1 equiv) in chloroform (40 
mL / g) and the resulting mixture was refluxed for 3 h. Methyl 4-
amino-2,5-diisobutoxybenzoate 2.16 (331 mg, 1.12 mmol, 1 equiv) 
was subsequently added and heated at reflux overnight. The solvents 
were removed under reduced pressure and the resulting mixture 
dissolved, without further isolation of compound 2.17, in a 1:1 mixture of methanol : 
tetrahydrofuran (30 mL / g) and palladium on carbon (10 wt. %). The flask was evacuated and 
flushed with nitrogen (3 times) and left under vacuum, then hydrogen was drawn into the flask 
and the reaction was left stirring at rt overnight. On completion, the reaction mixture was 
filtered through a celite pad and washed with methanol and tetrahydrofuran. The resulting solid 
was reacted, without further purification of compound 2.19, with a 10% sodium hydroxide 
solution (10 mL / g) in tetrahydrofuran (100 mL / g) at rt. On completion, the organic solvent 
was evaporated under reduced pressure and the solid residue subjected to HPLC [(50-95% 
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MeCN:water and 0.1% Formic acid) t = 8 min, 20 mL min
-1
, XBridge Prep C18 column] to 
isolate the title compound 2.21 (36 % overall yield) as a beige amorphous solid; H (500 MHz, 
CDCl3) 8.84 (s, broad, 1 H, 2-NH), 8.55 (s, 1 H, 2-H3), 7.66 (s, 1 H, 2-H6), 7.43 (d, J = 2.0 Hz, 
1 H, 1-H2), 7.32 (dd, J = 2.0, 8.0 Hz, 1 H, 1-H6), 6.88 (d, J = 8.0 Hz, 1 H, 1-H5), 4.09 (d, J = 
6.5 Hz, 2 H, 2-H), 3.92 (d, J = 6.5 Hz, 2 H, 2-H’), 3.87 (d, J = 6.5 Hz, 2 H, 1-H), 2.27 – 
2.16 (m, 3 H, 1-H, 2-H 2-H’), 1.11 (d, J = 6.5 Hz, 6 H, 2-H’), 1.10 (d, J = 7.0 Hz, 6 H, 2-
H), 1.07 (d, J = 7.0 Hz, 6 H, 1-H); δC (125 MHz, CDCl3) 165.5, 165.1, 152.9, 141.9, 139.5, 
134.1, 132.6, 120.1, 119.7, 114.0, 110.9, 110.8, 110.5, 103.7, 75.5, 75.1, 75.0, 28.4, 28.3, 28.2, 
19.4, 19.3, 19.2; νmax/cm
-1
 (solid state) = 3494, 3354, 2960, 2873, 1717, 1513, 1433, 1257, 1192, 
1022, 751; ESI-HRMS found m/z 473.2664 [M-H]
-
, C26H35N2O6 requires 473.2646. 
 
 
4-(4-amino-2,5-diisobutoxyphenylcarbamoyl)-2-isobutoxybenzoic acid (2.52) 
tert-Butyl 2,5-diisobutoxy-1,4-phenylenedicarbamate 2.35 (300 
mg, 0.66 mmol, 1 equiv) was dissolved in anhydrous hydrogen 
chloride (4M) solution in 1,4- dioxane (30 mL / g) and stirred for 3 
h at rt. The solvent was evaporated under reduced pressure and the 
solid residue redissolved in anhydrous chloroform (150 mL / g) 
before the addition of triethylamine (115 µL, 0.83 mmol, 1.25 
equiv). The resulting mixture was heated to reflux and a solution of 
4-(ethoxycarbonyl)-3-isobutoxybenzoic acid 2.50 (88 mg, 0.33 mmol, 0.5 equiv) and Ghosez’s 
reagent (218 μL, 0.33 mmol, 0.5 equiv) in anhydrous chloroform (100 mL / g), previously 
stirred at 50 °C for 3 h, was added dropwise via a cannula. The reaction was stirred at reflux 
overnight. Up to this point, air free conditions were required. The organic solvent was 
evaporated under reduced pressure and the resulting solid was reacted, without further 
purification, with a 10% sodium hydroxide solution (10 mL / g) in tetrahydrofuran (100 mL / g) 
at rt. On completion, the organic solvent was evaporated under reduced pressure and the solid 
residue subjected to HPLC [(50-95% MeCN:water and 0.1% Formic acid) t = 8 min, 20 mL 
min
-1
, XBridge Prep C18 column]  to yield the target dimer 2.52 (14% overall yield) as a brown 
solid; H (500 MHz, CDCl3) 8.56 (s, broad, 1 H, 1-NH), 8.30 (d, J = 8.0 Hz, 1 H, 2-H6), 8.15 (s, 
1 H, 1-H6), 7.72 (d, J = 1.0 Hz, 1 H, 2-H3), 7.45 (dd, J = 1.0, 8.0 Hz, 1 H, 2-H5), 6.40 (s, 1 H, 
1-H3), 4.13 (d, J = 6.5 Hz, 2 H, 2-H), 3.82 (d, J = 6.5 Hz, 2 H, 1-H’), 3.78 (d, J = 6.5 Hz, 2 
H, 1-H), 2.31 – 2.23 (m, 1 H, 2-H), 2.18 – 2.08 (m, 2 H, 1-H, 1-H’), 1.12 (d, J = 7.0 Hz, 6 
H, 2-H), 1.07 (d, J = 7.0 Hz, 6 H, 1-H), 1.05 (d, J = 7.0 Hz, 6 H, 1-H’); δC (125 MHz, 
CDCl3) 164.6, 162.3, 158.1, 142.4, 141.4, 140.2, 134.3, 133.1, 120.0, 118.5, 118.4, 112.3, 
105.4, 100.1, 75.6, 75.6, 75.5, 28.5, 28.4, 28.1, 19.4, 19.3, 19.1; νmax/cm
-1
 (solid state) = 3364, 
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2958, 2872, 1660, 1530, 1431, 1217, 1196, 1026, 743; ESI-HRMS found m/z 473.2659 [M-H]
-
, 
C26H35N2O6 requires 473.2646. 
 
4-(4-amino-2,5-diisobutoxyphenylcarbamoyl)-3-isobutoxybenzoic acid (2.53) 
Initial hydrolysis step: A lithium hydroxide (14 mg, 0.33 mmol, 1 
equiv) solution in water was added to a solution of 4-tert-butyl 1-
ethyl 2-isobutoxyterephthalate 2.51 (106 mg, 0.33 mmol, 1 equiv) 
in tetrahydrofuran (25 mL / g) and the resulting mixture was stirred 
at rt overnight. The organic solvent was removed under reduced 
pressure, an additional amount of water was added and then 
acidified via the addition of 1 M potassium bisulfate solution to pH 
5. The resulting precipitate was extracted into dichloromethane, evaporated to dryness to yield a 
4-(tert-butoxycarbonyl)-2-isobutoxybenzoic acid crude mixture which was used without further 
purification. 
Coupling step: tert-Butyl 2,5-diisobutoxy-1,4-phenylenedicarbamate 2.35 (300 mg, 0.66 mmol, 
1 equiv) was dissolved in anhydrous hydrogen chloride (4M) solution in 1,4- dioxane (30 mL / 
g) and stirred for 3 h at rt. The solvent was evaporated under reduced pressure and the solid 
residue redissolved in anhydrous chloroform (150 mL / g) before the addition of triethylamine 
(115 µL, 0.83 mmol, 1.25 equiv). The resulting mixture was heated to reflux and a solution of 
crude 4-(tert-butoxycarbonyl)-2-isobutoxybenzoic acid derived from 2.51 (97 mg, 0.33 mmol, 
0.5 equiv) and Ghosez’s reagent (218 μL, 0.33 mmol, 0.5 equiv) in anhydrous chloroform (100 
mL / g), previously stirred at 50 °C for 3 h, was added dropwise via a cannula. The reaction was 
stirred at reflux overnight. Up to this point, air free conditions were required. The organic 
solvent was evaporated under reduced pressure and the resulting solid was reacted, without 
further purification with a 10% TFA solution in tetrahydrofuran (100 mL / g) at rt. On 
completion, the organic solvent was evaporated under reduced pressure and the solid residue 
subjected to HPLC [(50-95% MeCN:water and 0.1% Formic acid) t = 8 min, 20 mL min
-1
, 
XBridge Prep C18 column] to yield the target dimer 2.53 (23% overall yield) as a brown solid; 
H (500 MHz, CDCl3) 9.89 (s, broad, 1 H, 1-NH), 8.32 (d, J = 8.0 Hz, 1 H, 2-H5), 8.15 (s, 1 H, 
1-H6), 7.82 (dd, J = 1.0, 8.0 Hz, 1 H, 2-H6), 7.73 (d, J = 1.0 Hz,  1 H, 2-H2),  6.41 (s, 1 H, 1-
H3), 4.04 (d, J = 7.0 Hz, 2 H, 2-H), 3.83 (d, J = 6.5 Hz, 2 H, 1-H’), 3.74 (d, J = 7.0 Hz, 2 H, 
1-H), 2.30 – 2.22 (m, 1 H, 2-H), 2.17 – 2.03 (m, 2 H, 1-H, 1-H’), 1.05 (d, J = 6.5 Hz, 6 H, 
1-H’), 1.03 (d, J = 6.5 Hz, 6 H, 2-H), 0.98 (d, J = 7.0 Hz, 6 H, 1-H); δC (125 MHz, CDCl3) 
165.1, 162.0, 156.6, 143.1, 140.5, 132.6, 132.4, 127.7, 122.6, 119.3, 114.4, 110.1, 107.1, 101.1, 
76.1, 76.3, 75.4, 28.5, 28.2, 27.9, 19.4, 19.3, 19.2; νmax/cm
-1
 (solid state) = 3421, 3345, 2964, 
1535, 1230, 1177, 1029, 824, 514; ESI-HRMS found m/z 473.2647 [M+H]
+
, C26H37N2O6 
requires 473.2646. 
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4-(4-amino-3-isobutoxyphenylcarbamoyl)-2,5-diisobutoxybenzoic acid (2.54) 
Under a nitrogen atmosphere, thionyl chloride (586 μL, 8.06 mmol,  
5 equiv) was added to a stirred solution of 2,5-
diisobutoxyterephthalic acid 2.32 (500 mg, 1.62 mmol, 1 equiv) in 
anhydrous dichloromethane (50 mL / g), and the resulting mixture 
was stirred at reflux overnight. The organic solvent and the excess 
thionyl chloride were co-evaporated under a nitrogen flow; this was 
repeated 3 times with further additions of dichloromethane to yield a 
yellow solid. The resulting 2,5-diisobutoxyterephthaloyl dichloride (558 mg, 1.61 mmols, 1 
equiv) was dissolved in anhydrous chloroform (100 mL / g) and a solution of (9H-Fluoren-9-
yl)methyl 4-amino-2-isobutoxyphenylcarbamate 2.45 (216 mg, 0.54 mmol, 0.3 equiv) in 
anhydrous chloroform (30 mL / g) was added dropwise. The resulting mixture was stirred at 
reflux under a nitrogen atmosphere. The organic solvent was evaporated under reduced pressure 
and the solid residue reacted, without further purification, with a 10% sodium hydroxide 
solution (10 mL / g) in tetrahydrofuran (100 mL / g) at rt. On completion, the organic solvent 
was evaporated under reduced pressure and the solid residue subjected to HPLC [(50-95% 
MeCN:water and 0.1% Formic acid) t = 8 min, 20 mL min
-1
, XBridge Prep C18 column] to 
afford the desired product 2.54 (10% overall yield) as a yellow solid; H (500 MHz, CDCl3) 
10.04 (s, broad, 1 H, 1-NH), 8.04 (s, 1 H, 2-H3), 7.83 (s, 1 H, 2-H6), 7.61 (d, J = 2.0 Hz, 1 H, 1-
H5), 6.78 (dd, J = 2.0, 8.0 Hz, 1 H, 1-H6), 6.75 (d, J = 8.0 Hz, 1 H, 1-H2), 4.11 (d, J = 7.5 Hz, 2 
H, 2-H), 4.04 (d, J = 6.5 Hz, 2 H, 2-H’), 3.83 (d, J = 6.5 Hz, 2 H, 1-H), 2.33 – 2.12 (m, 3 H, 
1-H, 2-H, 2-H’), 1.16 (d, J = 7.0 Hz, 6 H, 2-H’), 1.10 (d, J = 7.0 Hz, 6 H, 2-H), 1.06 (d, J 
= 7.0 Hz, 6 H, 1-H); δC (125 MHz, CDCl3) 164.6, 161.0, 151.6, 151.1, 147.0, 132.8, 130.0, 
127.3, 120.5, 117.0, 116.5, 115.0, 112.4, 105.2, 77.2, 76.7, 74.7, 28.5, 28.4, 28.1, 19.4, 19.4, 
19.2; νmax/cm
-1
 (solid state) = 3355, 2959, 2875, 1738, 1652, 1532, 1417, 1196, 1015, 741; ESI-
HRMS found m/z 473.2664 [M-H]
-
, C26H35N2O6 requires 473.2646. 
 
 
4-(4-amino-3-(benzyloxy)phenylcarbamoyl)-2,5-bis(benzyloxy)benzoic acid (2.55) 
 Under a nitrogen atmosphere, thionyl chloride (479 μL, 6.61 
mmol, 5 equiv) was added to a stirred solution of 2,5-
bis(benzyloxy)terephthalic acid 2.33 (500 mg, 1.32 mmol, 1 
equiv) in anhydrous dichloromethane (50 mL / g), and the 
resulting mixture was stirred at reflux overnight. The organic 
solvent and the excess thionyl chloride were co-evaporated 
under a nitrogen flow; this was repeated 3 times with further 
additions of dichloromethane to yield a yellow solid. The resulting 2,5-
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bis(benzyloxy)terephthaloyl dichloride (548 mg, 1.32 mmol, 1 equiv) was dissolved in 
anhydrous chloroform (100 mL / g) and a solution of (9H-fluoren-9-yl)methyl 4-amino-2-
(benzyloxy)phenylcarbamate 2.46 (192 mg, 0.44 mmol, 0.3 equiv) in anhydrous chloroform (30 
mL / g) was added dropwise. The resulting mixture was stirred at reflux under a nitrogen 
atmosphere. The organic solvent was evaporated under reduced pressure and the solid residue 
reacted, without further purification, with a 10% solution of piperidine in tetrahydrofuran (100 
mL / g) at rt. On completion, the organic solvent was evaporated under reduced pressure and the 
solid residue subjected to HPLC [(50-95% MeCN:water and 0.1% Formic acid) t = 8 min, 20 
mL min
-1
, XBridge Prep C18 column] to afford the desired product 2.55 (44% overall yield) as 
a yellow solid; H (500 MHz, CDCl3) 9.99 (s, broad, 1 H, 1-NH), 8.23 (s, 1 H, 2-H3), 7.99 (s, 1 
H, 2-H6), 7.56 – 7.55 (m, 2 H, 2-HAr’), 7.50 – 7.35 (m, 13 H, 2-HAr, 2-HAr’, 1-HAr), 7.24 (d, 
J = 1.5 Hz, 1 H, 1-H2), 6.60 – 6.55 (m, 2 H, 1-H5, 1-H6), 5.37 (s, 2 H, 2-H), 5.27 (s, 2 H, 2-
H’), 4.94 (s, 2 H, 1-H); δC (125 MHz, CDCl3) 164.3, 160.5, 151.6, 151.1, 146.3, 136.8, 
134.8, 134.1, 133.4, 129.6, 129.4, 129.3, 129.2, 129.2, 128.9, 128.6, 128.4, 128.1, 127.8, 127.6, 
121.1, 117.4, 117.1, 114.8, 112.9, 105.0, 73.1, 72.7, 70.5; νmax/cm
-1
 (solid state) = 3469, 3359, 
1730, 1515, 1413, 1219, 1000, 735; ESI-HRMS found m/z 575.2191 [M+H]
+
, C35H30N2O6 
requires 575.2177. 
 
4-(4-amino-2-isobutoxyphenylcarbamoyl)-2,5-diisobutoxybenzoic acid (2.56) 
Under a nitrogen atmosphere, thionyl chloride (586 μL, 8.06 mmol,  
5 equiv) was added to a stirred solution of 2,5-
diisobutoxyterephthalic acid 2.32 (500 mg, 1.62 mmol, 1 equiv) in 
anhydrous dichloromethane (50 mL / g), and the resulting mixture 
was stirred at reflux overnight. The organic solvent and the excess 
thionyl chloride were co-evaporated under a nitrogen flow; this was 
repeated 3 times with further additions of dichloromethane to yield a 
yellow solid. The resulting 2,5-diisobutoxyterephthaloyl dichloride (558 mg, 1.61 mmols, 1 
equiv) was dissolved in anhydrous chloroform (100 mL / g) and a solution of 2-isobutoxy-4-
nitroaniline 2.41 (169 mg, 0.81 mmol, 0.5 equiv) in anhydrous chloroform (30 mL / g) was 
added dropwise. The resulting mixture was stirred at reflux under a nitrogen atmosphere. The 
organic solvent was evaporated under reduced pressure and the solid redisolved in a 1:1 mixture 
of methanol : tetrahydrofuran (30 mL / g), palladium on carbon (10 wt. %) was added and the 
flask evacuated and flushed with nitrogen (3 times) and left under vacuum. Hydrogen was 
drawn into the flask and the reaction was left stirring at rt overnight. On completion, the 
reaction mixture was filtered through a celite pad and washed with methanol and 
tetrahydrofuran. The organic solvents were evaporated to dryness to yield the target dimer 2.56 
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(42% overall yield) as a orange solid; H (500 MHz, CDCl3) 9.97 (s, broad, 1 H, 1-NH), 8.20 (d, 
J = 8.5 Hz, 1 H, 1-H6), 7.98 (s, 1 H, 2-H3), 7.83 (s, 1 H, 2-H6), 6.33 (dd, J = 2.0, 8.5 Hz, 1 H, 
1-H5), 6.31 (d, J = 2.0 Hz, 1 H, 1-H3), 4.09 (d, J = 6.5 Hz, 2 H, 2-H), 4.01 (d, J = 7.0 Hz, 2 H, 
2-H’), 3.78 (d, J = 7.0 Hz, 2 H, 1-H), 2.26 – 2.09 (m, 3 H, 1-H, 2-H, 2-H’), 1.09 (d, J = 
7.0 Hz, 6 H, 2-H), 1.02 (d, J = 6.5 Hz, 6 H, 1-H), 0.99 (d, J = 6.5 Hz, 6 H, 2-H’); δC (125 
MHz, CDCl3) 164.8, 161.2, 151.6, 151.1, 150.0, 144.0, 128.7, 123.1, 120.2, 119.3, 117.8, 116.4, 
107.0, 99.8, 77.1, 77.0, 75.2, 28.1 (2 C), 27.9, 19.2, 19.2, 19.1; νmax/cm
-1
 (solid state) = 3355, 
2959, 2875, 1738, 1652, 1532, 1417, 1196, 1015, 741; ESI-HRMS found m/z 471.2493 [M-H]
-
, 
C26H35N2O6 requires 471.2493; Found: C, 66.15; H, 7.40; N, 5.90; C26H36N2O6 requires: C, 
66.08; H, 7.68; N, 5.93%. 
 
 
6.3.3. Molecullar modeling 
 
A conformational search was performed on the complete set of dimers. The structures were 
minimised by employing a full Monte Carlo search in the software Macromodel® using the 
Merk Molecular Force Fields (MMFFs) method and sampling a total of 50,000 structures. 
Water was chosen as implicit solvent and free rotation around the amide bonds was allowed in 
order to increase the accuracy of the conformational search. 
 
All the conformations within 1.5 kJ/mol from the lowest energy conformation were 
superimposed with the ER co-activator helix (PDB: 2QZO) and AR co-activator helices (PDB: 
1T7F and 1T73 for compound 2.55). A mean value of the Root Mean Square Deviation 
(RMSD) was calculated from the superimposition of the oxygen of the alkoxy group and the 
alpha carbon of the key aminoacids of the co-activator helix. The alignment was also 
investigated in the reverse dipole sequence. 
 
6.3.4. Docking studies 
 
The LBDs of ERα (PDB ID: 2QZO) and AR (PDB: 1T7F) were prepared for docking using the 
Protein Preparation Wizard (Schrödinger) function in Maestro. Once the protein was refined, 
Glide (Schrödinger) was then used to create a grid box for docking. The structures of the ER 
and AR are dimeric; therefore, only one monomer was used within the docking grid. The 
dimensions and position of the grid box were adjusted according to the coactivator binding 
pose, which must be centered and lie fully within the grid. The LigPrep (Schrödinger) function 
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was then used to prepare the set of compounds for docking. Once arranged, the resulting 
compounds were docked into the LBDs of the prepared protein using Glide XP (extra precision) 
mode. 
 
6.3.5. Fluorescence Polarization assays  
 
All proteins (Sumo-Erα, His-RXRα, Erβ), SRC-Box2 peptide and its fluorescein-labelled 
analogue FITC-SRC-Box2 were obtained in the laboratory of Prof. Luc Brunsveld (Technische 
Universiteit Eindhoven). Fluorescein-labelled FITC-D22 peptide was purchased from 
ThermoFisher Scientific.  
The Fluorescence Polarization Assays were performed in triplicate and were measured with a 
Tecan Safire monochromator microplate reader. The assays were performed in freshly prepared 
HTRF buffer (10 mM HEPES buffer at pH 7.50, containing 150 mM NaCl, 0.01 mg mL
-1
 
bovine serum albumin (BSA) and 5 mM DTT). Serial dilutions of the compounds in DMSO 
(starting point: 10 mM; 12-points, 1/3.16 dilution) were performed. Then, a Mastermix solution 
was prepared containing the following components: 
-  Assay in Agonistic mode: Mastermix (10) Protein + tracer + buffer (+ DMSO). 
- Assay in Antagonistic mode: Mastermix (10) Protein + tracer + ligand + buffer (+ 
DMSO) 
 
The preparation of the wells goes as follows: 
1) 99 μL of Mastermix were added to each well (96 well plates, white). 
2) 1 μL of compound stock solution was added to each well (96 well plates, white).  
3) The plates were incubated for 1 h at 4 °C and protected from light. 
4) The assay mixture was transferred (3 30 μL) to the final wells (384 well plates, low 
volume black) for measurements. 
All the assays contain a final concentration of 5% DMSO. 
 
Processing of the Fluorescence Polarization data 
The data obtained for both the P (perpendicular intensity) and S (parallel (same) intensity) 
channels was used to calculate the polarization for each well using the following equation: 
𝑝 =  
𝑆 − 𝑃
𝑆 + 𝑃
 
Where: p = polarization, P = perpendicular intensity, S = parallel intensity.  
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6.4. Optimization of the hybrid oligoamide proteomimetic 
scaffold (Chapter 3)  
6.4.1. General procedures for Solid Phase Synthesis of the hybrid 
scaffold 
A generic procedure was followed by adapting the previously reported solid phase synthesis of 
3-O-alkylated oligobenzamides
135
 (See section 6.5.2).  
 
Resin preparation and Fmoc deprotection 
Fmoc protected pre-loaded Wang resin (0.1 mmol, 1 equiv) was loaded onto a Liberty CEM™ 
microwave peptide synthesiser after being swelled for a total of 30 min in dichloromethane. 
Standard washing cycles were carried out and two deprotection cycles using 6 mL of a 20% 
piperidine in DMF solution, under microwave at 75 °C, performed before coupling of each 
monomer and after the last coupling reaction. 
 
Coupling of 2-O and 3-O-alkylated monomers  
Each protected monomer (2 equiv per coupling) was dissolved in anhydrous DMF (2.5 mL per 
coupling) and pre-activated with HATU (3 equiv per coupling) and DIPEA (5 equiv per 
coupling) at rt. A double coupling method of 30 min was carried out under microwave at 60 °C. 
 
Coupling of central amino acids 
Each protected amino acid (2.5 equiv per coupling) was dissolved in anhydrous DMF (2.5 mL 
per coupling) and pre-activated with HATU (3 equiv per coupling) and DIPEA (5 equiv per 
coupling) at rt. For natural amino acid derivatives, a double coupling of 30 minutes was carried 
out under microwave at 60 °C. For non-natural amino acids, a triple coupling of 30 minutes was 
carried out under microwave at 60 °C. 
 
Coupling of challenging monomers and amino acids  
Monomers and amino acids that could not be coupled using the standard methodology were 
activated using procedure I: acyl chloride formation (See section 6.5.2). NMP was used as a 
solvent for these couplings. 
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Reductive amination on resin 
The resin bound hybrid was transferred to a reservoir and washed with DMF (2 × 3 mL × 2 
min). A solution of aldehyde (5 equiv) in 2.5 mL of 1:1 methanol:DMF (1% acetic acid) 
followed by a suspension of NaBH3CN (5 equiv) in 1 mL of methanol was added to the resin 
beads and the mixture stirred at rt. Reaction times varied from 2 to 15 h and further portions of 
aldehyde and reducing agent NaBH3CN were added when the reaction was shown incomplete 
by LC-MS. 
 
Cleavage 
After complete synthesis, the resin was transferred to a reservoir, washed with dichloromethane 
(2 × 3 mL × 2 min) and cleaved with a cleavage cocktail (3 mL, 2  30 min) consisting of a 1:1 
mixture of TFA:dichloromethane. After the reaction had reached completion, the cleavage 
cocktail was evaporated under N2 (g).  
 
Mass – Directed HPLC Purification 
The resulting crude product was dissolved in either DMSO or methanol at an approximate 
concentration of 20 mg mL
-1
 and purified using reversed phase mass directed HPLC [Agilent 
XBridge C18 preparative column; variable gradient of MeCN to water (plus 0.1% formic acid 
v/v in both solvents) and flow rate of 20 mL min
-1
 during 8 min]. The resulting fractions are 
concentrated by centrifugal evaporation (Genevac). 
 
6.4.2. O-Alkylated monomer syntheses and characterization 
 
The O-alkylated monomers employed in the hybrid scaffold syntheses were obtained using the 
same general procedures as for the 3-O-alkylated monomers unless stated otherwise (See 
section 6.5.1). Only the characterization of the novel monomers has been included in the 
experimental section; the monomers which have been routinely synthesised and reported 
previously in the group have not been included.
125, 127, 135
 
 
 Methyl 2-methoxy-4-nitrobenzoate (3.5) 
Procedure A; methyl 2-hydroxy-4-nitrobenzoate 2.4 (2.0 g, 10.1 mmol), potassium 
carbonate (3.5 g, 25.3 mmol), in dimethylformamide (120 mL), methyl iodide (7.7 
mL, 50.5 mmol). Work up afforded the title compound 3.5 (2.08 g, 9.9 mmol, 98 
%) as a pale yellow solid; H (500 MHz, CDCl3) 7.90 (d, J = 8.2 Hz, 1 H, H6), 7.85 
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(dd, J = 8.2, 1.8 Hz, 1 H, H5), 7.83 (d, J = 1.8 Hz, 1 H, H3), 4.01 (s, 3 H, Hα), 3.95 (s, 3 H, 
CO2CH3); δC (125 MHz, CDCl3) 165.3, 159.3, 150.8, 132.1, 126.0, 115.0, 107.0, 56.6, 52.6; 
νmax/cm
-1
 (solid state) = 3121, 2952, 2848, 1733, 1517, 1245, 1079, 735; ESI-HRMS found m/z 
212.0552 [M+H]
+
, C9H10NO5 requires 212.0553. 
 
Methyl 2-sec-butoxy-4-nitrobenzoate (3.7) 
 Procedure B; methyl 2-hydroxy-4-nitrobenzoate 2.4 (1.0 g, 5.1 mmol), sec-
butanol (415 mg, 5.6 mmol), triphenylphosphine (2.0 g, 7.6 mmol) in 
anhydrous tetrahydrofuran (40 mL) and diisopropyl azodicarboxylate (1.5 mL, 
7.6 mmol). An extra portion of sec-butanol (1 equiv), triphenylphosphine (1 
equiv) and diisopropyl azodicarboxylate (1 equiv) was added to bring the reaction to 
completion. The reaction mixture was purified by column chromatography (Stationary Phase: 
Silica; Mobile Phase: ethyl acetate/hexane, 1:1) to afford the desired product 3.7  (850 mg, 3.4 
mmol, 66%) as a yellow oil; H (500 MHz, CDCl3) 7.84 (d, J = 9.0 Hz, 1 H, H6), 7.75 – 7.81 
(m, 2 H, H3, H5), 4.47 – 4.53 (m, 1 H, Hα), 3.92 (s, 3 H, CO2CH3), 1.86 – 1.78 (m, 1 H, Hβ), 
1.69 – 1.78 (m, 1 H, Hβ), 1.38 (d, J = 6.2 Hz, 3 H, CHα(CH3)), 1.03 (t, J = 7.4 Hz, 3 H, Hγ); δC 
(125 MHz, CDCl3) 165.7, 157.9, 150.6, 131.9, 127.4, 114.5, 109.1, 52.4, 33.6, 29.1, 18.8, 9.4; 
νmax/cm
-1
 (solid state) = 3108, 2973, 2880, 1736, 1526, 1346, 1245, 1077, 736; ESI-HRMS 
found m/z 254.1025 [M+H]
+
, C12H16NO5 requires 254.1023. 
 
 Methyl 4-amino-2-methoxybenzoate  (3.10) 
Procedure D; methyl 2-methoxy-4-nitrobenzoate 3.5 (2.08 g, 9.9 mmol) in a 1:1 
mixture of tetrahydrofuran/methanol (20 mL). After work up, the reaction mixture 
was purified by column chromatography (Stationary Phase: Silica; Mobile Phase: 
ethyl acetate/hexane, 3:1) to yield the title compound 3.10 (1.78 g, 9.9 mmol, 
quant.) as a pale orange solid; H (500 MHz, CDCl3) 7.75 (d, J = 8.5 Hz, 1 H, H6), 6.24 (dd, J = 
8.5, 1.9 Hz, 1 H, H5), 6.21 (d, J = 1.9 Hz, 1 H, H3), 4.05 (s, broad, 2 H, NH2), 3.87 (s, 3 H, Hα), 
3.83 (s, 3 H, CO2CH3); δC (125 MHz, CDCl3) 166.2, 161.8, 152.0, 134.2, 109.1, 106.4, 97.7, 
55.8, 51.4; νmax/cm
-1
 (solid state) = 3461, 3364, 3236, 2948, 2837, 1698, 1606, 1434, 1254, 
1217, 1086, 830, 774; ESI-HRMS found m/z 182.0814 [M+H]
+
, C9H12NO3 requires 182.0812. 
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Methyl 4-amino-2-sec-butoxybenzoate  (3.12) 
Procedure D; methyl 2-sec-butoxy-4-nitrobenzoate 3.7 (850 mg, 3.4 mmol) in 
a 1:1 mixture of tetrahydrofuran/methanol (40 mL). Work up yielded the title 
compound 3.12 (747 mg, 3.4 mmol, quant.) as a purple brown oil; H (500 
MHz, CDCl3) 7.72 (d, J = 8.5 Hz, 1 H, H6), 6.23 (dd, J = 8.5, 2.1 Hz, 1 H, 
H5), 6.20 (d, J = 2.1 Hz, 1 H, H3), 4.27 – 4.33 (m, 1 H, Hα), 3.97 (s, broad, 2 H, NH2), 3.82 (s, 
3 H, CO2CH3), 1.74 – 1.86 (m, 1 H, Hβ), 1.62 – 1.74 (m, 1 H, Hβ), 1.33 (d, J = 6.2 Hz, 3 H, 
CHα(CH3)), 1.01 (t, J = 7.4 Hz, 3 H, Hγ); δC (125 MHz, CDCl3) 166.5, 160.5, 151.6, 134.2, 
110.8, 106.7, 100.9, 76.5, 51.3, 29.2, 19.1, 9.6; νmax/cm
-1
 (solid state) = 3463, 3365, 3234, 2971, 
2946, 2878, 1699, 1598, 1448, 1432, 1246, 1140, 1080, 773; ESI-HRMS found m/z 246.1103 
[M+Na]
+
, C12H17NNaO3 requires 246.1101. 
 
 4-Amino-2-methoxybenzoic acid (3.15) 
Procedure E; methyl 4-amino-2-methoxybenzoate 3.10 (1.60 g, 8.8 mmol) in a 1:1 
mixture of tetrahydrofuran/methanol (40 mL), 10% aqueous sodium hydroxide (30 
mL). Additional 1:1 mixture of tetrahydrofuran/methanol (150 mL) was added to 
aid solubility over the course of the 4 day reaction. Work up yielded the title 
compound 3.15 (1.15 g, 6.9 mmol, 78%) as a colourless solid; H (500 MHz, MeOD) 7.69 (d, J 
= 8.5 Hz, 1 H, H6), 6.34 (d, J = 1.9 Hz, 1 H, H3), 6.28 (dd, J = 8.5, 1.9 Hz, 1 H, H5), 3.87 (s, 3 
H, Hα); δC (125 MHz, MeOD) 169.4, 162.8, 156.8, 135.6, 107.9, 106.2, 97.3, 56.3; νmax/cm
-1
 
(solid state) = 3420, 3337, 3226, 1698, 1603, 1333, 1267, 1022, 823; ESI-HRMS found m/z 
190.0476 [M+Na]
+
, C8H9NNaO3 requires 190.0475. 
 
4-Amino-2-sec-butoxybenzoic acid (3.17) 
Procedure E; methyl 4-amino-2-sec-butoxybenzoate 3.12 (750 mg, 3.4 mmol) 
in a 1:1 mixture of tetrahydrofuran/methanol (100 mL), 10% aqueous sodium 
hydroxide (30 mL). Further aliquots of 10% aqueous sodium hydroxide were 
added to bring the reaction to completion. Work up yielded the title compound 
3.17 (700 g, 3.3 mmol, quant.) as an orange oil; H (500 MHz, CDCl3) 10.94 (s, broad, 1 H, 
CO2H), 7.96 (d, J = 8.5 Hz, 1 H, H6), 6.36 (dd, J = 8.5, 2.1 Hz, 1 H, H5), 6.23 (d, J = 2.1 Hz, 1 
H, H3), 4.53 – 4.59 (m, 1 H, Hα), 4.23 (s, broad, 2 H, NH2), 1.81 – 1.92 (m, 1 H, Hβ), 1.71 – 
1.81 (m, 1 H, Hβ), 1.41 (d, J = 6.2 Hz, 3 H, CHα(CH3)), 1.03 (t, J = 7.6 Hz, 3 H, Hγ); δC (125 
MHz, CDCl3) 165.9, 158.5, 152.7, 135.5, 108.6, 108.3, 98.7, 78.5, 29.1, 19.2, 9.6; νmax/cm
-1
 
(solid state) = 3468, 3358, 3233, 2973, 2936, 2880, 1707, 1601, 1458, 1394, 1268, 988; ESI-
HRMS found m/z 210.1128 [M+H]
 +
, C11H16NO3 requires 210.1125. 
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 4-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-2-methoxybenzoic acid (3.21) 
 Procedure G; 4-amino-2-methoxybenzoic acid 3.15 (1.0 g, 6.0 mmol) in 
tetrahydrofuran (40 mL) and fluorenylmethyloxycarbonyl chloride (2.6 g, 9.0 
mmol) in tetrahydrofuran (20 mL). After work up, the reaction mixture was 
purified by column chromatography (Stationary Phase: Silica; Mobile Phase: A 
gradient of dichloromethane to dichloromethane/ethylacetate 1:1 to ethylacetate/methanol 
9.5:0.5) to yield the title compound 3.21 (1.13 g, 2.9 mmol, 48%) as a beige solid; H (500 
MHz, CDCl3) 10.60 (s, broad, 1 H, CO2H), 8.09 (d, J = 8.5 Hz, 1 H, H6 ), 7.79 (d, J = 8.5 Hz, 2 
H, FHAr5), 7.65 (s, 1 H, H3), 7.64 (d, J = 7.5 Hz, 2 H, FHAr2), 7.43 (t, J = 7.5 Hz, 2 H, 
FHAr4), 7.34 (t, J = 7.5 Hz, 2 H, FHAr3), 7.16 (s, broad, 1 H, NH), 6.81 (dd, J = 8.5, 1.5 Hz, 1 
H, H5), 4.59 (d, J = 6.5 Hz, 2 H, FH), 4.28 (t, J = 6.5 Hz, 1 H, FH), 4.06 (s, 3 H, H); δC 
(125 MHz, CDCl3) 165.1, 159.2, 152.9, 144.3, 143.4, 141.4, 134.6, 128.0, 127.4, 124.8, 120.2, 
112.1, 111.4, 101.1, 67.2, 56.8, 47.0; νmax/cm
-1
 (solid state) = 3276, 3018, 2948, 1714, 1594, 
1530, 1215, 755, 740; ESI-HRMS found m/z 390.1340 [M+H]
+
, C23H20NO5 requires 390.1336. 
 
 4-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-2-sec-butoxybenzoic acid (3.23) 
Procedure G; 4-amino-2-sec-butoxybenzoic acid 3.17 (700 mg, 3.3 mmol) in 
tetrahydrofuran (50 mL) and fluorenylmethyloxycarbonyl chloride (1.3 g, 5.0 
mmol) in tetrahydrofuran (10 mL). Work up yielded the title compound 3.23 
(435 mg, 1.0 mmol, 31%) as an off-white solid; H (500 MHz, CDCl3) 11.06 
(s, broad, 1 H, CO2H), 8.10 (d, J = 8.5 Hz, 1 H, H6 ), 7.80 (d, J = 7.5 Hz, 2 H, FHAr5), 7.68 (s, 
1 H, H3), 7.63 (d, J = 7.5 Hz, 2 H, FHAr2), 7.44 (t, J = 7.5 Hz, 2 H, FHAr4), 7.34 (t, J = 7.5 Hz, 
2 H, FHAr3), 7.02 (s, broad, 1 H, NH), 6.76 (dd, J = 8.5, 1.5 Hz, 1 H, H5), 4.65 – 4.72 (m, 1 H, 
Hα), 4.58 (d, J = 6.5 Hz, 2 H, FH), 4.29 (t, J = 6.5 Hz, 1 H, FH), 1.85 – 1.93 (m, 1 H, Hβ), 
1.74 – 1.84 (m, 1 H, Hβ), 1.45 (d, J = 6.2 Hz, 3 H, CHα(CH3)), 1.04 (t, J = 7.4 Hz, 3 H, Hγ); δC 
(125 MHz, CDCl3) 165.3, 157.8, 152.9, 149.6, 143.9, 143.4, 141.4, 134.6, 128.0, 127.2, 124.8, 
120.2, 111.4, 103.2, 79.0, 67.2, 47.0, 29.0, 19.2, 9.6; νmax/cm
-1
 (solid state) = 3273, 2972, 2938, 
1713, 1592, 1531, 1449, 1216, 736; ESI-HRMS found m/z 432.1810 [M+H]
+
, C26H26NO5 
requires 432.1805. 
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6.4.3. Hybrids characterization 
 
H2N-[O-4-Cl-Bn-(3-HABA)]-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.27) 
Pale brown solid; isolated yield: 23 mg, 35%;
 δH (500 MHz, 
MeOD) 7.95 (d, J = 8.5 Hz, 1 H, 3-H6), 7.60 (d, J = 1.7 Hz, 1 H, 3-
H3), 7.44 (d, J = 8.3 Hz, 2 H, 1-HAr2), 7.37 – 7.36 (m, 3 H, 1-
HAr3, 1-H2), 7.33 – 7.28 (m, 3 H, 2-Phe-HAr2, 1-H6), 7.25 – 7.23 
(m, 2 H, 2-Phe-HAr3), 7.21 – 7.16 (m, 1 H, 2-Phe-HAr4), 7.07 (dd, 
J = 8.5, 1.7 Hz, 1 H, 3-H5), 6.72 (d, J = 8.3 Hz, 1 H, 1-H5), 5.10 (s, 
2 H, 1-H), 4.90 (dd, J = 8.3, 6.6 Hz, 1 H, 2-Phe-H), 4.77 (spt, J 
= 6.1, 1 H, 3-H4.16 (s, 2 H, 4-Gly-Hα), 3.27 (dd, J = 13.7, 6.6 
Hz, 1 H, 2-Phe-H), 3.17 (dd, J = 13.7, 8.3 Hz, 1 H, 2-Phe-H), 
1.46 (d, J = 6.1 Hz, 3 H, 3-H), 1.44 (d, J = 6.1 Hz, 3 H, 3-H); δC (125 MHz, MeOD) 172.9, 
170.1, 167.2, 158.3, 146.4, 144.2, 143.1, 138.3, 137.3, 134.7, 133.1, 127.8, 122.9, 117.9, 114.5, 
113.0, 112.4, 106.5, 73.6, 70.6, 57.6, 42.6, 38.9, 22.1; νmax/cm
-1
 (solid state) = 3357, 2979, 2930, 
1683, 1522, 1407, 1211, 698; ESI-HRMS found m/z 659.2278 [M+H]
+
, C35H36ClN4O7 requires 
659.2267. 
 
H2N-[O-4-CF3-Bn-(3-HABA)]-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.28) 
Beige solid; isolated yield: 29 mg, 42%;
 δH (500 MHz, DMSO-
d6) 10.42 (s. broad, 1 H, 4-Gly-CO2H), 8.46 (t, J = 4.9 Hz, 1 H, 
4-Gly-NH), 8.32 (d, J = 8.0 Hz, 1 H, 2-Phe-NH), 7.89 (d, J = 8.5 
Hz, 1 H, 3-H6), 7.88 – 7.81 (m, 2 H, 1-HAr2), 7.70 – 7.64 (m, 1 
H, 1-HAr3), 7.61 (d, J = 1.9 Hz, 1 H, 3-H3), 7.42 (d, J = 1.8 Hz, 
1 H, 1-H2), 7.38 (d, J = 7.3 Hz, 2 H, 2-Phe-HAr2), 7.33 (dd, J = 
8.5, 1.9 Hz, 1 H, 3-H5), 7.28 – 7.22 (m, 3 H, 1-H6, 2-Phe-HAr3), 
7.17 (t, J = 8.5 Hz, 1 H, 2-Phe-HAr4), 6.65 (d, J = 8.2 Hz, 1 H, 
1-H5), 5.40 (s. broad, 2 H, 1-NH2), 5.24 (s, 2 H, 1-Hα), 4.84 – 
4.76 (m, 2 H, 2-Phe-Hα), 4.71 (quin, J = 5.9 Hz, 1 H, 3-Hα), 4.04 (d, J = 5.0 Hz, 2 H, 4-Gly-
Hα), 3.16 – 3.04 (m, 2 H, 2-Phe-Hβ), 1.41 (dd, J = 8.5, 6.5 Hz, 6 H, 3-Hβ); δC (125 MHz, 
DMSO-d6) 171.4, 171.2, 166.3, 163.9, 156.2, 143.9, 143.0, 141.7, 138.8, 138.1, 131.9, 131.4, 
129.4, 129.2, 128.0, 126.3, 123.9, 122.0, 120.8, 116.6, 112.4, 111.6, 111.3, 104.7, 71.9, 68.7, 
55.8, 41.6, 37.1, 21.6, 21.6; νmax/cm
-1
 (solid state) = 3340, 2979, 2923, 1615, 1595, 1497, 1213, 
1122, 699; ESI-HRMS found m/z 693.2549 [M+H]
+
, C36H36F3N4O7 requires 693.2531. 
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H2N-[O-4-tBu-Bn-(3-HABA)]-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.29) 
Beige solid; isolated yield: 24 mg, 35%;
 δH (500 MHz, MeOD) 
7.95 (d, J = 8.7 Hz, 1 H, 3-H6), 7.59 (d, J = 1.8 Hz, 1 H, 3-H3), 
7.43– 7.38 (m, 3 H, 1-H2, 1-HAr2), 7.38 – 7.34 (m, 2 H, 1-
HAr3), 7.33 – 7.28 (m, 3 H, 2-Phe-HAr2, 1-H6), 7.25 – 7.23 (m, 
2 H, 2-Phe-HAr3), 7.21 – 7.16 (m, 1 H, 2-Phe-HAr4), 7.08 (dd, J 
= 8.7, 1.8 Hz, 1 H, 3-H5), 6.71 (d, J = 8.1 Hz, 1 H, 1-H5), 5.05 
(s, 2 H, 1-H), 4.92 (dd, J = 8.2, 6.9 Hz, 1 H, 2-Phe-H), 4.74 
(spt, J = 6.1, 1 H, 3-H4.16 (s, 2 H, 4-Gly-Hα), 3.27 (dd, J = 
13.8, 6.9 Hz, 1 H, 2-Phe-H), 3.17 (dd, J = 13.8, 8.3 Hz, 1 H, 2-
Phe-H), 1.42 (d, J = 6.1 Hz, 3 H, 3-H), 1.44 (d, J = 6.1 Hz, 3 H, 3-H), 1.31 (s, 9 H, 1-HAr4-
C(CH3)3); δC (125 MHz, MeOD) 173.0, 172.6, 170.2, 167.2, 158.3, 152.1, 146.7, 144.2, 143.0, 
138.3, 135.4, 133.1, 130.3, 129.4, 128.6, 127.8, 126.4, 123.0, 122.7, 117.9, 114.4, 113.0, 112.2, 
106.5, 73.6, 71.3, 57.6, 42.6, 39.0, 35.3, 31.7, 22.1; νmax/cm
-1
 (solid state) = 3356, 2962, 2870, 
1596, 1493, 1408, 1213, 1004, 699; ESI-HRMS found m/z 703.3104 [M+Na]
+
, C39H44N4NaO7 
requires 703.3102. 
 
H2N-[O-4-tBu-Bn-(3-HABA)]-D-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.50) 
Beige solid; isolated yield: 34 mg, 50%;
 δH (500 MHz, MeOD) 
7.94 (d, J = 8.6 Hz, 1 H, 3-H6), 7.58 (d, J = 1.9 Hz, 1 H, 3-H3), 
7.42 – 7.38 (m, 3 H, 1-H2, 1-HAr2), 7.37 – 7.33 (m, 2 H, 1-
HAr3), 7.32 – 7.29 (m, 3 H, 2-Phe-HAr2, 1-H6), 7.25 – 7.23 (m, 
2 H, 2-Phe-HAr3), 7.19 – 7.17 (m, 1 H, 2-Phe-HAr4), 7.08 (dd, J 
= 8.6, 1.9 Hz, 1 H, 3-H5), 6.70 (d, J = 8.2 Hz, 1 H, 1-H5), 5.03 
(s, 2 H, 1-H), 4.94 (dd, J = 8.2, 7.0 Hz, 1 H, 2-Phe-H),  4.74 
(spt, J = 6.3 Hz, 1 H, 3-H4.15 (s, 2 H, 4-Gly-Hα), 3.27 (dd, J 
= 13.9, 7.0 Hz, 1 H, 2-Phe-H), 3.17 (dd, J = 13.9, 8.2 Hz, 1 H, 
2-Phe-H), 1.41 (d, J = 6.3 Hz, 3 H, 3-H), 1.42 (d, J = 6.3 Hz, 3 H, 3-H), 1.30 (s, 9 H, 1-
HAr4-C(CH3)3); δC (125 MHz, MeOD) 173.0, 171.4, 170.2, 167.2, 158.3, 152.1, 146.7, 144.2, 
143.0, 138.3, 135.4, 133.1, 130.3, 129.4, 128.6, 127.8, 126.4, 122.9, 122.8, 117.9, 114.4, 113.0, 
112.2, 106.573.6, 71.3, 57.6, 42.6, 39.0, 35.3, 31.7, 22.1; νmax/cm
-1
 (solid state) = 3362, 2960, 
2929, 2868, 1651, 1496, 1445, 1404, 1218, 818; ESI-HRMS found m/z 681.3297 [M+H]
+
, 
C39H45N4O7 requires 681.3283. 
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H2N-[O-4-tBu-Bn-(3-HABA)]-p-Br-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.51) 
Beige solid; isolated yield: 23 mg, 30%;
 δH (500 MHz, DMSO-
d6) 10.43 (s. broad, 1 H, 4-Gly-CO2H), 8.46 (t, J = 4.9 Hz, 1 H, 
4-Gly-NH), 8.34 (d, J = 8.1 Hz, 1 H, 2-Phe-NH), 7.90 (d, J = 8.8 
Hz, 1 H, 3-H6), 7.60 (d, J = 1.5 Hz, 1 H, 3-H3), 7.46 (d, J = 8.3 
Hz, 2 H, 1-HAr2), 7.44 – 7.38 (m, 5 H, 1-H2, 1-HAr3, 2-Phe-
HAr3), 7.36 (d, J = 7.3 Hz, 2 H, 2-Phe-HAr2), 7.30 (dd, J = 8.3, 
1.7 Hz, 1 H, 3-H5), 7.25 (dd, J = 8.5, 1.7 Hz, 1 H, 1-H6), 6.63 (d, 
J = 8.3 Hz, 1 H, 1-H5), 5.30 (s. broad, 2 H, 1-NH2), 5.11 (d, J = 
2.1 Hz, 2 H, 1-Hα), 4.84 – 4.76 (m, 2 H, 2-Phe-Hα), 4.71 (quin, J 
= 5.9 Hz, 1 H, 3-Hα), 4.04 (d, J = 5.1 Hz, 2 H, 4-Gly-Hα), 3.16 – 3.04 (m, 2 H, 2-Phe-Hβ), 1.41 
(dd, J = 8.5, 6.5 Hz, 6 H, 3-Hβ), 1.28 (s, 9 H, 1-HAr4-C(CH3)3); δC (125 MHz, DMSO-d6) 
171.2, 171.2, 166.4, 163.9, 156.2, 150.1, 144.1, 143.0, 141.6, 137.7, 134.2, 132.0, 131.5, 130.9, 
127.4, 125.1, 121.7, 120.7, 119.5, 116.6, 112.3, 111.3, 111.1, 104.7, 71.9, 69.1, 55.6, 41.6, 36.4, 
34.3, 31.1, 21.6; νmax/cm
-1
 (solid state) = 2960, 2925, 2864, 1594, 1508, 1489, 1260, 1215, 1011; 
ESI-HRMS found m/z 759.2398 [M+H]
+
, C39H44BrN4O7 requires 759.2388. 
 
 
H2N-[O-2-Nph-(3-HABA)]-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.30) 
Pale brown; isolated yield: 11 mg, 16%;
 δH (500 MHz, MeOD) 
7.95 (d, J = 8.6 Hz, 1 H, 3-H6), 7.92 – 7.81 (m, 4 H, 1-HAr4, 1-
HAr5, 1-HAr8, 1-HAr7), 7.59 – 7.54 (m, 2 H, 1-HAr6, 3-H3), 
7.49 - 7.42 (m, 3 H, 1-HAr1, 1-HAr3, 1-H2), 7.33 – 7.26 (m, 3 H, 
2-Phe-HAr2, 1-H6), 7.24 – 7.21 (m, 2 H, 2-Phe-HAr3), 7.19 – 
7.14 (m, 1 H, 2-Phe-HAr4), 7.07 (dd, J = 8.6, 1.8 Hz, 1 H, 3-H5), 
6.73 (d, J = 8.3 Hz, 1 H, 1-H5), 5.27 (s, 2 H, 1-H), 4.91 (dd, J = 
8.3, 6.6 Hz, 1 H, 2-Phe-H), 4.74 (spt, J = 6.1, 1 H, 3-H4.15 
(s, 2 H, 4-Gly-Hα), 3.26 (dd, J = 13.8, 6.6 Hz, 1 H, 2-Phe-H), 
3.17 (dd, J = 13.8, 8.3 Hz, 1 H, 2-Phe-H), 1.42 (d, J = 6.1 Hz, 3 H, 3-H), 1.43 (d, J = 6.1 Hz, 
3 H, 3-H); δC (125 MHz, MeOD) 172.9, 170.1, 167.2, 158.3, 146.7, 144.2, 143.6, 143.1, 
138.3, 135.9, 134.7, 134.5, 133.1, 130.3, 129.4, 129.2, 128.9, 128.6, 127.8, 127.4, 127.2, 127.0, 
126.4, 123.0, 122.9, 117.9, 114.5, 113.0, 112.5, 106.5, 73.6, 71.5, 57.6, 42.7, 39.0, 22.1; 
νmax/cm
-1
 (solid state) = 3357, 3276, 2979, 2929, 2872, 1594, 1507, 1496, 1213; ESI-HRMS 
found m/z 675.2827 [M+H]
+
, C39H39N4O7 requires 675.2813. 
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H2N-[O-sBu-(3-HABA)]-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.31) 
Beige solid; isolated yield: 22 mg, 37%;
 δH (500 MHz, MeOD) 7.95 (d, J 
= 8.5 Hz, 1 H, 3-H6), 7.60 (d, J = 1.8 Hz, 1 H, 3-H3), 7.34 – 7.28 (m, 3 H, 
2-Phe-HAr2, 1-H2), 7.28 – 7.23 (m, 3 H, 2-Phe-HAr3, 1-H6), 7.21 – 7.16 
(m, 1 H, 2-Phe-HAr4), 7.07 (dd, J = 8.5, 1.8 Hz, 1 H, 3-H5), 6.71 (d, J = 
8.3 Hz, 1 H, 1-H5), 4.90 (dd, J = 8.2, 6.8 Hz, 1 H, 2-Phe-H), 4.77 (spt, J 
= 6.1 Hz, 1 H, 3-H4.41 – 4.37 (m, 1 H, 1-H), 4.16 (s, 2 H, 4-Gly-
Hα), 3.27 (dd, J = 13.5, 6.8 Hz, 1 H, 2-Phe-H), 3.17 (dd, J = 13.5, 8.2 
Hz, 1 H, 2-Phe-H), 1.80 – 1.71 (m, 1 H, 1-H), 1.69 – 1.62 (m, 1 H, 1-
H), 1.45 (d, J = 6.1 Hz, 3 H, 3-H), 1.44 (d, J = 6.1 Hz, 3 H, 3-H), 
1.28 (dd, J = 6.0, 4.3 Hz, 3 H, 1-CH(CH3)), 1.00 – 0.91 (m, 3 H, 1-H); δC (125 MHz, MeOD) 
172.9, 172.6, 170.3, 167.2, 158.3, 145.8, 144.2, 138.3, 133.1, 130.3, 129.4, 127.8, 123.1, 122.3, 
117.9, 114.6, 113.6, 113.6, 113.0, 106.5, 77.0, 73.6, 57.6, 42.5, 38.9, 30.2, 22.1, 19.6, 10.0; 
νmax/cm
-1
 (solid state) = 3350, 3034, 2973, 2929, 1670, 1497, 1215, 699; ESI-HRMS found m/z 
591.2824 [M+H]
+
, C32H39N4O7 requires 591.2813. 
 
H2N-[O-CH2-CH2-CH2-S-CH2-(3-HABA)]-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.32) 
Dark yellow solid; isolated yield: 60 mg, 96%;
 δH (500 MHz, MeOD) 
7.95 (d, J = 8.5 Hz, 1 H, 3-H6), 7.60 (d, J = 1.8 Hz, 1 H, 3-H3), 7.33 
– 7.28 (m, 3 H, 2-Phe-HAr2, 1-H2), 7.28 – 7.23 (m, 3 H, 2-
Phe-HAr3, 1-H6), 7.21 – 7.16 (m, 1 H, 2-Phe-HAr4), 7.06 (dd, J = 
8.5, 1.8 Hz, 1 H, 3-H5), 6.71 (d, J = 7.9 Hz, 1 H, 1-H5), 4.90 (dd, J = 
8.3, 6.8 Hz, 1 H, 2-Phe-H), 4.77 (spt, J = 6.1, 1 H, 3-H4.16 (s, 2 
H, 4-Gly-Hα), 4.12 (t, J = 6.0 Hz, 2 H, 1-H), 3.27 (dd, J = 13.5, 6.8 
Hz, 1 H, 2-Phe-H), 3.17 (dd, J = 13.5, 8.3 Hz, 1 H, 2-Phe-H), 2.69 
(t, J = 7.2 Hz, 2 H, 1-H), 2.09 (m, 5 H, 1-H1-SCH3), 1.45 (d, J = 
6.1 Hz, 3 H, 3-H), 1.44 (d, J = 6.1 Hz, 3 H, 3-H); δC (125 MHz, MeOD) 172.9, 170.2, 167.2, 
158.3, 152.3, 146.9, 144.2, 138.3, 133.1, 130.3, 129.4, 127.8, 123.3, 122.6, 117.9, 116.2, 114.5, 
113.0, 111.8, 106.5, 73.6, 67.9, 57.6, 42.5, 38.9, 31.6, 29.8, 22.1, 15.3; νmax/cm
-1
 (solid state) = 
3357, 2974, 2918, 1595, 1508, 1497, 1212; ESI-HRMS found m/z 623.2540 [M+H]
+
, 
C32H39N4O7S requires 623.2534. 
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H2N-[O-4-Cl-Bn-(3-HABA)]-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.33) 
Off-white solid, > 95% pure by NMR; isolated yield: 55 mg, 93%;
 δH 
(500 MHz, DMSO-d6) 10.47 (s. broad, 1 H, 4-Gly-CO2H), 8.63 (s. broad, 
1 H, 4-Gly-NH), 8.41 (d, J = 8.1 Hz, 1 H, 2-Phe-NH), 7.90 (d, J = 8.5 Hz, 
1 H, 3-H6), 7.57 (s, 1 H, 3-H3), 7.39 (m, 3 H, 1-H2, 2-Phe-HAr2), 7.32 – 
7.22 (m, 4 H, 3-H5, 1-H6, 2-Phe-HAr3), 7.17 (t, J = 8.5 Hz, 1 H, 2-Phe-
HAr4), 6.61 (d, J = 8.5 Hz, 1 H, 1-H5), 5.20 (s. broad, 2 H, 1-NH2), 4.84 
– 4.76 (m, 2 H, 2-Phe-Hα), 4.68 (quin, J = 5.9 Hz, 1 H, 3-Hα), 3.83 (d, J 
= 6.8 Hz, 2 H, 4-Gly-Hα), 3.16 – 3.09 (m, 2 H, 2-Phe-Hβ), 1.40 (dd, J = 
8.5, 6.5 Hz, 6 H, 3-Hβ), 0.91 – 0.82 (m, 1 H, 1-Hα), 0.60 – 0.52 (m, 2 H, 
1-Hβ), 0.37 – 0.32 (m, 2 H, 1-Hβ); δC (125 MHz, DMSO-d6) 171.4, 166.4, 163.0, 156.2, 144.4, 
142.7, 141.4, 141.0, 138.3, 131.8, 129.2, 128.0, 126.3, 121.6, 121.0, 117.2, 112.2, 111.3, 111.1, 
104.6, 72.5, 71.6, 56.0, 37.1, 29.0, 21.6, 10.3, 3.1; νmax/cm
-1
 (solid state) = 3324, 3090, 2926, 
2852, 1595, 1509, 1496, 1406, 1105, 1007, 919; ESI-HRMS found m/z 589.2669 [M+H]
+
, 
C32H37N4O7 requires 589.2657. 
 
H2N-[O-Bn-(3-HABA)]-2-Nal-[O-iPr-(2-HABA)]-Gly-CO2H (3.34) 
Brown solid; isolated yield: 18 mg, 27%;
 δH (500 MHz, MeOD) 7.93 
(d, J = 8.5 Hz, 1 H, 3-H6), 7.81 – 7.68 (m, 4 H, 2-HAr4, 2-HAr5, 2-
HAr8, 2-HAr7), 7.48 (d, J = 1.8 Hz, 1 H, 3-H3), 7.45 (dd, J = 8.5, 1.5 
Hz, 1 H, 1-H2), 7.40 – 7.38 (m, 4 H, 1-Phe-HAr2, 2-HAr1, 2-HAr6), 
7.37 – 7.26 (m, 5 H, 2-HAr3, 1-Phe-HAr3, 1-Phe-HAr4, 1-H6), 7.07 
(dd, J = 8.7, 1.7 Hz, 1 H, 3-H5), 6.70 (d, J = 7.9 Hz, 1 H, 1-H5), 5.06 – 
4.95 (m, 3 H, 1-H2-Nal-H), 4.65 (spt, J = 6.1, 1 H, 3-H4.15 (s, 
2 H, 4-Gly-Hα), 3.44 (dd, J = 13.5, 8.0 Hz, 1 H, 2-Nal-H), 3.34 (dd, J 
= 13.5, 7.0 Hz, 1 H, 2-Nal-H), 1.38 (d, J = 5.5 Hz, 3 H, 3-H), 1.39 
(d, J = 5.5 Hz, 3 H, 3-H); δC (125 MHz, MeOD) 172.9, 172.3, 170.2, 167.2, 158.3, 146.6, 
144.1, 143.0, 138.4, 135.8, 134.9, 133.9, 133.1, 129.4, 129.0, 129.0, 128.9, 128.7, 128.6, 128.5, 
128.4, 127.0, 126.6, 123.0, 122.8, 117.9, 114.4, 113.1, 112.3, 106.5, 73.6, 71.4, 57.5, 39.1, 22.1, 
22.1; νmax/cm
-1
 (solid state) = 3357, 2921, 2851, 1602, 1507, 1217, 697; ESI-HRMS found m/z 
675.2827 [M+H]
+
, C39H39N4O7 requires 675.2813. 
 
 
 
 
  
132 
H2N-[O-Bn-(3-HABA)]-2-Nal-[O-iPr-(2-HABA)]-Gly-CO2H (3.35) 
Brown solid; isolated yield: 25 mg, 37%;
 δH (500 MHz, MeOD) 7.91 
(d, J = 8.8 Hz, 1 H, 3-H6), 7.77 – 7.66 (m, 4 H, 2-HAr4, 2-HAr5, 2-
HAr8, 2-HAr7), 7.44 – 7.42 (m, 2 H, 3-H3, 1-H2), 7.38 – 7.34 (m, 2 
H, 2-HAr1, 2-HAr6), 7.34 – 7.22 (m, 7 H, 1-Phe-HAr2, 2-HAr3, 1-
Phe-HAr3, 1-Phe-HAr4, 1-H6), 7.08 (dd, J = 8.7, 1.8 Hz, 1 H, 3-H5), 
6.67 (d, J = 7.9 Hz, 1 H, 1-H5), 5.10 (dd, J = 8.3, 6.8 Hz, 1 H, 2-Nal-
H), 4.88 (d, J = 7.9 Hz, 2 H, 1-H), 4.53 (spt, J = 6.1, 1 H, 3-
H4.14 (s, 2 H, 4-Gly-Hα), 3.44 (dd, J = 13.5, 8.0 Hz, 1 H, 2-Nal-
H), 3.34 (dd, J = 13.5, 7.0 Hz, 1 H, 2-Nal-H), 1.31 (d, J = 6.0 Hz, 6 
H, 3-H); δC (125 MHz, MeOD) 173.1, 172.6, 170.1, 167.1, 158.2, 146.6, 144.1, 143.0, 138.3, 
135.8, 134.9, 133.8, 133.1, 129.4, 129.0, 129.0, 128.9, 128.7, 128.5, 128.5, 128.4, 127.0, 126.6, 
122.9, 122.9, 117.8, 114.4, 113.0, 112.2, 106.4, 73.5, 71.3, 57.6, 39.1, 22.1, 22.0; νmax/cm
-1
 
(solid state) = 3376, 3054, 2979, 2929, 1603, 1443, 757, 697; ESI-HRMS found m/z 675.2820 
[M+H]
+
, C39H39N4O7 requires 675.2813. 
 
H2N-[O-Bn-(3-HABA)]-N-Me-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.36) 
Beige solid; isolated yield: 15 mg, 23%; δH (500 MHz, DMSO-d6) 
10.28 (s. broad, 1 H, 4-Gly-CO2H), 8.48 (t, J = 4.8 Hz, 1 H, 4-Gly-
NH), 7.91 (d, J = 8.5 Hz, 1 H, 3-H6), 7.64 (s, 1 H, 3-H3), 7.30 – 7.20 
(m, 11 H, 1-HAr2, 1-HAr3, 2-Phe-HAr3, 2-Phe-HAr2, 3-H5, 2-Phe-
HAr4, 1-HAr4), 6.61 – 6.50 (m, 3 H, 1-H5, 1-H6, 1-H2), 5.15 (s. 
broad, 2 H, 1-NH2), 4.99 – 4.83 (m, 2 H, 1-Hα), 4.71 (spt, J = 5.9 Hz, 
1 H, 3-Hα), 4.00 (d, J = 4.7 Hz, 2 H, 4-Gly-Hα), 3.29 (d, J = 12.2 Hz, 
2 H, 2-Phe-Hα), 3.12 (dd, J = 14.5, 10.9 Hz, 2 H, 2-Phe-Hβ), 2.88 (s, 3 
H, 2-NCH3), 1.39 (d, J = 6.0 Hz, 6 H, 3-Hβ); δC (125 MHz, DMSO-d6) 
171.9, 171.2, 170.1, 163.8, 156.2, 143.9, 142.8, 140.0, 137.6, 137.0, 131.9, 128.7, 128.3, 128.3, 
127.6, 127.1, 126.4, 122.7, 121.4, 116.9, 112.7, 111.6, 105.0, 71.9, 69.3, 42.0, 34.9, 34.6, 34.5, 
21.6; νmax/cm
-1
 (solid state) = 3366, 3033, 2979, 2930, 1604, 1454, 1389, 1235, 699; ESI-HRMS 
found m/z 639.2820 [M+H]
+
, C36H39N4O7 requires 639.2813. 
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H2N-[O-Bn-(3-HABA)]-Phe-[O-iBu-(2-HABA)]-Gly-CO2H (3.41) 
 Brown solid; isolated yield: 41 mg, 63%;
 δH (500 MHz, MeOD) 7.90 
(d, J = 8.6 Hz, 1 H, 3-H6), 7.47 (d, J = 1.7 Hz, 1 H, 3-H3), 7.38 (d, J = 
1.9 Hz, 1 H, 1-H2), 7.37 - 7.33 (m, 2 H, 1-HAr2), 7.33 - 7.24 (m, 6 H, 
1-HAr3, 1-HAr4, 2-Phe-HAr2, 1-H6), 7.18 - 7.24 (m, 2 H, 2-
Phe-HAr3), 7.14 - 7.18 (m, 1 H, 2-Phe-HAr4), 7.09 (dd, J = 8.6, 1.7 
Hz, 1 H, 3-H5), 6.67 (d, J = 8.3 Hz, 1 H, 1-H5), 5.00 (dd, J = 8.2, 6.8 
Hz, 1 H, 2-Phe-H), 4.96 (d, J = 3.2 Hz, 2 H, 1-H), 4.15 (s, 2 H, 4-
Gly-Hα), 3.68 - 3.80 (m, 2 H, 3-H), 3.13 - 3.29 (dd, J = 8.2, 6.8 Hz, 2 
H, 2-Phe-H), 2.17 (m, 1 H, 3-H), 0.97 (dd, J = 4.5, 6.8 Hz, 6 H, 3-
H); δC (125 MHz, MeOD) 173.3, 172.7, 170.0, 167.2, 159.4, 146.6, 144.3, 143.0, 138.4, 133.1, 
130.3, 130.3, 129.5, 129.4, 128.9, 128.6, 127.8, 122.9, 122.8, 117.0, 114.4, 112.8, 112.3, 104.9, 
76.8, 71.3, 57.8, 42.6, 38.9, 29.0, 19.6; νmax/cm
-1
 (solid state) = 3370, 2956, 2924, 2873, 1600, 
1498, 1394, 1215, 1016, 697; ESI-HRMS found m/z 639.2830 [M+H]
+
, C36H39N4O7 requires 
639.2813. 
 
H2N-[O-Bn-(3-HABA)]-Phe-[O-sBu-(2-HABA)]-Gly-CO2H (3.42) 
 Brown solid; isolated yield: 15 mg, 23%;
 δH (500 MHz, MeOD) 7.94 
(d, J = 8.5 Hz, 1 H, 3-H6), 7.53 (d, J = 1.6 Hz, 1 H, 3-H3), 7.40 – 7.39 
(m, 3 H, 1-H2, 1-HAr2), 7.36 – 7.25 (m, 6 H, 1-HAr3, 1-HAr4, 2-
Phe-HAr2, 1-H6), 7.23 (t, J = 7.4 Hz, 2 H, 2-Phe-HAr3), 7.20 – 7.14 
(m, 1 H, 2-Phe-HAr4), 7.10 (dd, J = 8.5, 1.6 Hz, 1 H, 3-H5), 6.73 (d, J 
= 8.3 Hz, 1 H, 1-H5), 5.02 (s, 2 H, 1-H), 4.99 – 4.96 (m, 1 H, 2-Phe-
H), 4.50 – 4.41 (m, 1 H, 3-H), 4.15 (s, 2 H, 4-Gly-Hα), 3.28 – 3.16 
(m, 2 H, 2-Phe-H), 1.91 – 1.83 (m, 1 H, 3-H), 1.73 – 1.65 (m, 1 H, 
3-H), 1.34 (dd, J = 11.2, 6.1 Hz, 3 H, 3-CH(CH3)), 1.00 – 0.91 (m, 
3 H, 3-H); δC (125 MHz, MeOD) 173.1, 172.5, 170.0, 167.2, 158.5, 147.0, 144.2, 141.8, 138.3, 
138.3, 133.2, 130.3, 129.5, 128.9, 128.7, 127.8, 123.7, 122.8, 117.7, 115.0, 112.9, 112.3, 106.3, 
78.6, 71.2, 57.7, 42.5, 38.9, 29.8, 19.5, 10.1; νmax/cm
-1
 (solid state) = 3334, 2966, 2924, 2853, 
1696, 1495, 1219, 1201, 650; ESI-HRMS found m/z 639.2826 [M+H]
+
, C36H39N4O7 requires 
639.2813. 
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H2N-[O-Bn-(3-HABA)]-Phe-[O-Me-(2-HABA)]-Gly-CO2H (3.43) 
 Brown solid; isolated yield: 30 mg, 50%;
 δH (500 MHz, MeOD) 7.93 
(d, J = 8.5 Hz, 1 H, 3-H6), 7.58 (d, J = 1.8 Hz, 1 H, 3-H3), 7.47 – 7.45 
(m, 2 H, 1-HAr2), 7.41 – 7.34 (m, 3 H, 1-H2, 1-HAr3), 7.34 – 7.28 (m, 
4 H, 1-HAr4, 2-Phe-HAr2, 1-H6), 7.27 – 7.24 (m, 2 H, 2-Phe-HAr3), 
7.22 – 7.17 (m, 1 H, 2-Phe-HAr4), 7.09 (dd, J = 8.6, 1.7 Hz, 1 H, 3-
H5), 6.72 (d, J = 7.9 Hz, 1 H, 1-H5), 5.12 (s, 2 H, 1-H), 4.91 (dd, J = 
8.1, 6.9 Hz, 1 H, 2-Phe-H), 4.11 (s, 2 H, 4-Gly-Hα), 3.97 (s, 3 H, 3-
H), 3.27 (dd, J = 13.5, 6.8 Hz, 1 H, 2-Phe-H), 3.17 (dd, J = 13.5, 8.3 
Hz, 1 H, 2-Phe-H); δC (125 MHz, MeOD) 172.9, 170.2, 169.6, 
167.2, 160.0, 146.7, 144.3, 143.0, 138.4, 138.3, 133.0, 130.3, 129.5, 129.4, 128.9, 128.7, 127.8, 
123.0, 122.8, 117.3, 114.4, 112.9, 112.3, 104.2, 79.4, 71.4, 57.6, 56.5, 38.9; νmax/cm
-1
 (solid 
state) = 3370, 3029, 2924, 2852, 1601, 1498, 1452, 1405, 1217, 1026, 698; ESI-HRMS found 
m/z 597.2355 [M+H]
+
, C33H33N4O7 requires 597.2344. 
 
3-NH2-Pr-HN-[O-Bn-(3-HABA)]-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.44) 
Off-white solid; isolated yield: 26 mg, 38%;
 δH (500 MHz, MeOD) 
7.92 (d, J = 8.6 Hz, 1 H, 3-H6), 7.48 (d, J = 1.7 Hz, 1 H, 3-H3), 7.40 
(dd, J = 8.4, 1.7 Hz, 1 H, 1-H6), 7.36 (d, J = 1.7 Hz, 1 H, 1-H2), 7.35 – 
7.25 (m, 7 H, 2-Phe-HAr2, 1-HAr2, 1-HAr3, 1-HAr4), 7.24 – 7.21 (m, 
2 H, 2-Phe-HAr3), 7.18 – 7.15 (m, 1 H, 2-Phe-HAr4), 7.10 (dd, J = 
8.6, 1.7 Hz, 1 H, 3-H5), 6.54 (d, J = 8.4 Hz, 1 H, 1-H5), 5.06 (dd, J = 
8.5, 7.0 Hz, 1 H, 2-Phe-H), 4.94 (d, J = 4.5 Hz, 2 H, 1-H), 4.58 
(sept, J = 6.1 Hz, 1 H, 3-H), 3.95 (s, 2 H, 4-Gly-H), 3.29 – 3.25 (m, 
3 H, 2-Phe-H-NHCH2), 3.23 (dd, J = 7.5, 13.5 Hz, 1 H, 2-Phe-
H), 2.96 (t, J = 7.5, 2 H, 1-NHCH2CH2CH2, 1.95 – 1.86 (m, 2 H, 1-
NHCH2CH2 1.35 (d, J = 10.9 Hz, 3 H, 3-H), 1.34 (d, J = 10.6 Hz, 3 
H, 3-H); νmax/cm
-1
 (solid state) = 3355, 3033, 2979, 2928, 1594, 1509, 1491, 1256, 1211, 
1105, 697; ESI-HRMS found m/z 341.6654 [M+2H]
2+
, C38H45N5O7 requires 341.6654. 
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2-MeNH-Et-HN-[O-Bn-(3-HABA)]-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.45) 
Pale orange solid; isolated yield: 11 mg, 16%;
 δH (500 MHz, DMSO-
d6) 10.47 (s. broad, 1 H, 4-Gly-CO2H), 8.57 – 8.35 (m, 2 H, 4-Gly-NH, 
2-Phe-NH), 7.90 (d, J = 8.7 Hz, 1 H, 3-H6), 7.64 (s, 1 H, 3-H3), 7.50 
(d, J = 8.5 Hz, 2 H, 2-Phe-HAr2), 7.45 (s, 1 H, 1-H2), 7.43 – 7.37 (m, 
5 H, 1-HAr2, 1-HAr3, 1-HAr4), 7.34 (t, J = 8.5 Hz, 2 H, 2-Phe-HAr3), 
7.26 (m, 3 H, 1-H6, 3-H5, 3-NH), 7.17 (t, J = 8.5 Hz, 1 H, 2-Phe-
HAr4), 6.68 (d, J = 8.7 Hz, 1 H, 1-H5), 5.71 (s. broad, 1 H, 1-NH), 
5.19 (s, 2 H, 1-Hα), 4.88 – 4.77 (m, 2 H, 2-Phe-Hα), 4.71 (quin, J = 5.9 
Hz, 1 H, 3-Hα), 4.05 (d, J = 4.8 Hz, 2 H, 4-Gly-Hα), 3.47 (m, 2 H, 1-
NHCH2), 3.19 – 3.03 (m, 4 H, 2-Phe-Hβ, 1-NHCH2CH2), 2.61 (s, 3 H, 
1-NHCH2CH2NHCH3), 1.41 (dd, J = 8.5, 6.5 Hz, 6 H, 3-Hβ); δC (125 
MHz, DMSO-d6) 171.4, 171.2, 166.2, 163.9, 156.2, 144.6, 143.1, 
140.5, 138.1, 137.0, 131.9, 129.2, 128.4, 128.1, 127.8, 127.5, 126.3, 121.9, 121.2, 116.6, 111.3, 
110.5, 108.0, 104.7, 71.9, 69.6, 55.9, 47.1, 41.6, 38.8, 37.1, 32.8, 21.6; ESI-HRMS found m/z 
682.3253 [M+H]
+
, C38H44N5O7 requires 682.3235. 
 
3-Pyridyl-CH2-HN-[O-Bn-(3-HABA)]-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.46) 
Pale brown solid; isolated yield: 12mg, 17%;
 δH (500 MHz, MeOD) 
8.71 (s, 1 H, 1-NHPyr-H2), 8.49 (d, J = 8.0 Hz, 1 H, 1-NHPyr-H6), 
7.98 (dd, J = 8.0, 5.8 Hz, 1 H, 1-NHPyr-H4), 7.93 (d, J = 8.5 Hz, 1 H, 
3-H6), 7.53 (d, J = 1.7 Hz, 1 H, 3-H3), 7.48 – 7.40  (m, 3 H, 1-H6, 1-
H2, 1-NHPyr-H5), 7.40 - 7.27 (m, 7 H, 2-Phe-HAr2, 1-HAr2, 1-
HAr3, 1-HAr4), 7.25 - 7.22 (m, 2 H, 2-Phe-HAr3), 7.21 - 7.15 (m, 1 
H, 2-Phe-HAr4), 7.10 (dd, J = 8.6, 1.7 Hz, 1 H, 3-H5), 6.41 (d, J = 8.5 
Hz, 1 H, 1-H5), 5.12 (d, J = 4.6 Hz, 2 H, 1-H), 4.94 (dd, J = 8.2, 6.9 
Hz, 1 H, 2-Phe-H), 4.76 – 4.63 (m, 3 H, 2-H, 1-NHCH2), 4.16 (s, 2 
H, 4-Gly-H), 3.27 (dd, J = 13.9, 6.8 Hz, 1 H, 2-Phe-H), 3.18 (dd, J 
= 7.5, 13.5 Hz, 1 H, 2-Phe-H), 1.43 (d, J = 6.2 Hz, 3 H, 3-H), 1.40 
(d, J = 6.2 Hz, 3 H, 3-H); δC (125 MHz, MeOD) 173.0, 172.6, 169.9, 167.2, 158.3, 146.7, 
144.2, 143.7, 143.5, 143.4, 142.1, 138.3, 138.1, 133.1, 130.3, 129.5, 129.4, 129.1, 129.0, 128.7, 
127.8, 127.4, 123.0, 122.8, 117.9, 113.0, 111.7, 109.9, 106.5, 73.6, 71.7, 57.6, 44.6, 42.5, 38.9, 
22.1; νmax/cm
-1
 (solid state) = 3383, 2980, 2930, 1603, 1441, 1406, 1239, 1202, 1119, 700; ESI-
HRMS found m/z 716.3085 [M+H]
+
, C41H41N5O7 requires 716.3079. 
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2-Furyl-CH2-HN-[O-Bn-(3-HABA)]-Phe-[O-iPr-(2-HABA)]-Gly-CO2H (3.47) 
Brown solid; isolated yield: 14 mg, 20%;
 δH (500 MHz, MeOD) 7.93 
(d, J = 8.7 Hz, 1 H, 3-H6), 7.54 (d, J = 1.6 Hz, 1 H, 3-H3), 7.41 – 
7.26 (m, 10 H, 1-H6, 1-H2, 2-Phe-HAr2, 1-HAr2, 1-HAr3, 1-HAr4, 
1-NHFur-H5), 7.24 - 7.21 (m, 2 H, 2-Phe-HAr3), 7.20 - 7.15 (m, 1 
H, 2-Phe-HAr4), 7.08 (dd, J = 8.6, 1.7 Hz, 1 H, 3-H5), 6.62 (d, J = 
8.2 Hz, 1 H, 1-H5), 6.30 (dd, J = 3.1, 1.8 Hz, 1 H, 1-NHFur-H4), 
6.19 (d, J = 3.1 Hz, 1 H, 1-NHFur-H3), 5.03 (d, J = 2.7 Hz, 2 H, 1-
H), 4.95 (dd, J = 8.3, 6.9 Hz, 1 H, 2-Phe-H), 4.67 (sept, J = 6.1 
Hz, 1 H, 3-H), 4.36 (s, 2 H, 1-NHCH2), 4.15 (s, 2 H, 4-Gly-H), 
3.27 (dd, J = 6.9, 13.6 Hz, 1 H, 2-Phe-H), 3.17 (dd, J = 8.3, 13.6 
Hz, 1 H, 2-Phe-H),1.40 (d, J = 6.1 Hz, 3 H, 3-H), 1.37 (d, J = 6.1 
Hz, 3 H, 3-H); δC (125 MHz, MeOD) 173.1, 172.6, 170.1, 167.2, 158.3, 154.1, 146.6, 144.2, 
143.0, 142.9, 138.3, 138.2, 133.1, 130.3, 129.5, 129.4, 129.0, 128.8, 127.8, 123.0, 122.0, 117.9, 
113.0, 111.5, 111.2, 110.0, 107.8, 106.5, 73.6, 71.6, 57.6, 42.5, 41.0, 38.9, 22.1; νmax/cm
-1
 (solid 
state) = 3423, 3032, 2980, 2930, 1603, 1441, 1406, 1228, 699; ESI-HRMS found m/z 705.2920 
[M+H]
+
, C40H41N4O8 requires 705.2919. 
 
H2N-[O-Bn-(3-HABA)]-Phe-[O-iPr-(2-HABA)]-Lys-CO2H (3.48) 
 Brown solid; isolated yield: 41 mg, 59%;
 δH (500 MHz, MeOD) 7.94 
(d, J = 8.5 Hz, 1 H, 3-H6), 7.55 (d, J = 1.8 Hz, 1 H, 3-H3), 7.45 – 
7.44 (m, 2 H, 2-Phe-HAr2), 7.41 (d, J = 1.7 Hz, 1 H, 1-H2), 7.37 – 
7.33 (m, 2 H, 1-HAr2), 7.33 – 7.24 (m, 4 H, 1-HAr3, 1-HAr4, 1-H6), 
7.27 – 7.24 (m, 2 H, 2-Phe-HAr3), 7.21 – 7.18 (m, 1 H, 2-Phe-HAr4), 
7.12 (dd, J = 8.5, 1.8 Hz, 1 H, 3-H5), 6.76 (d, J = 8.3 Hz, 1 H, 1-H5), 
5.11 (d, J = 1.5 Hz, 2 H, 1-H), 4.90 (dd, J = 8.1, 7.1 Hz, 1 H, 2-Phe-
H), 4.80 – 4.74 (m, 1 H, 3-H), 4.69 (dd, J=6.8, 5.6 Hz, 1 H, 4-Lys-
H), 3.29 – 3.23 (dd, 2 H, 2-Phe-H), 2.92 (t, J = 7.0 Hz, 2 H, 4-Lys-
H, 2.11 – 1.81 (m, 2 H, 4-Lys-H, 1.79 – 1.64 (m, 2 H, 4-Lys-
H1.58 – 1.48 (m, 2 H, 4-Lys-H 1.47 (d, J = 6.2 Hz, 3 H, 3-H) 1.40 (d, J = 6.0 Hz, 3 H, 3-
H); δC (125 MHz, MeOD) 174.7, 173.0, 170.1, 166.8, 158.2, 147.1, 144.3, 141.8, 138.3, 
133.1, 130.3, 129.6, 129.5, 129.4, 129.0, 128.7, 127.8, 123.9, 122.7, 117.8, 115.1, 113.0, 112.4, 
106.3, 73.5, 71.5, 57.7, 53.5, 40.4, 38.9, 33.2, 28.1, 23.3, 22.3, 22.0; νmax/cm
-1
 (solid state) = 
3032, 2932, 1670, 1626, 1600, 1495, 1198, 1182, 1132, 698, 681; ESI-HRMS found m/z 
696.3410 [M+H]
+
, C39H46N5O7 requires 696.3392. 
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6.4.4. Fluorescence anisotropy assays  
 
WT-p53(15-31) transactivation domain peptide and its fluorescein-labelled analogue p53 (15-
31) Flu were purchased from Peptide Protein Research Ltd and used without further 
purification. WT-NOXA B (68-87) and its fluorescein-labelled analogue FITC-NOXA B (68-
87) were synthesised and purified by Dr P. Prabhakaran and Dr. D. J. Yeo. Molecular cloning 
and expression of hDM2(17-126) L33E (no tag) and Mcl-1 (172-327) proteins were 
performed by Dr A. Bartlett and Dr J. Miles. 
 
The Fluorescence Anisotropy Assays were run in 384 well plates (Greiner Bio-one) in triplicate 
and were scanned using a Perkin Elmer EnVisionTM 2103 MultiLabel plate reader. Fluorescein 
labeled peptides used an excitation and emission wavelength of 480 nm (30 nm bandwidth) and 
535 nm (40 nm bandwidth) respectively. All the assays were performed in phosphate buffer (40 
mM phosphate buffer at pH 7.50, containing 200 mM NaCl and 0.02 mg mL
-1
 bovine serum 
albumin (BSA). 
 
Fluorescence Anisotropy Competition Assay 
 
For the fluorescence anisotropy competition assays, compound stock solutions (400 μM in 
90:10 (v/v) assay buffer:DMSO) were used to carry out the serial dilutions across the plate 
(starting point: 100 μM; 24-points, 3/4 serial dilution). The fluorescently labeled peptide and 
protein were added to each well to give a final concentration of 50 nM and 150 nM, 
respectively. The assays consist of four rows (three containing the compound of interest and one 
control row). For control wells, the tracer peptide was replaced with an identical volume of 
assay buffer. The additions to the wells go as follows: 
 
1) 20 L of assay buffer 
2) 80 L of compound stock solution were added to the first well of each row, mixed and 
80 L transferred to the next well to complete the serial dilution. 
3) 20 L of fluorescently labeled peptide solution to the wells with compound and 20 L 
of assay buffer to the control wells. 
4) 20 L of protein solution 
 
The plates were incubated for 2 h at rt and protected from light.  
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Processing of the fluorescent anisotropy data 
 
The data obtained for both the P (perpendicular intensity) and S (parallel (same) intensity) 
channels was corrected by subtracting the corresponding control wells. The resulting values 
were used to calculate the intensity and anisotropy for each well using the following equations: 
𝐼 = 2𝑃𝐺 + 𝑆 
𝑟 =  
𝑆 − 𝑃𝐺
𝐼
 
Where: r = anisotropy, I = total intensity, P = perpendicular intensity, S = parallel intensity, G = 
1 (instrumental factor).  
 
The average anisotropy (across three replicates) and the standard deviation for these values were 
calculated and fit to a logisitic model (for calculation of IC50 values) using Origin Pro 9.0: 
 
𝑦 =  𝑟𝑚𝑖𝑛 +  
𝑟𝑚𝑎𝑥 −  𝑟𝑚𝑖𝑛
1 +  10(𝑥−𝑙𝑜𝑔𝑥0)
 
 
Where for the logisitic model; y = r = anisotropy, x0 = mid-point of the curve between the rmax 
and rmin plateaux.  
 
 
6.5. Design, synthesis and evaluation of inhibitors for the 
Asf1/H3 PPI (Chapter 4) 
6.5.1. General procedures for 3-O-alkylated monomer synthesis
125
 
 
Procedure A: RBr Alkylation 
To a stirred solution of methyl-3-hydroxy-4-nitrobenzoate 2.3 (1 equiv) and potassium 
carbonate (3 equiv) in DMF (20 mL / g), was added RBr (1.2 equiv) and the resulting mixture 
stirred at 50 ºC overnight under a nitrogen atmosphere. Further portions of the RBr were added 
when the reaction was shown incomplete by TLC. The resultant mixture was allowed to cool to 
rt, poured into water (40 mL / g) and extracted with ethyl acetate. The combined organic 
fractions were thoroughly washed with water and further washed with brine, dried with MgSO4 
and evaporated to dryness.  
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Procedure B: Mitsunobu  
A stirred solution containing methyl-3-hydroxy-4-nitrobenzoate 2.3 (1 equiv), ROH (1.1 equiv) 
and triphenylphosphine (1.5 equiv) in anhydrous tetrahydrofuran (30 mL / g) was cooled to 0 
°C. Diisopropyl azodicarboxylate (1.5 equiv) was added and the resulting solution allowed to 
warm to rt and left stirring overnight under a nitrogen atmosphere. Organic solvents were 
removed under reduced pressure and the product was purified via column chromatography.  
 
Procedure C: Tin Reduction  
To a stirred solution containing either i) nitro/ester or ii) nitro/acid (1 equiv) in ethyl acetate (20 
mL / g), tin(II) chloride dihydrate (6 equiv) was added and the resulting mixture stirred at 50 ºC 
overnight, under a nitrogen atmosphere. On completion, the reaction mixture was allowed to 
cool to rt and poured over ice. The pH was made slightly basic (~pH 8) by addition of a 1 M 
NaOH solution and the resulting basic mixture was filtered under vacuum to remove 
SnO·H2O(s) in the suspension. The aqueous mixture was extracted with ethyl acetate and the 
combined organic fractions washed thoroughly with brine, dried with MgSO4 and evaporated to 
dryness. 
 
Procedure D: Hydrogenation  
A solution containing either i) nitro/ester or ii) nitro/acid (1 equiv) in methanol (20 mL / g) and 
palladium on carbon (10 wt %) was evacuated and flushed with nitrogen (3 times) and left 
under vacuum. Hydrogen was drawn into the flask and the reaction left stirring at rt overnight. 
On completion, the reaction mixture was filtered through a celite pad and evaporated to dryness.  
 
Procedure E: NaOH Saponification  
To a solution containing either i) amine/ester or ii) nitro/ester (1 equiv) in a 1:1 mixture of 
methanol: tetrahydrofuran (25 mL / g), a 10 % sodium hydroxide solution (5 mL / g) was added 
and the resulting mixture was allowed to stir at rt overnight. Further portions of the hydroxide 
solution were added when the reaction was shown incomplete by TLC. The organic solvents 
were removed under reduced pressure, the remaining solution was poured into water and 
extracted with dichloromethane (unreacted starting material). The aqueous layer was acidified 
via the addition of hydrochloric acid (conc) to pH 4 and the resulting precipitate was extracted 
into dichloromethane. The combined organic extracts were washed with water and brine, dried 
with MgSO4 and evaporated to dryness.  
 
 
  
140 
Procedure F: LiOH Saponification  
To a solution containing either i) amine/ester or ii) nitro/ester (1 equiv) in a 1:1 mixture of 
tetrahydrofuran / water (25 mL / g), a lithium hydroxide (1 equiv) solution in water was added 
and the resulting mixture was stirred at rt overnight. The organic solvent was removed under 
reduced pressure and an additional amount of water was added. The resulting solution was 
extracted with dichloromethane (unreacted starting material) and the aqueous layer acidified via 
the addition of 1 M potassium bisulfate solution to pH 4. The resulting precipitate was extracted 
into dichloromethane and the combined organic extracts were washed with water and brine, 
dried with MgSO4 and evaporated to dryness.  
 
Procedure G: Fmoc protection  
A solution of amine/acid (1 equiv) in anhydrous tetrahydrofuran (20 mL / g) was held at a reflux 
under a nitrogen atmosphere. A solution of fluorenylmethyloxycarbonyl chloride (1.5 equiv) in 
anhydrous tetrahydrofuran (10 mL / g) was then added dropwise and the resulting solution was 
stirred at reflux overnight. The reaction mixture was evaporated to dryness, the resulting solid 
was crystallized from a chloroform/hexane mixture and the precipitate collected via filtration. 
 
Procedure H: Fmoc protection  
A solution of amine/acid (1 equiv) and sodium bicarbonate (3 equiv) in anhydrous 
tetrahydrofuran (20 mL / g) was held at a reflux under a nitrogen atmosphere. A solution of 
fluorenylmethyloxycarbonyl chloride (1.5 equiv) in anhydrous tetrahydrofuran (10 mL / g) was 
then added dropwise and the resulting solution was stirred at reflux overnight. Sodium 
bicarbonate was removed via hot filtration and the reaction mixture was evaporated to dryness. 
The resulting solid was crystallized from a chloroform/hexane mixture and the precipitate 
collected via filtration. 
 
6.5.2. General procedures for Solid Phases Synthesis of the 3-O-
alkylated scaffold
125
  
 
General Points for Solid Phase Synthesis: Fmoc-Gly-Wang resin (0.79 mmol/g, 100-200 mesh; 
carrier: polystyrene, crosslinked with 1% DVB), was purchased from Merck. All solvents used 
were HPLC grade. Anhydrous N-methyl-2-pyrrolidone was purchased from Acros Organics. 1-
Chloro-N, N, 2-trimethyl-1-propenylamine (Ghosez’s reagent) was purchased from Sigma-
Aldrich and stored in a schlenk tube under a nitrogen atmosphere in the freezer as a 20% 
solution in chloroform. Oligomer formation was carried out on a CEM™ Liberty automated 
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microwave peptide synthesiser. The volume of the reaction mixture in the reaction vessel was 
2.5 mL. 
 
Procedure I:  Acyl Chloride Formation 
To a stirred solution of an Fmoc protected building block in anhydrous dichloromethane (20 mL 
/ g), thionyl chloride (10 equiv) was added and the resulting mixture refluxed overnight. The 
organic solvent and thionyl chloride were removed under N2 (g) to yield the corresponding acyl 
chloride monomer, which was stored under an inert atmosphere for a maximum of 12 h before 
being re-dissolved in anhydrous NMP (2.5 mL) and added to the resin for microwave treatment. 
 
Procedure J:  Acyl Chloride Preactivation 
To a solution containing Fmoc protected monomers (1 equiv) functionalised with acid sensitive 
protecting groups in anhydrous NMP (2.5 mL), 0.9 equiv of Ghosez’s reagent was added. The 
resulting mixture was stirred under an inert atmosphere for 3 h at 50 ºC before the addition to 
the resin and microwave treatment.  
 
Procedure K: Oligomer Formation 
Fmoc-glycine pre-loaded Wang resin (127 mg, 0.1 mmol, 1 equiv) was loaded onto a Liberty 
CEM™ microwave peptide synthesiser after being swelled for a total of 30 min in 
dichloromethane. A series of washes (3  NMP), deprotection (2  20 % Piperidine/NMP, total 
of 3.5 min at 75 °C) and further washes (5  NMP) prepared the resin for coupling.  
 
Single coupling: Fmoc protected acyl chloride (0.4 mmol, 4 equiv) obtained by pre-activation or 
prepared separately was dissolved in NMP (2.5 mL), delivered to the reaction vessel and 
submitted to microwave irradiation at 50 °C for 30 min.  
 
Double coupling: Fmoc protected acyl chloride (0.2 mmol, 2 equiv) obtained by pre-activation 
or prepared separately was dissolved in NMP (2.5 mL), delivered to the reaction vessel and 
submitted to microwave irradiation at 50 °C for 30 min. A second solution containing Fmoc 
protected acyl chloride (0.2 mmol, 2 equiv) (preactivated or isolated) in NMP (2.5 mL) was 
delivered to the reaction vessel and submitted to microwave power at 50 °C for 30 min.  
A coupling cycle finished with a final series of washes of the reaction vessel (3  NMP). After 
the required number of cycles, a final Fmoc deprotection was carried out and then the resin was 
removed from the synthesiser and transferred to a reservoir for manual cleavage. 
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Procedure L:  Cleavage  
The resin was washed with dichloromethane (2 × 3 mL × 2 min) and cleaved with a 3 mL 
cleavage cocktail (2  30 min) consisting of TFA:dichloromethane:triisopropylsilane 
(49.5:49.5:1). If no protecting groups were present, a simple 1:1 TFA:dichloromethane mixture 
was sufficient without the need for a scavenger. Once cleavage was complete, the cleavage 
solution was isolated and evaporated under N2 (g). 
 
Procedure M: Mass – Directed HPLC Purification 
The resulting crude mixture was dissolved in either DMSO or methanol at an approximate 
concentration of 20 mg mL
-1
 and purified using reversed phase mass directed HPLC [Agilent 
XBridge C18 preparative column; 50-95% gradient of MeCN to water (plus 0.1% formic acid 
v/v in both solvents) and flow rate of 20 mL min
-1
 during 8 min]. The resulting fractions were 
concentrated by centrifugal evaporation (Genevac). 
 
6.5.3. 3-O-Alkylated monomer syntheses and characterization 
 
Only the characterization of the novel monomers has been included in the experimental section; 
the monomers which have been routinely synthesised and reported previously in the group have 
not been included.
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 Methyl 3-sec-butoxy-4-nitrobenzoate (3.8) 
Procedure B; methyl 3-hydroxy-4-nitrobenzoate 2.3 (2.42 g, 12.3 mmol), sec-
butanol (1.0 g, 13.5 mmol),  triphenylphosphine (4.8 g, 18.4 mmol) in 
anhydrous tetrahydrofuran (80 mL) and diisopropyl azodicarboxylate (3.61 
mL, 18.4 mmol). The reaction mixture was purified by column 
chromatography (Stationary Phase: Silica; Mobile Phase: ethyl acetate/hexane, 1:1) to afford 
the desired product 3.8  (3.10 g, 12.2 mmol, quant.) as a yellow oil; H (500 MHz, CDCl3) 7.76 
(d, J = 8.2 Hz, 1 H, H5), 7.73 (d, J = 1.0 Hz, 1 H, H2), 7.66 (dd, J = 8.2, 1.0 Hz, 1 H, H6), 4.52 
– 4.60 (m, 1 H, Hα), 3.97 (s, 3 H, CO2CH3), 1.85 – 1.76 (m, 1 H, Hβ), 1.67 – 1.76 (m, 1 H, Hβ), 
1.37 (d, J = 6.0 Hz, 3 H, CHα(CH3)), 1.01 (t, J = 7.4 Hz, 3 H, Hγ); δC (125 MHz, CDCl3) 165.4, 
151.1, 143.7, 134.4, 125.1, 120.9, 116.7, 77.8, 52.8, 29.0, 19.0, 9.5; νmax/cm
-1
 (solid state) = 
2974, 2937, 2880, 1726, 1605, 1528, 1290, 1235, 744; ESI-HRMS found m/z 276.0843 
[M+Na]
+
, C12H15NNaO5 requires 276.0842. 
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Methyl 4-amino-3-sec-butoxybenzoate  (3.13) 
Procedure D; methyl 3-sec-butoxy-4-nitrobenzoate 3.8 (3.10 g, 12.2 mmol) in 
a 1:1 mixture of tetrahydrofuran/methanol (40 mL). Work up yielded the title 
compound 3.13 (2.72 g, 12.2 mmol, quant.) as a yellow oil; H (500 MHz, 
CDCl3) 7.52 (dd, J = 8.2, 1.5 Hz, 1 H, H6), 7.46 (d, J = 1.5 Hz, 1 H, H2), 6.67 
(d, J = 8.2 Hz, 1 H, H5), 4.39 – 4.45 (m, 1 H, Hα), 3.86 (s, 3 H, CO2CH3), 1.73 – 1.83 (m, 1 H, 
Hβ), 1.62 – 1.72 (m, 1 H, Hβ), 1.32 (d, J = 6.2 Hz, 3 H, CHα(CH3)), 1.00 (t, J = 7.4 Hz, 3 H, 
Hγ); δC (125 MHz, CDCl3) 167.4, 144.4, 142.1, 123.8, 119.5, 113.9, 113.4, 75.8, 51.6, 29.2, 
19.3, 9.8; νmax/cm
-1
 (solid state) = 3486, 3369, 2971, 2878, 1698, 1614, 1518, 1440, 1290, 1258, 
1210, 728; ESI-HRMS found m/z 224.1285 [M+H]
+
, C12H18NO3 requires 224.1281. 
 
 4-Amino-3-sec-butoxybenzoic acid (3.18) 
Procedure E; methyl 4-amino-3-sec-butoxybenzoate 3.13 (2.72 g, 12.2 mmol) 
in a 1:1 mixture of tetrahydrofuran/methanol (40 mL), 10% aqueous sodium 
hydroxide (20 mL). Work up yielded the title compound 3.18 (2.34 g, 11.2 
mmol, 92%) as a pale purple solid; H (500 MHz, CDCl3) 7.61 (dd, J = 8.2, 
1.5 Hz, 1 H, H6), 7.51 (d, J = 1.5 Hz, 1 H, H2), 6.70 (d, J = 8.2 Hz, 1 H, H5), 4.43 (app sxt, J = 
6.0 Hz, 1 H, Hα), 1.75 – 1.85 (m, 1 H, Hβ), 1.62 – 1.74 (m, 1 H, Hβ), 1.34 (d, J = 6.0 Hz, 3 H, 
CHα(CH3)), 1.01 (t, J = 7.4 Hz, 3 H, Hγ); δC (125 MHz, CDCl3) 172.0, 144.3, 143.0, 124.8, 
118.3, 114.2, 113.3, 75.8, 29.2, 19.3, 9.8; νmax/cm
-1
 (solid state) = 3494, 3387, 2971, 2936, 2879, 
1672, 1612, 1445, 1293, 1265, 1223, 769; ESI-HRMS found m/z 210.1122 [M+H]
+
, C11H16NO3 
requires 210.1125. 
 
 4-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-3-sec-butoxybenzoic acid (3.24) 
Procedure G; 4-amino-3-sec-butoxybenzoic acid 3.18 (1.0 g, 4.78 mmol) in 
tetrahydrofuran (40 mL) and fluorenylmethyloxycarbonyl chloride (1.86 g, 
7.17 mmol) in tetrahydrofuran (20 mL). Work up yielded the title compound 
3.24 (1.90 g, 4.40 mmol, 92%) as off-white solid; H (500 MHz, CDCl3) 8.17 
(s, broad, 1 H, NH), 7.80 (d, J = 7.5 Hz, 2 H, FHAr5), 7.73 (d, J = 8.0 Hz, 1 H, H5), 7.64 (d, J = 
7.5 Hz, 2 H, FHAr2), 7.59 (s, 1 H, H2), 7.56 (s, broad, 1 H, H6), 7.44 (t, J = 7.5 Hz, 2 H, 
FHAr4), 7.34 (t, J = 7.5 Hz, 2 H, FHAr3), 4.63 – 4.45 (m, 3 H, Hα, FH), 4.35 (t, J = 6.5 Hz, 1 
H, FH), 1.91 – 1.80 (m, 1 H, Hβ), 1.80 – 1.70 (m, 1 H, Hβ), 1.39 (d, J = 6.2 Hz, 3 H, 
CHα(CH3)), 1.05 (t, J = 7.4 Hz, 3 H, Hγ); δC (125 MHz, CDCl3) 169.9, 156.7, 145.5, 143.7, 
141.4, 133.6, 127.9, 127.2, 125.0, 124.1, 123.1, 120.1, 117.4, 113.7, 76.9, 67.5, 47.1, 29.1, 19.3, 
9.9; νmax/cm
-1
 (solid state) = 3431, 2958, 2928, 2874, 1743, 1687, 1594, 1534, 1188, 1026, 738; 
ESI-HRMS found m/z 432.1807 [M+H]
+
, C26H26NO5 requires 432.1805. 
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6.5.4. 3-O-Alkylated oligomers characterization 
 
NH2-[O-CH2-CH2-CH2-NH2-(3-HABA)]-[O-iBu-(3-HABA)]-[O-sBu-(3-HABA)]-Gly-CO2H 
(4.5) 
Brown solid; isolated yield: 63 mg, 97%; H (500 MHz, MeOD) 8.34 (d, 
J = 8.1 Hz, 1 H, 2-H5), 8.30 (d, J = 8.3 Hz, 1 H, 3-H5), 7.55 (d, J = 1.7 
Hz, 1 H, 2-H2), 7.49 – 7.46 (m, 3 H, 3-H2, 3-H6, 2-H6), 7.42 (d, J = 1.9 
Hz, 1 H, 1-H2), 7.37 (dd, J = 8.1, 1.9 Hz, 2 H, 1-H6), 6.91 (d, J = 8.1 Hz, 
1 H, 1-H5), 4.61 – 4.55 (m, 1 H, 2-Hα), 4.21 (t, J = 5.8 Hz, 2 H, 1-Hα), 
4.10 (s, 2 H, 4-Hα), 3.95 (d, J = 6.6 Hz, 2 H, 3-Hα), 3.23 (t, J = 7.4 Hz, 2 
H, 1-Hγ), 2.26 – 2.16 (m, 4 H, 1-Hβ, 3-Hβ), 1.88 – 1.84 (m, 1 H, 2-Hβ), 
1.84 – 1.74 (m, 1 H, 2-Hβ), 1.41 (d, J = 6.0 Hz, 3 H, 2-CHα(CH3)), 1.12 
(d, J = 6.6 Hz, 6 H, 3-Hγ), 1.06 (t, J = 7.5 Hz, 3 H, 2-Hγ); δC (125 MHz, 
MeOD) 173.2, 169.6, 167.0, 166.5, 161.0, 160.7, 150.1, 148.9, 147.8, 
133.4, 131.8, 131.1, 130.8, 125.7, 122.0, 121.3, 121.0, 120.6, 116.3, 
113.1, 112.0, 111.3, 77.9, 76.2, 66.6, 42.3, 38.4, 30.2, 29.5, 28.3, 19.6, 19.5, 9.9; νmax/cm
-1
 (solid 
state) = 3356, 2964, 2936, 1670, 1596, 1506, 1193, 1123, 1024, 721; ESI-HRMS found m/z 
650.3198 [M+H]
+
, C34H44N5O8 requires 650.3184. 
 
NH2-[O-CH2-CH2-CH2-NH2-(3-HABA)]-[O-sBu-(3-HABA)]-[O-iBu-(3-HABA)]-Gly-CO2H 
(4.6) 
Brown solid; isolated yield: 61 mg, 94%; H (500 MHz, MeOD) 8.37 (d, 
J = 8.3 Hz, 1 H, 2-H5), 8.26 (d, J = 8.1 Hz, 1 H, 3-H5), 7.57 (d, J = 1.9 
Hz, 1 H, 2-H2), 7.53 (s, 1 H, 3-H2), 7.52 – 7.47 (m, 2 H, 3-H6, 2-H6), 
7.44 (d, J = 1.9 Hz, 1 H, 1-H2), 7.35 (dd, J = 8.1, 1.9 Hz, 2 H, 1-H6), 
6.93 (d, J = 8.1 Hz, 1 H, 1-H5), 4.64 – 4.56 (m, 1 H, 2-Hα), 4.22 (t, J = 
5.8 Hz, 2 H, 1-Hα), 4.10 (s, 2 H, 4-Hα), 3.94 (d, J = 6.6 Hz, 2 H, 3-Hα), 
3.23 (t, J = 7.3 Hz, 2 H, 1-Hγ), 2.25 – 2.17 (m, 4 H, 1-Hβ, 3-Hβ), 1.88 – 
1.84 (m, 1 H, 2-Hβ), 1.84 – 1.74 (m, 1 H, 2-Hβ), 1.41 (d, J = 6.0 Hz, 3 
H, 2-CHα(CH3)), 1.11 (d, J = 6.8 Hz, 6 H, 3-Hγ), 1.06 (t, J = 7.5 Hz, 3 H, 
2-Hγ); δC (125 MHz, MeOD) 173.2, 169.6, 167.0, 166.8, 161.0, 160.7, 
150.3, 148.9, 147.9, 133.4, 131.8, 131.1, 131.0, 125.8, 121.8, 121.2, 
121.0, 120.6, 116.4, 113.0, 112.0, 111.6, 78.1, 76.2, 66.6, 42.3, 38.4, 30.2, 29.5, 28.2, 19.6, 
19.5, 9.9; νmax/cm
-1
 (solid state) = 3421, 2964, 1595, 1507, 1127, 1026, 747; ESI-HRMS found 
m/z 650.3197 [M+H]
+
, C34H44N5O8 requires 650.3184. 
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NH2-[O-sBu-(3-HABA)]-[O-iBu-(3-HABA)]-[O-CH2-CH2-NH2-(3-HABA)]-Gly-CO2H (4.7) 
Beige solid; isolated yield: 8 mg, 13%; H (500 MHz, DMSO-d6) 8.99 
(s, 1 H, 2-NH), 8.44 (s, broad, 1 H, 4-NH), 8.25 (d, J = 8.5 Hz, 1 H, 2-
H5), 8.11 (d, J = 8.3 Hz, 1 H, 3-H5), 7.66 – 7.61 (m, 2 H, 2-H2, 2-H6), 
7.59 (s, 1 H, 3-H2), 7.53 (d, J = 8.1 Hz, 1 H, 3-H6), 7.39 – 7.29 (m, 2 
H, 1-H2, 1-H6), 6.72 (d, J = 7.9 Hz, 1 H, 1-H5), 5.42 (s, broad, 1 H, 1-
NH), 4.42 – 4.37 (m, 1 H, 1-Hα), 4.30 (s, 2 H, 4-Hα), 4.21 (t, J = 5.8 
Hz, 2 H, 3-Hα), 3.97 (d, J = 6.0 Hz, 2 H, 2-Hα), 3.74 (s, 2 H, 3-NH), 
3.21 (s, 2 H, 3-Hβ), 2.21 – 2.12 (m, 1 H, 2-Hβ), 1.77 – 1.70 (m, 1 H, 1-
Hβ), 1.68 – 1.60 (m, 1 H, 1-Hβ), 1.27 (d, J = 6.0 Hz, 3 H, 1-
CHα(CH3)), 1.06 (d, J = 6.6 Hz, 6 H, 2-Hγ), 0.96 (t, J = 7.5 Hz, 3 H, 1-
Hγ); δC (125 MHz, DMSO-d6) 172.0, 165.0, 164.8, 164.5, 148.5, 148.4, 
143.4, 143.3, 131.2, 130.6, 130.0, 129.6, 121.9, 121.3, 120.9, 120.4, 120.3, 120.1, 112.7, 112.2, 
111.1, 110.9, 75.3, 74.6, 66.9, 42.8, 35.6, 28.6, 27.8, 19.1, 19.1, 9.6; νmax/cm
-1
 (solid state) = 
3351, 2963, 2931, 1575, 1508, 1382, 1252, 1025, 753; ESI-HRMS found m/z 636.3043 [M+H]
+
, 
C33H42N5O8 requires 636.3028. 
 
NH2-[O-sBu-(3-HABA)]-[O-sBu-(3-HABA)]-[O-sBu-(3-HABA)]-Gly-CO2H (4.8) 
Beige solid; isolated yield: 48 mg, 74%; H (500 MHz, CDCl3) 8.85 (s, 1 
H, 3-NH), 8.75 (s, 1 H, 2-NH), 8.68 (d, J = 8.3 Hz, 1 H, 2-H5), 8.59 (d, J 
= 8.1 Hz, 1 H, 3-H5), 7.58 (d, J = 1.0 Hz, 1 H, 2-H2), 7.53 (s, 1 H, 3-H2), 
7.44 (d, J = 1.8 Hz, 1 H, 1-H2), 7. 42 – 7.37 (m, 2 H, 3-H6, 2-H6), 7.27 
(dd, J = 8.1, 1.8 Hz, 2 H, 1-H6), 7.04 (s, broad, 1 H, 4-NH), 6.75 (d, J = 
8.1 Hz, 1 H, 1-H5), 4.61 – 4.54 (m, 2 H, 3-Hα, 2-Hα), 4.49 – 4.43 (m, 1 
H, 1-Hα), 4.25 (s, 2 H, 4-Hα), 1.89 – 1.65 (m, 6 H, 1-Hβ, 2-Hβ, 3-Hβ), 
1.43 – 1.33 (m, 9 H, 1-CHα(CH3), 2-CHα(CH3), 3-CHα(CH3)), 1.08 – 
0.97 (m, 9 H, 1-Hγ, 2-Hγ, 3-Hγ); δC (125 MHz, CDCl3) 167.7, 165.3, 
164.8, 146.6, 146.6, 145.1, 141.5, 132.8, 132.3, 129.1, 128.2, 126.0, 
124.6, 124.1, 119.9, 119.5, 119.0, 118.7, 113.7, 112.3, 111.9, 111.8, 76.7, 
76.7, 76.0, 42.1, 29.3, 29.2, 29.2, 19.4, 19.3, 19.3, 9.8, 9.7, 9.6; νmax/cm
-1
 (solid state) = 3441, 
3310, 3181, 2967, 2930, 1750, 1595, 1505, 1323, 1255, 1033, 746; ESI-HRMS found m/z 
649.3245 [M+H]
+
, C35H45N4O8 requires 649.3232. 
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NH2-[O-sBu-(3-HABA)]-[O-sBu-(3-HABA)]-Gly-CO2H (4.9) 
Dark yellow solid; isolated yield: 20 mg (isolated as a side product in the 
synthesis of the corresponding trimer); H (500 MHz, MeOD) 8.37 (d, J = 
8.4 Hz, 1 H, 2-H5), 7.57 (d, J = 1.9 Hz, 1 H, 2-H2), 7.51 (dd, J = 8.4, 1.9 
Hz, 1 H, 2-H6), 7.38 (d, J = 1.9 Hz, 1 H, 1-H2), 7.31 (dd, J = 8.2, 1.9 Hz, 1 
H, 1-H6), 6.79 (d, J = 8.2 Hz, 1 H, 1-H5), 4.63 – 4.57 (m, 1 H, 2-Hα), 4.48 
– 4.41 (m, 1 H, 1-Hα), 4.09 (s, 2 H, 3-Hα), 1.90 – 1.67 (m, 4 H, 1-Hβ, 2-
Hβ), 1.39 (dd, J = 6.1, 0.9 Hz, 3 H, 2-CHα(CH3)), 1.35 (dd, J = 6.0, 1.8 Hz, 
3 H, 1-CHα(CH3)), 1.07 – 1.02 (m, 6 H, 1-Hγ, 2-Hγ); δC (125 MHz, MeOD) 
173.3, 169.7, 167.6, 148.5, 146.0, 144.5, 133.3, 130.3, 123.3, 121.8, 121.0, 120.8, 114.6, 113.2, 
113.2, 78.0, 77.2, 42.4, 30.2, 30.2, 19.6, 19.5, 10.1, 9.9; νmax/cm
-1
 (solid state) = 3347, 2970, 
2930, 2878, 612, 1503, 1476, 1250, 1202, 756; ESI-HRMS found m/z 458.2298 [M+H]
+
, 
C24H32N3O6 requires 458.2286. 
 
NH2-[O-sBu-(3-HABA)]-[O-iBu-(3-HABA)]-Gly-CO2H (4.10) 
Dark yellow solid; isolated yield: 28 mg, 41%; H (500 MHz, MeOD) 8.32 
(d, J = 8.3 Hz, 1 H, 2-H5), 7.55 (d, J = 1.9 Hz, 1 H, 2-H2), 7.51 (dd, J = 8.3, 
1.9 Hz, 1 H, 2-H6), 7.39 (d, J = 1.9 Hz, 1 H, 1-H2), 7.34 (dd, J = 8.2, 1.9 
Hz, 1 H, 1-H6), 6.78 (d, J = 8.2 Hz, 1 H, 1-H5), 4.48 – 4.41 (m, 1 H, 1-Hα), 
4.09 (s, 2 H, 3-Hα), 3.96 (d, J = 6.4 Hz, 2 H, 2-Hα), 1.24 – 1.16 (m, 1 H, 2-
Hβ), 1.85 – 1.77 (m, 1 H, 1-Hβ), 1.74 – 1.68 (m, 1 H, 1-Hβ), 1.34 (d, J = 
6.1 Hz, 3 H, 2-CHα(CH3)), 1.11 (d, J = 6.7 Hz, 6 H, 2-Hγ), 1.03 (t, J = 7.5 
Hz, 3 H, 1-Hγ,); δC (125 MHz, MeOD) 173.2, 169.8, 167.6, 149.8, 146.0, 
144.5, 132.3, 130.4, 123.3, 121.9, 121.0, 121.0, 114.6, 113.2, 111.5, 77.2, 76.2, 42.3, 30.2, 29.5, 
19.6, 19.5, 10.0; νmax/cm
-1
 (solid state) = 3354, 2960, 2928, 2873, 1611, 1503, 1482, 1249, 1205, 
756; ESI-HRMS found m/z 458.2294 [M+H]
+
, C24H32N3O6 requires 458.2286. 
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6.5.5. General methods for manual Solid Phase Peptide Synthesis 
 
Method A:  Resin Swelling 
Rink amide MBHA resin (0.1 mmol) was used for all syntheses unless stated otherwise. The 
resin was placed in a vaculate reservoir, dichloromethane (3 mL) was added and the resin was 
agitated on a blood-spinner for 30 min to allow its swelling. 
 
Method B:  Fmoc Deprotection 
N-terminal Fmoc protecting groups were removed by the addition of 20% piperidine in DMF (5 
× 2 mL × 2 min), followed by washing of the resin with DMF (5 × 2 mL × 2 min).  
 
Method C:  Kaiser Test
207
 
The Kaiser Test was employed to determine the successful coupling of most of the amino acid 
residues. A small amount of resin beads was rinsed with dichloromethane and placed in a vial, 
followed by the addition of two drops of each of the following three solutions in the respective 
order:  
 
1) Ninhydrin (5% w/v) in ethanol;  
2) Phenol (80% w/v) in ethanol;  
3) 1 mM KCN(aq.) in pyridine (2% v/v).  
 
The solution was then heated to ca. 100 °C for 1 min. Yellow solution and no change in the 
colour of the beads indicate successful couplings, whereas blue solution and dark colour of the 
beads indicate presence of primary amines as a result of incomplete couplings. In the second 
case, a double coupling was necessary. This colour test can be used to identify free primary 
amines, however is inconclusive for Asp, Ser, Pro and Asn residues.  
 
Method D: Chloranil Test
214
  
The chloranil test was also employed to determine successful couplings of some amino acid 
residues. A small amount of beads was rinsed in dichloromethane and placed in a vial, followed 
by the addition of two drops of each of the following solutions in the respective order:  
1) Acetaldehyde (2% v/v) in DMF;  
2) p-Chloranil (2% w/v) in DMF.  
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The solution was left at rt for 5 min. No change in colour of the beads showed successful 
couplings, whereas the change of bead colour to pale green/bright blue indicate presence of 
primary amines as a result of incomplete couplings. In the second case, a double coupling was 
necessary. This test is a reliable method to detect secondary amines; therefore, it was 
particularly useful for Pro residues. 
 
Method E:  Chain Elongation 
The coupling of the desired amino acids (5 equiv) was performed with HCTU or HATU (5 
equiv) and DIPEA (5 equiv) dissolved in DMF (2 mL) and added to the resin, followed by 
agitation for 1 h (2 h for problematic couplings). For double couplings, this step was repeated. 
After draining the reagents, the resin was washed with DMF (3 × 2 mL × 2 min) and the success 
of coupling determined by a negative colour test (Method C or D). Once a coupling was 
confirmed successful, the N-terminal Fmoc was deprotected (Method B) and a subsequent 
coupling or N-terminal acetylation (Method F) was performed. 
 
Method F:  N-terminal Acetylation 
After complete peptide chain elongation, N-terminal acetylation was performed with acetic 
anhydride (10 equiv) and DIPEA (10 equiv) dissolved in DMF (2 mL), which was transferred to 
the resin for 2 h. Later the resin was drained, washed with DMF (3 × 2 mL × 2 min) and 
successful capping determined by a negative colour test (Method C or D). 
 
Method G:  On-Resin Olefin Metathesis  
After N-terminal acetylation, on-resin olefin metathesis was performed using a 10 mM solution 
of Grubbs 1
st
 Generation Catalyst in degassed dichloroethanol (2 mL), which was transferred to 
the vessel (2 × 2 h). 
 
Method H:  Cleavage and Deprotection 
After N-terminal acetylation (and on-resin olefin metathesis when required), the resin was 
washed with DMF (5 × 2 mL × 2 min.), dichloromethane (5 × 2 mL × 2 min.), and then Et2O (3 
× 2mL × 2min.). Peptides were then simultaneously cleaved and side chain deprotected with 
cleavage “Reagent K” TFA : EDT :  Thioanisole : Phenol : H2O, 87:3:5:5:5 (2 × 2 mL × l h). 
Peptides with large number of Arg(Pbf) residues required incubation times up to 3 h for 
complete deprotection of the side chains. The resin was washed with fresh TFA (2 mL × 2 min) 
and the TFA evaporated under N2 (g).  
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The resulting oil was precipitated with ice-cold ether and placed in a centrifuge (3000 rpm × 2 
min). The supernatants were removed, the precipitate rinsed with ice-cold ether (3 × 3000 rpm × 
2 min) and dried in vacuo. 
 
Method I:  Mass – Directed HPLC Purification 
Crude peptides were dissolved in either DMSO, 1:1 dioxane:water or 9:1 
water:hexafluoroisopropanol at an approximate concentration of 20 mg mL
-1
.  
 
Peptides were purified using reversed phase mass directed HPLC with software Masshunter by 
ChemStation (Agilent). The columns used were a Jupiter Proteo or an Agilent XBridge 5 μm 
19×100 mm C18 preparative column. An increasing gradient of MeCN to water (plus 0.1% 
formic acid v/v in both solvents) at a flow rate of 20 mL min
-1
 was used as mobile phase; in 
each case the gradient was optimized to obtain the best separation of the desired peptide from 
the rest of impurities from the crude mixture. Mass directed chromatography allows the 
collection of the desired peptide by mass, with the eluent split into an Agilent 6120 Quadrupole 
LCMS which triggers collection of eluent at a programmed m/z. This technique is particularly 
useful for peptides with weak UV traces. When the separation of the desired peptide from the 
impurities was problematic, the collection was performed using time slices at the required time 
interval. 
 
The resulting fractions were checked on the analytical HPLC, concentrated by centrifugal 
evaporation (Genevac), re-suspended in water and lyophilized. 
 
6.5.6. General methods for automated Solid Phase Peptide Synthesis  
 
The synthesis of peptides using the microwave assisted Liberty CEM™ Peptide Synthesiser 
follows the cycle below: 
 
Resin Loading 
Clean reaction vessel; wash with DMF; wash with dichloromethane; transfer resin to reaction 
vessel; wash with DMF; wash with dichloromethane; transfer resin to reaction vessel; wash with 
DMF; wash with dichloromethane; vessel draining. 
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Deprotection and coupling  
Clean resin dip tube, wash with DMF (15 mL), add 20% piperidine in DMF (6 mL), agitation at 
rt (10 min), wash with DMF (15 mL), add 20% piperidine in DMF (6 mL), agitation at rt (10 
min), wash with DMF (15 mL), clean resin dip tube, wash with DMF (15 mL), add amino acid 
(2.5 mL), add coupling reagent (1 mL), add activator base (0.5 mL), agitation at rt (90 min), 
wash with DMF (15 mL), drain. After the final residue, the resin is ejected from the reaction 
vessel, N-terminal acetylation and cleavage/deprotection were performed manually (Methods F 
and H).  
 
6.5.7. Peptides characterization data 
 
Below are the analytical HPLC and HRMS data of the peptides that have been synthesised. The 
chromatograms correspond to the UV signal obtained at 220 nm in the following conditions: (5-
95% MeCN:water and 0.1% TFA v/v in both solvents), t = 4.91 min, 0.5 mL min
-1
, Ascentis 
Express C18 column. Peptide identity was confirmed by the assessment of multiple charge 
states, which are tabulated as the monoisotopic peak for the Expected and Observed masses. The 
mass spectra shown below report the most abundant isotope peaks. The peptides were dissolved 
in pure water or DMSO for its characterization. 
 
Native H3 peptide 
 
 
The native H3 peptide was obtained using the general methods for SPPS (See sections 6.5.5 and 
6.5.6), 11 mg (11% yield), > 97 % purity. 
Ac - GAMGKDIQLARRIRGERA - CONH2 
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Analytical HPLC data for native H3 peptide  
 
 
 
HRMS data for native H3 peptide 
 
 
 
 
 
 
 
 
 
 
 
Native peptide Observed Expected 
[M+3H]
3+
 680.3848 680.3850 
[M+4H]
4+
 510.5413 510.5405 
[M+5H]
5+
 408.6344 408.6339 
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Stapled 1 H3 peptide 
 
 
 
 
The stapled 1 H3 peptide was obtained using the general methods for SPPS (See sections 6.5.5 
and 6.5.6), 10 mg (5% yield), > 90 % purity. 
 
 
Analytical HPLC data for stapled H3 position 1 peptide  
 
 
 
HRMS data for stapled 1 H3 peptide 
 
 
Ac - GAXGKDXQLARRIRGERA - CONH2 
  
153 
 
Stapled 1 peptide  Observed Expected 
[M+2H]
2+
 1009.1023 1009.0799 
[M+3H]
3+
 673.0500 673.0557 
[M+4H]
4+
 504.9862 505.0436 
[M+5H]
5+
 404.1218 404.2363 
 
 
 
Stapled 2 H3 peptide 
 
 
 
The stapled 2 H3 peptide was obtained using the general methods for SPPS (See sections 6.5.5 
and 6.5.6), 6 mg (3% yield), > 90% purity 
 
 
Analytical HPLC data for stapled 2 H3 peptide 
 
 
 
Ac - GAMGKXIQLXRRIRGERAGCA - CONH2 
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HRMS data for stapled H3 position 2 peptide 
 
 
 
 
 
 
 
 
6.5.8. Circular Dichroism  
 
Circular Dichroism was performed on an Applied Photophysics ChiraScan Apparatus and 
Software. For each scan, the following parameters were used: 180-260 nm range; point time 1 s; 
1 nm per point; step = 1; bandwidth 4.3 nm; path length 1 mm; temperature 20 °C. Scans were 
done in duplicate. Samples were dissolved in 40 mM sodium phosphate buffer pH 7.50 at 
concentrations between 10 - 100 μM. DMSO was not used in the samples for CD measurements 
due to its high absorbance below 230 nm. The solvent signal was subtracted to the raw circular 
dichroism data obtained for the peptides before conversion to the mean residue ellipticity: 
 
[θ] =
θ
10 ×  c ×  l
 
 
[θ]MRE =
[θ]
(R − 1)
 
 
Where θ = circular dichroism at a given wavelength, c = molar concentration, l = path length in 
cm, R = number of residues in the peptide sequence.  
 
Stapled 2 peptide  Observed Expected 
[M+2H]
2+
 1153.6446 1153.6441 
[M+3H]
3+
 769.4320 769.4318 
[M+4H]
4+
 577.3255 577.3257 
[M+5H]
5+
 462.0613 462.0620 
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